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This is my first foreword to the NDSC annual report. It was a
great honour for me to be appointed as Chairperson of the
National Disease Surveillance Centre, in January 2004, having
been a board member since the establishment of NDSC in
1998. During this time I have witnessed the organisation
evolve from a small expert unit based in a corner of Sir Patrick
Dun’s Hospital to the dynamic, focused and dedicated centre
at Gardiner Street today. From humble beginnings, NDSC
now employs over 40 professionals to meet the public health
challenges that face Ireland today.
At the outset, I would like to pay tribute to my predecessor,
Professor Dermot Hourihane, who served NDSC so well from
1998 until his retirement in 2002.
The NDSC Annual Report reflects the diligence,
professionalism, vision and sheer hard work of our Director, Dr
Darina O’Flanagan and all the staff at NDSC.
During 2003, NDSC continued to make a valuable
contribution to public health in Ireland, through the provision
of expert advice, epidemiological investigation, scientific
research, data collection and participation in health
promotion and training.
The wide range of important work carried out at NDSC was
enhanced by the recruitment of additional, highly qualified
and committed staff across a number of disciplines, during the
year.
The health services in Ireland are facing an exciting and
challenging future. NDSC is well placed to confidently take
part and contribute to the changes ahead and continue its
invaluable work to improve the health of the Irish population.
It remains for me to thank the present Board members, our
Director, and all the staff whose efforts have made such a
huge contribution to the ongoing success of NDSC.
Dr Elizabeth Keane
Chairperson
Board of the National Disease Surveillance Centre
Foreword
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Introduction
This the fifth Annual Report from the National Disease
Surveillance Centre.
2003 was a difficult year for the surveillance and control of
infectious diseases, not least due to the emergence of Severe
Acute Respiratory Syndrome (SARS) – which has a severe
fatality rate - in March 2003.
SARS, and its speed of transmission around the world, acted
as an international warning to improve public health
infrastructure and hospital infection control systems.
Between March and July 2003, over 8000 probable SARS
cases and 900 deaths were reported in approximately 30
countries. Healthcare workers accounted for 21% of
documented cases. Ireland was particularly fortunate that
none of the 50 cases investigated here were confirmed as
caused by the SARS coronavirus.
‘Traditional’ public health measures –even before the
aetiological agent was identified - effectively contained SARS
and prevented its spread from reaching frightening
proportions.
Endemic diseases continued to cause problems. Sexually
transmitted infections continued to rise and notified numbers
in 2002 were the highest for any year on record. During 2003
there was also a 10% increase in the number of newly
diagnosed HIV cases. A decrease in the quality of data on
HIV during 2003 is a cause for concern. No information on
exposure category was provided in 10% of cases and serious
consideration should now be given to make HIV a mandatory
notifiable disease using anonymous identifiers, to safeguard
patient confidentiality.
Campylobacter infections remain the single biggest bacterial
cause of gastroenteric infection in Ireland. E.coli O157
remains a serious concern with 86 confirmed cases in 2003.
One in eight children under 15 years of age with confirmed
VTEC O157 develop haemolytic uraemic syndrome, a form of
renal failure.
Members of households, which are not on main public water
supplies, are over represented among VTEC cases and the
potential for waterborne outbreaks of VTEC and
cryptosporidiosis is a cause for concern.
Ongoing surveillance of disease outbreaks demonstrates the
huge burden caused by the emergence of a variant strain of
Norovirus which was responsible for over 154 outbreaks of
gastroenteritis in 2002.
Over 5000 people were ill in the hospital sector alone due to
this pathogen. As a result a subcommittee of the NDSC
Scientific Advisory Committee was formed and guidelines on
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the management of Norovirus in the hospital setting were
published and launched by the Minister for Health and
Children in December 2003.
The 2003 influenza season started early and resulted in higher
incidence rate of influenza in young children. NDSC
monitored the situation closely in collaboration with general
practitioners, the National Virus Reference Laboratory, hospital
clinicians and public health departments. Situation updates
were reported to the Royal College of Physicians of Ireland
Immunisation Advisory Committee. Developments in the
spread of avian influenza in South-East Asia continue to be
monitored closely. NDSC worked closely with the
Department of Health and Children to further develop
contingency plans on pandemic influenza and other major
threats.
Data on anti-microbial consumption patterns in Ireland has
been added to the report this year to inform the policies of
the SARI committee (implementing the Strategy to control
Antimicrobial Resistance in Ireland). The proportion of MRSA
isolates in Ireland remains one of the highest in the countries
reporting to the EARSS surveillance scheme.
On a positive note, annual immunisation rates for all vaccines
improved in 2003. Uptake rates reached 92-94% in three
health boards. The challenge now is to reduce the regional
disparity and to continue the upward trend. Other advances
include the successful piloting of Computerised Infectious
Disease Reporting System during 2004 and the changes in the
Infectious Disease Legislation at the end of 2003 which
specified a number of important pathogens and which
introduced reporting from microbiologists.
Finally, a thank you to all who have served voluntarily on
NDSC’s scientific advisory committees. They represent a
successful multidisciplinary collaboration between
professionals with an interest in reducing the burden of ill
health from infectious diseases in this country. Thanks also
to all staff at NDSC, whose professionalism is reflected
throughout this report.
Dr Darina O'Flanagan
Director
National Disease Surveillance Centre
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Management Board
Dermot Hourihane
Professor of Histopathology, TCD
Consultant Histopathologist, St James’s Hospital (Retired)
(Left in 2003)
Mary Cafferkey
Consultant Microbiologist, The Children’s Hospital
Temple Street, Dublin 1 
Eibhlin Connolly
Deputy Chief Medical Officer
Department of Health and Children (Joined in 2003)
John Devlin
Deputy Chief Medical Officer,
Department of Health and Children (Left in 2003)
Elizabeth Keane
Director of Public Health,
Southern Health Board
John Magner
Regional Manager,
South Eastern Health Board
Brian Mullen
Principal Officer,
Department of Health and Children
Brian O’Herlihy
Specialist in Public Health Medicine,
Eastern Regional Health Authority
NDSC Annual Report 2003 7
Scientific Advisory 
Committee
Edmond Smyth
RCPI Faculty of Pathology (Chair)
Marina Burd
Infection Control Nurses Association
Karina Butler
RCPI Faculty of Paediatrics (Left in 2003)
Luke Clancy
Royal College of Physicians of Ireland (Left in 2003)
Catherine Cosgrove
Environmental Health Officers Association (Left in 2003)
Stephen Flint 
Trinity College, School of Dental Science
Phil Jennings
RCPI Faculty of Public Health Medicine
Micheál O’Mahony
Dept. of Veterinary Medicine, UCD
Noel Shanaghy
Academy of Medical Laboratory Science
David Thomas
Irish College of General Practitioners
Patrick Wall
Food Safety Authority of Ireland (Left in 2003)
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Subgroups and Committees
CJD Infection Control Sub-committee
Robert Cunney
National Disease Surveillance Centre (Chair)
Nick Breen
Irish College of General Practitioners
Helen Cleary
Neurosurgical Theatre Nurse, Beaumont Hospital
Stephen Flint
School of Dental Science, Trinity College
Hilary Humphreys
Consultant Microbiologist, Beaumont Hospital
Rory McConn – Walsh
Consultant Otolaryngologist, Beaumont Hospital
Margaret Nadin
Infection Control Nurses Association
Darina O’Flanagan
National Disease Surveillance Centre
Joan O’Riordan
Consultant Haematologist, IBTS
Christopher Pidgeon 
Consultant Neurosurgeon, Beaumont Hospital
Oonagh Ryan
CSSD Manager, Beaumont Hospital
Michelle Tait
CSSD Manager, School of Dental Science, Trinity College
Beryl – Ann Waldron
Department of Clinical Microbiology, Beaumont Hospital
SARI Community Antibiotic Stewardship Sub-committee
Colin Bradley
University College Cork (Chair)
Fiona Bogan
Pharmaceutical Society of Ireland
Bartley Cryan
Irish Society of Clinical Microbiologists
Robert Cunney
National Disease Surveillance Centre 
John Farrell
Irish Pharmaceutical Healthcare Association
Mary Favier
Continuing Medical Education
Cliodhna Foley-Nolan
RCPI Faculty of Public Health
Dorothy Gallagher
The Consumers’ Association of Ireland
Nuala O’Connor
Irish College of General Practitioners
EARSS Steering Group
Martin Cormican
Consultant Microbiologist, UCH Galway
Robert Cunney
National Disease Surveillance Centre
Frank Dennehy
Surveillance Scientist, St Vincent’s University Hospital 
(Joined in 2003)
Lynda Fenelon
Consultant Microbiologist, St Vincent’s University Hospital
Hilary Humphreys
Consultant Microbiologist, Beaumont Hospital
Derval Igoe
National Disease Surveillance Centre
Conor Keane
Consultant Microbiologist, St James’s Hospital (Left in 2003)
Stephen Murchan
National Disease Surveillance Centre (Data Manager)
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Olive Murphy
Consultant Microbiologist, Bon Secours Hospital, Cork
Brian O’Connell
Consultant Microbiologist, St James’s Hospital 
(Joined in 2003)
Darina O’Flanagan
National Disease Surveillance Centre (Left in 2003)
Angela Rossney
National MRSA Reference Laboratory
EPI-INSIGHT Editorial Committee
Darina O’Flanagan
National Disease Surveillance Centre (Managing Editor)
Lorraine Hickey
National Disease Surveillance Centre (Editor)
Colm Bergin
Irish Infection Society
Derval Igoe
National Disease Surveillance Centre 
Dermot Nolan
Irish College of General Practitioners
Edwin O’Kelly
National Virus Reference Laboratory (Joined in 2003)
James O’Leary
Academy of Medical Laboratory Science
Niamh O’Sullivan 
Irish Society of Clinical Microbiologists
Jackie Quinn
National Virus Reference Laboratory (Left in 2003)
Nicholas van der Spek
RCPI Faculty of Paediatrics
Lelia Thornton
RCPI Faculty of Public Health Medicine
Food Handlers Sub-committee
Margaret O’Sullivan
RCPI Faculty of Public Health Medicine (Chair)
Colette Bonner
Specialist in Public Health Medicine, ERHA
Mary Cronin
National Disease Surveillance Centre
Dan Crowley
Cork County Council
Margaret Fitzgerald
Specialist in Public Health Medicine, ERHA
Barbara Foley
National Disease Surveillance Centre
Catherine Lawlor
Dept of Agriculture, Food & Rural Development
Anne Maloney
RCPI Faculty of Pathology
Dan Murphy
Health & Safety Authority of Ireland
Nuala O’Connor
Irish College of General Practitioners
Tom Prendergast
Environment Health Officers Association
Emer Ward
Infection Control Nurses Association
SARI Hospital Antibiotic Stewardship Sub-committee
Edmond Smyth
Irish Society of Clinical Microbiologists (Chair)
Colm Bergin
Royal College of Physicians of Ireland
Robert Cunney
National Disease Surveillance Centre
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Emer Fitzgerald
Hospital Pharmacists Association
Olivia Flynn
Hospital Pharmacists Association
Cathal Kelly
Royal College of Surgeons in Ireland
Geraldine Nolan
RCPI Faculty of Paediatrics
Bernard Silke
Royal College of Physicians of Ireland
John Stinson
Irish Pharmaceutical Association
SARI Antibiotic Consumption Surveillance Sub-committee
Robert Cunney
National Disease Surveillance Centre (Chair)
Michael Barry
National Centre for Pharmacoeconomics
Collette Bonner
RCPI Faculty of Public Health
Celine Brosnan
Department of Health and Children
Martina Dempsey
Irish Pharmaceutical Healthcare Association
Michael Fitzpatrick
Hospital Pharmacists Association
Marita Kinsella
Pharmaceutical Association of Ireland
Anne Moloney
Irish Society of Clinical Microbiologists
Emer O’Reilly
Irish College of General Practitioners 
Ajay Oza
National Disease Surveillance Centre
SARI Infection Control Sub-committee
Hilary Humphreys
RCPI Faculty of Pathology
Mary Crowe
Irish Society of Clinical Microbiologists
Robert Cunney
National Disease Surveillance Centre
Eleanor Devitt
Infection Control Nurses Association
Mary Durkin
An Bord Altranais
Patricia Garry
Institute of Community Health Nursing
Blánaid Hayes
RCPI Faculty of Occupational Medicine
Ceppy Merry
Royal College of Physicians of Ireland
Maire O’Connor
RCPI Faculty of Public Health 
SARI Surveillance of Antibiotic Sub-committee
Robert Cunney
National Disease Surveillance Centre (Chair)
Martin Cormican
Irish Society of Clinical Microbiologists
Margaret Fitzpatrick
Academy of Medical Laboratory Science
Helena McGrath
Infection Control Nurses Association
Stephen Murchan
EARSS
Joan O’Donnell
RCPI Faculty of Public Health
NDSC Annual Report 2003 11
Ajay Oza
National Disease Surveillance Centre
STI Sub-committee
Mary Cronin
National Disease Surveillance Centre (Chair)
Mary Cafferkey
Consultant Microbiologist, The Children’s Hospital
Temple Street
Lisa Domegan
National Disease Surveillance Centre
Margaret Fitzgerald
Specialist in Public Health Medicine, ERHA (Joined in 2003)
Cliodhna Foley-Nolan
Specialist in Public Health Medicine, SHB (Joined in 2003)
Derek Freedman
Irish College of General Practitioners
Eleanor Kehoe
Infection Control Nurses Association
Ann Maloney
Consultant Clinical Microbiologist
Waterford Regional Hospital
Fiona Mulcahy
Consultant in Genito – Urinary Medicine, St James’s Hospital
Maire O’Connor
Specialist in Public Health Medicine, SEHB (Left in 2003)
Nuala O’ Connor
Irish College of General Practitioners
Mary O’Mahoney
Specialist in Public Health Medicine, SHB (Left in 2003)
Therese Wilson
Regional AIDS Co-ordinator, SEHB
Viral Gastroenteritis Sub-committee
Paul McKeown
National Disease Surveillance Centre (Chair)
Robbie Breen
Department of Health and Children
Marina Burd
Infection Control Nurses Association
Sue Codd
Environmental Health Officers Association
Patrick Costigan
Academy of Medical Laboratory Science
Seamus Fanning
Faculty of Veterinary Medicine, UCD
Margaret Fitzgerald
RCPI Faculty of Public Health Medicine
Barbara Foley
National Disease Surveillance Centre
Patricia Garvey
National Disease Surveillance Centre
William Hall
National Virus Reference Laboratory
Velma Harkins
Irish College of General Practitioners
Maureen Lynch
Irish Society of Clinical Microbiologists
Jeffrey Moon
Food Safety Authority of Ireland 
John O’Brien
CEO, St James’s Hospital
Gerry O’Dwyer
Asst. General Manager, Cork University Hospital 
(Joined in 2003)
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Margaret O’Sullivan
Specialist in Public Health Medicine, SHB
Thomas Quigley
Food Safety Promotion Board
VTEC Sub-committee
Paul McKeown
National Disease Surveillance Centre (Chair)
Colm Bergin
Consultant in Infectious Diseases (Left 2003)
St. James’s Hospital
Margaret Byrne
Chief Technologist 
OLHSC, Crumlin
Susan Clarke
Locum ID Physician (Joined in 2003)
St James’s Hospital
Margaret Fitzgerald
Specialist in Public Health Medicine, ERHA
Barbara Foley
National Disease Surveillance Centre
Cliodhna Foley-Nolan
Specialist in Public Health Medicine, SHB
Patricia Garvey
National Disease Surveillance Centre
Velma Harkins
Irish College of General Practitioners
Eleanor McNamara
Irish Society of Clinical Microbiologists
Bernice Martin
Environment Health Officers Association
Helen Murphy
Infection Control Nurses Association
Gerardine Sayers
RCPI Faculty of Public Health Medicine
Mary Waldron
Consultant Paediatrician
OLHSC, Crumlin
Waterborne Cryptosporidiosis Sub-committee
Derval Igoe
National Disease Surveillance Centre (Chair)
Bartley Cryan
Irish Society Of Clinical Microbiologists
Fiona Doyle
Infection Control Nurses Association (Left in 2003)
Geraldine Duffy
Teagasc
Oliver Fogarty
Department of the Environment, Heritage and 
Local Government
Tessa Greally
RCPI Faculty of Public Health Medicine
Lorraine Hickey
National Disease Surveillance Centre
Mary Horgan
Royal College of Physicians of Ireland
Lenora Leonard
Infection Control Nurses Association
Gavin McDonnell
Environmental Health Officers Association
Anthony McNally
Dublin City Council
John Mulcahy
Fingal County Council
Brendan O’Reilly
Academy of Medical Laboratory Science
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Darina O’Flanagan 
Director
Emma Baldwin 
Administrative Assistant (Left in 2003)
Orla Bannon 
Senior Executive – Administrative Services
John Brazil 
Information Systems Manager
Aline Brennan 
Surveillance Scientist
Mícheál Carton 
Surveillance Scientist
Fiona Cloak 
Surveillance Assistant
Mary Cronin 
Specialist in Public Health Medicine
Gillian Cullen 
Surveillance Scientist – CIDR
Robert Cunney 
Microbiologist
Costas Danis 
EPIET Fellow (Left in 2003)
Max Di Renzi 
EPIET Fellow
Lisa Domegan 
Surveillance Scientist
Margaret Fitzgerald 
Senior Surveillance Scientist
Seán Flood 
Accountant
Barbara Foley 
Surveillance Scientist
John Foy 
IT Officer - CIDR
Patricia Garvey 
Surveillance Scientist
Sarah Gee 
Surveillance Scientist
Colm Grogan 
Senior Surveillance Scientist
Lorraine Hickey 
Medical Officer
Myles Houlden 
IT Specialist
Deirdre Hyland 
Administrative Assistant
Derval Igoe 
Specialist in Public Health Medicine
Sarah Jackson 
Surveillance Assistant
Stephen Keily 
IT Officer
Maurice Kelly 
Communications Officer
Máire McClarnon 
Librarian
Kirsty MacKenzie 
PA to Director
Paul McKeown 
Specialist in Public Health Medicine
Stephen Murchan 
Surveillance Scientist
Niamh Murphy 
Surveillance Assistant
Helena Murray 
Medical Officer
Emer O’Connell 
Specialist Registrar in Public Health Medicine (Left in 2003)
Olivia O’Connell 
Finance Officer
Liam O’Connor 
IT Officer - CIDR
Joan O’Donnell
Specialist in Public Health Medicine
Kate O’Donnell 
Surveillance Scientist
Lynette O’Neill 
Receptionist
Ajay Oza 
Surveillance Scientist
Biagio Pedalino 
EPIET Fellow (Left in 2003)
Annette Rhatigan 
Specialist Registrar in Public Health Medicine (Left in 2003)
Emer Ruane 
IT Officer
Karen Savage 
Administrative Assistant
Natasha Sheehan 
Administrative Assistant
Lelia Thornton 
Specialist in Public Health Medicine
Staff of the National 
Disease Surveillance Centre
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Bacterial Meningitis, 2003
Key Points
• In 2003, 311 cases of bacterial meningitis were notified
in Ireland
• Two hundred and thirty seven of these notifications
were due to meningococcal disease (including one
imported case)
• Only five serogroup C meningococcal disease cases
occurred in 2003, compared with 139 in 2000,
highlighting the impact of the MenC vaccine
• There were 18 deaths due to bacterial meningitis in
2003, this included 12 deaths due to meningococcal
disease
Introduction
Neisseria meningitidis is the leading cause of bacterial
meningitis in Ireland. This can be a potentially fatal condition.
The peak age specific incidence rate for invasive
meningococcal disease (IMD) is in infants under one year of
age, with a second peak occurring in teenagers. Although not
as common, this life threatening disease can also occur in
adults.
The introduction of Haemophilus influenzae type b (Hib)
vaccination in 1992 and serogroup C meningococcal (MenC)
vaccination in 2000 has led to the near elimination of the
these two forms of bacterial meningitis in Ireland. However,
no suitable or effective vaccine is currently available for
serogroup B IMD and this form remains a significant burden of
disease in this country.
Materials and methods
An enhanced surveillance system for bacterial meningitis
(including meningococcal septicaemia) commenced in Ireland
in 1997. For each suspected case of bacterial meningitis
notified, a Medical Officer in the Community Care Area
completes part 1 of the enhanced form on the day of
notification, which is faxed to the Department of Public
Health and to NDSC. Within two weeks of the initial
notification, part 2 of the enhanced form is completed which
provides laboratory and epidemiological information as well
as a final diagnosis. At NDSC, notifications are entered onto
an MS Access database. The Irish Meningococcal and
Meningitis Reference Laboratory (IMMRL) performs active
surveillance on laboratory confirmed cases of IMD. The NDSC
database is reconciled monthly with the IMMRL database and
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quarterly with the Departments of Public Health databases. A
final data validation step is performed with Departments of
Public Health and IMMRL following year-end.
The incidence rates for the years 2000-2003 were calculated
using population figures from the 2002 Census of Population,
as the denominator. The 1996 census was used when
calculating incidence rates for 1999. The direct method of
age standardisation was used to control for the confounding
effect of age and thereby enable comparisons of incidence
rates be made between different health boards/geographical
areas. The Irish population was used as the standard
population.
The case definitions used for invasive meningococcal disease
were as recommended by the National Meningitis Working
Group in 1999.1 The case definitions are also described in the
NDSC Case Definitions for Notifiable Diseases” booklet.2 A
summary of these definitions are as follows:
Definite: A case where Neisseria meningitidis is detected by
culture or PCR in a normally sterile site (CSF, blood, synovial
fluid etc.).
Presumed: A case where the convalescent serology test is
positive or Gram-negative diplococci are detected in CSF or
skin-scrapings or N. meningitidis is isolated from an eye, throat
or nasal swab together with either the characteristic purpuric
rash or clinical or laboratory features of bacterial meningitis
(CSF pleocytosis).
Possible: A case with evidence of acute sepsis with or without
meningitis, together with the characteristic purpuric rash or a
case with clinical evidence of sepsis without a purpuric rash
and in whom N. meningitidis is isolated from an eye, throat or
nasal swab.
Results
Three hundred and eleven cases of bacterial meningitis were
notified in Ireland in 2003. The majority of these notifications
were due to invasive meningococcal disease (n=237; 76%),
followed by pneumococcal meningitis (n=25), Haemophilus
influenzae (n=7), Escherichia coli (n=4), group B streptococcus
(n=2), listeria (n=2), TB (n=5), salmonella (n=1), Enterobacter
cloacae (n=1) and bacterial agent unknown (n=27).
Invasive Meningococcal Disease
Imported case
During 2003 one imported case of invasive meningococcal
disease (IMD) was notified in Ireland. An imported case is
defined as a case where onset of illness is within two days of
arrival in the country or where the infection is known to have
been acquired abroad. This one imported case in 2003 was
classified as possible and was notified by SEHB and will be
excluded from subsequent analysis in this report.
Total IMD
Excluding the one imported case, 236 cases of IMD were
notified in Ireland in 2003 (6.0 /100,000 total population).
This was a very slight decrease from the previous year when
250 cases (excluding three imported cases) were notified.
Therefore, the incidence of IMD in Ireland continued to
decline in 2003 when compared with previous years (figure
1). Over 90% of IMD notifications were classified as definite
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Figure 1. Crude incidence rates of invasive meningococcal disease in Ireland, 1999-2003
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(n=215), 3% as presumed (n=8) and 6% as possible (n=13,
excluding the one imported case). Two hundred and twenty
one of the 236 notifications were laboratory confirmed, 64%
by PCR (n=142), 33% by culture (n=74), 2% by convalescent
serology (n=4) and <1% by microscopy (n=1).
IMD by serogroup
Serogroup B is the most common meningococcal serogroup
associated with IMD in Ireland, accounting for 87% of the
notifications in 2003. Since the MenC vaccine was introduced
in October 2000, the proportion of IMD due to serogroup B
has increased from approximately 50% in 1999-2000, to over
70% in 2001-2002 to 87% in 2003 (figure 2). On the other
hand the proportion of notifications due to serogroup C has
declined over the same period. Serogroup C accounted for
approximately 30% of IMD notifications in 2000, whereas it
only accounted for 2% of these in 2003 (figure 2). The
proportion of IMD notifications due to serogroups W135, Y or
non-groupable has not fluctuated greatly over the last five
years (range 2.5-3.8%). The proportion of notifications where
no organism was detected (no laboratory evidence IMD but
clinically the patient considered to have the infection) has
declined from 20% in 2000 to below 10% in 2003.
The breakdown of IMD notifications by serogroup in 2003
was: 206 serogroup B, five serogroup C, three serogroup
W135, two serogroup Y, four non-groupable and 16 (excluding
one imported case) no organism detected. The annual
incidence rates of serogroup B and C IMD between 1999-
2003 are presented in figure 1. Incidence rate of serogroup B
IMD increased very slightly in 2003 compared to 2002; 5.26 
and 5.00 per 100,000 total population, respectively. The
incidence rate of serogroup C disease continued to decline in
2003 with 0.13 per 100,000 cases occurring, compared to
0.36 per 100,000 in 2002. Comparing 2003 with 2000, the
incidence of rate of serogroup C IMD has fallen by 96%.
Only five serogroup C cases were notified during 2003. Four
of these occurred in the age groups that were targeted for
MenC vaccination. All four cases had not received the MenC
vaccine.
IMD by age and sex
The male female ratio for IMD in 2003 was 1.2:1.0. As in
previous years the age-specific incidence rates in 2003 for
IMD where highest in the <1 year olds (124.8 100,000),
followed by the 1-4 year olds (33.6/100,000). The frequencies
of the different forms of bacterial meningitis including IMD
notified by age group in 2003 are presented in table 1.
IMD by health board
The IMD crude incidence rates (CIR) and age standardised
incidence rates (ASIR) by health board for 2003 are presented
in figure 3. These rates fluctuated between health boards
even following direct standardisation of the data to control
for the confounding effect of age. The highest incidence rate
was in the MHB (9.49/100,000, 95% CI 5.6-13.4/100,000),
but this was not significantly different from the national rate
since the 95% confidence interval overlapped with the
national rate (6.02/100,000, 95% CI 5.3-6.8/100,000). The
WHB (2.94/100,000, 95% CI 1.2-4.7/100,000) has the lowest
incidence rate and this was significantly below the national 
rate (6.02/100,000, 95% CI 5.3-6.8/100,000). No statistical 
differences were observed between the national rate and
those for the other health boards.
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Figure 3.  Age standardised and crude incidence rates with 95% confidence 
intervals by health board for invasive meningococcal disease in 2003.
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IMD clusters
A cluster is defined as the occurrence of two or more cases of
meningococcal disease during a period of less than or equal to
three months among persons in the same defined setting
such as household, crèche, school/college or community. If
cases are of different serogroups then these are not regarded
as a cluster.
In 2003, two clusters were notified, with living in the same
household being the setting for both clusters. Two siblings 
in each household were infected with serogroup B    
N. meningitidis. In both clusters the secondary case 
occurred within days of the primary/index cases.
Pneumococcal meningitis
Twenty five cases of pneumococcal meningitis due to
Streptococcus pneumoniae were notified in 2003. This is an
increase from 15 cases the previous year. Fifty six percent
(14/25) of the cases occurred in children <5 years of age,
while 24% (6/25) of cases occurred in adults (table 1). The
annual number of pneumococcal meningitis notifications
tends to vary between 15 and 30, based on data available
since 1997 and the annual number of deaths notified has
ranged between one and four (figure 4).
Haemophilus influenzae meningitis
Seven cases of Haemophilus influenzae meningitis cases were
notified in 2003. All cases occurred in children <15 years of
age and six of the seven cases were <5 years of age (table 1).
Six of isolates were type b and the other non-capsular. One
child had been fully vaccinated against Hib and thereby
constitutes a true vaccine failure. Another child had received
one of the three recommended doses of Hib vaccine and this
is regarded as an apparent vaccine failure. The remaining four
Hib cases had not been vaccinated.
Group B streptococcal meningitis
During 2003 two cases of group B streptococcal meningitis
were notified, one case was in a neonate, the other in an
adult.
Listeria monocytogenes meningitis
Two cases of listeria meningitis cases were notified in 2003.
One case occurred in a neonate, the other in an infant 
(table 1).
Deaths due to Bacterial Meningitis
There were 18 deaths due to bacterial meningitis in 2003,
which was an increase from 12 deaths notified in 2002. Of
the 18 bacterial meningitis deaths notified in 2003, 12 were
due to meningococcal disease (11 serogroup B and 1
serogroup C), two pneumococcal, one group B streptococci,
one TB and two bacterial meningitis of unknown aetiology.
Meningococcal disease had a case fatality rate (CFR) of 5.1%
in 2003 (table 2). CFRs were highest in the 10-14 year olds at
14.3%, followed by the >25 year olds at 11.5% and the <1
year olds at 5.9% (table 2). The CFR for serogroup B disease
closely reflected that seen for total IMD since 11 of the 12
deaths notified were due to this serogroup (table 2). There
was one serogroup C death in 2003, this occurred in an adult.
Discussion
The downward trend in the incidence of IMD continued in
Ireland in 2003 with 6.0 per 100,000 cases occurring. The
Table 1.  Bacterial meningitis notifications by causative agent and age group in 2003 
Disease <1 1-4 5-9 10-14 15-19 20-24 >25 Total CIR
IMD* 69 75 19 14 26 8 26 237 6.0
S. pneumoniae 9 5 2 3 0 0 6 25 0.6
H. influenzae 4 2 0 1 0 0 0 7 0.2
L. monocytogenes 2 0 0 0 0 0 0 2 0.1
GBS** 1 0 0 0 0 0 1 2 0.1
TB 1 1 0 0 0 1 2 5 0.1
Other 11 3 0 3 2 3 11 33 0.8
Total 97 86 21 21 28 12 46 311 7.9
Population 54,499 223,131 264,090 285,708 313,188 328,334 2,448,253 3,917,203 
ASIR 176.2 38.5 8.0 7.4 8.9 3.7 1.9 7.9 
*The one imported case in the <1 yr old, included in the number of cases but not 
in the calculation of incidence rates. 
**GBS, group B streptococcus. CIR = Crude incidence rate per 100,000; 
ASIR = Age specific incidence rate per 100,000
Table 2.  Invasive meningococcal disease deaths and case fatality rates by age group, in 2003
Age group (years)  Total IMD  Serogroup B
  Deaths  Cases  CFR (%)  Deaths  Cases  CFR (%)
<1 4 68* 5.9 4 56 7.1
1-4 2 75 2.7 2 68 2.9
5-9 0 19 0.0 0 16 0.0
10-14 2 14 14.3 2 13 15.4
15-19 1 26 3.9 1 23 4.4
20-24 0 8 0.0 0 6 0.0
?25 3 26 11.5 2 24 8.3
Total 12 236 5.1 11 206 5.3
CFR = case fatality rate. *Excluding the one imported case.
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incidence of this disease has more than halved when
compared with 1999 and 2000. This decline can mainly be
attributed to the impact MenC vaccination has had in almost
eliminating serogroup C IMD with a 96% reduction in the
incidence of the disease seen in 2003 when compared with
2000.
The incidence of serogroup B IMD increased very slightly in
2003 compared with the previous year but overall there has
been a gradual decline in the incidence of serogroup B IMD
since 1999 although this decline is nowhere near the scale of
the serogroup C reduction seen over the same period.
Despite the downward trend in the incidence if IMD over the
last four years this disease is still the major cause of bacterial
meningitis in Ireland. IMD accounted for 76% of the
notifications in 2003 with serogroup B accounting for 87% of
these IMD notifications. Twelve IMD deaths occurred in
2003. Half of these deaths occurred in children <5 years of
age (n=6), a quarter in teenagers (n=3) and a quarter in
adults (n=3). The highest case fatality rates were in the
teenagers and adults.
As an infectious disease IMD especially serogroup B disease
remains an important cause of morbidity and mortality in
Ireland. The fact that a suitable serogroup B vaccine still
remains elusive, as always parents and health care
professionals are encouraged to be ever vigilant to the signs
and symptoms of bacterial meningitis/meningococcal disease 
and also to be aware that adults too can succumb to this
disease.3
Pneumococcal meningitis is the next most common form of
bacterial meningitis and resulted in 8% of notifications in
2003. Meningitis was the only form of pneumococcal disease
notifiable prior to January 1, 2004. Recent amendments to
the Infectious Diseases Regulations stipulate that all cases of
invasive S. pneumoniae are now notifiable and consequently
our understanding of the epidemiology of this disease should
improve.4 Pneumococcal disease is vaccine preventable. At
present in Ireland pneumococcal vaccination is recommended
for use in persons who are at increased risk of the disease and
its complications.5 To help inform future vaccination policy in
this country it is vital that the surveillance of pneumococcal
disease is strengthened.
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Key Points
• There were 408 new cases of TB notified in 2002, giving
a crude incidence rate of 10.4/100,000 population
• Mycobacterium tuberculosis was isolated in 234 cases
and Mycobacterium bovis was isolated in 5 cases
• Of the 408 cases reported in 2002, 305 cases had a
pulmonary component
• 123 (30.1%) cases were born outside Ireland
• Five deaths were attributed to TB in 2002
• Outcome data were reported in 77.2% of TB cases
Introduction
Since 1998, all information concerning TB notifications in
Ireland has been reported by each of the health boards to the
National Disease Surveillance Centre (NDSC) for analysis.
Beginning on January 1st 2000, this information has included
enhanced surveillance data based on the minimum dataset
reported to EuroTB, the European agency that collates
national TB data within Europe and contributes that data to
the WHO global TB control programme.1 The resulting
National Tuberculosis Surveillance System (NTBSS) was set up
following consultation between NDSC, the eight health
boards and the National Tuberculosis (TB) Advisory Group.
Materials and methods
For each individual case of tuberculosis notified in 2002, an
enhanced notification form was completed by public health
doctors, using the available clinical, microbiological,
histological and epidemiological data. These forms were then
collated in the regional Departments of Public Health. In each
regional Public Health department, data were also entered
onto an Epi Info 2000 database.2 From this database, an
anonymised dataset was submitted to NDSC on a quarterly
basis.
All cases of tuberculosis notified to NDSC were collated at a
national level on a single Epi Info 2000 database for detailed
analysis. Reports summarising results were produced on a
quarterly basis by NDSC. Information on all cases was
updated in late 2003 / early 2004 by each health board to
include outcome data.
Population figures, used as the denominator, were taken from
Tuberculosis in Ireland, 2002
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the 2002 census of population. In order to compare rates
between groups of interest, 95% confidence intervals were
used. Direct methods of standardisation were used to allow
comparison of rates between geographical areas using the
Irish population as the standard population.
As in previous years, the case definitions used were as
recommended by the National Tuberculosis (TB) Working
Group.3
A notified case of TB refers to clinically active disease due to
infection with organisms of the Mycobacterium tuberculosis
complex (M. tuberculosis, M. bovis, M. africanum). Active
disease is presumed if the patient is commenced on a full
curative course of anti-tuberculosis chemotherapy. Persons
placed on chemoprophylaxis for preventive treatment or
infected by mycobacteria other than M. tuberculosis complex
are not included as cases.
Pulmonary TB is defined as a laboratory-confirmed case –
either a positive smear, histology or culture of a respiratory
sample – with or without radiological abnormalities
consistent with active pulmonary TB or a case where the
physician takes the decision that the patient’s clinical
symptoms and/or radiological signs are compatible with
pulmonary TB.
Extrapulmonary TB is defined as a patient with a smear,
culture or histological specimen, from an extrapulmonary site,
that is positive for M. tuberculosis complex or a case with
clinical signs of active extrapulmonary disease in conjunction
with a decision taken by the attending physician to treat the
patient with a full curative course of anti-tuberculosis
chemotherapy.
Results
Four hundred and eight cases of TB were notified in 2002 in
Ireland, giving a notification rate of 10.4/100,000 population.
This represents a 7.1% increase on the corresponding figure in
2001 (381 cases: 9.7/100,000) (table 1).
The highest age standardised TB incidence rate was reported
in the Southern Health Board, at 13.1 per 100,000 population
(table 2). The North Western Health Board had the lowest rate
at 5.1/100,000. In addition, the rate in the NWHB was
significantly lower than the national age standardised
incidence rate (10.4 per 100,000).
Sex and age distribution
Two hundred and fifty nine cases were male (63.5%) and 148
were female (36.3%), giving a male:female ratio of 1.8:1. The
gender of one case was not recorded (0.2%). The average age
of those diagnosed with TB was 44.6 years with a range from
less than one year of age to 94 years. Almost a quarter
(22.8%) of cases occurred in those aged 65 and over (n=93).
The highest rates were observed in those aged over 65 years
(at 21.3/100,000 population). The age- and sex-specific
incidence rates per 100,000 population in Ireland, in 2001 are
illustrated in figure 1.
Geographic origin
One hundred and twenty three (30.1%) of the patients
diagnosed with TB in 2002 were born outside Ireland,
compared to 63 patients in 2001. In 2002, 49 cases were born
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Figure 1: Age- and sex-specific TB incidence rates in Ireland, 2002
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in Africa, 44 in Asia, 25 in Europe, three in South America and
one in North America. The country of origin was unknown in
one case. The crude rate of TB notifications in the indigenous
population only in 2002 was 7.8/100,000 population while
the national crude rate for all cases notified in 2002 was
10.4/100,000 population.
Diagnostic details
Of the 408 TB notifications, 249 (61%) were definite cases
which were culture confirmed. Of the 249 culture-confirmed
cases, 234 (97.9%) of the isolates were M. tuberculosis and
five (2.1%) were M. bovis. The isolate was not specified in 10
culture positive cases.
Two hundred and sixty eight cases were pulmonary (65.7%),
95 cases were extrapulmonary (23.3%) and 37 cases were
pulmonary and extrapulmonary TB (9.0%). In eight cases, the
TB site was unspecified (2%). Of the 305 TB cases with a
pulmonary disease component, 122 (40%) were sputum
positive by microscopy. There were 6 cases of TB meningitis
notified in 2002 giving an incidence rate of 1.5 cases per
million. The diagnostic breakdown in each health board is
shown in table 3.
Resistance
Resistance was documented in ten cases out of a total of 234
M. tuberculosis isolates (4.3% of M. tuberculosis isolates).
Mono-resistance to isoniazid was recorded in eight cases and
mono-resistance to streptomycin in one case. One further
case was resistant to both isoniazid and streptomycin. Seven
of the drug-resistant cases were born outside Ireland. In 2002,
no multi-drug resistant TB cases (defined as resistance to at
least isoniazid and rifampicin) were notified.
Outcome
Of the 408 cases notified in 2002, the outcome was recorded
in 315 cases (77.2%). Two hundred and fifty nine of the 315
cases (82.2%) completed treatment. Sixteen patients (5.1%)
were recorded as being lost to follow up. There were 30
deaths (9.5%) recorded, of which five were attributed to
tuberculosis. Treatment was interrupted in five cases (1.6%)
and five cases were continuing to receive treatment at time
of reporting (1.6%).
Of the 117 smear positive cases of pulmonary TB notified in
2002, 91 completed treatment, seven died, four were lost to
follow up and one was still on treatment at time of reporting.
The outcome was unknown in 14 cases.
A summary profile of the epidemiology of TB in Ireland from
2000 to 2002 is shown in table 4.
Discussion
When compared with 2001 figures (9.7/100,000), there was a
7.1% increase in TB notifications in 2002 giving a national
crude rate of 10.4/100,000 population. A similar increase was
observed in 1999 when the number of cases rose by 10.6%
from a crude rate of 11.7/100,000 in 1998 (n=424) to
12.9/100,000 (n=469) in 1999. The 3 year moving average
removes some of the yearly fluctuation and continues to fall.
Differences in age standardised TB incidence rates persist
between health board areas (figure 2). In 2002, the SHB had
Table 1. Notified TB cases in Ireland, 1991 – 2002, with 3-year moving averages, 
1992 - 2001
Year  Number    Crude rate per 100,000pop.  3 year moving average
1991 640 18.2 
1992 604 17.1 612
1993 598 17 581
1994 524 14.5 526
1995 458 12.6 469
1996 434 12 436
1997 416 11.5 423
1998 424 11.7 433
1999 469 12.9 439
2000 395 10.1 410
2001 381 9.7 391
2002 408 10.4 
Table 2: Number of cases of TB in Ireland and age standardised incidence rates with 
95% confidence intervals (CI) by health board, 2002
Health Board  TB cases  Age standardised incidence rate  95% CI
ERHA 162 11.5 9.7-13.3
MHB 19 8.8 4.8-12.8
MWHB 32 9.4 6.2-12.7
NEHB 24 7.1 4.3-9.9
NWHB 12 5.1 2.2-8.0
SEHB 49 11.7 8.4-14.9
SHB 77 13.1 10.2-16.1
WHB 33 8.6 5.6-11.5
Ireland 408 10.4 9.4-11.4
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the highest rates of TB (13.1/100,000) followed by SEHB
(11.7/100,000) and ERHA (11.5/100,000). In 2001, the
highest rates were seen in the ERHA and SHB while in 2000,
TB rates were highest in the MWHB and the SHB. In 2002,
rates were below the national average in the NWHB
(5.1/100,000).
Those aged 65 and over had the highest age-specific rate in
2002 (21.3/100,000 population). This was comparable with
the rate observed in this age group in 2001 (20.6/100,000
population). The male:female ratio of 1.8:1 reported in 2002
was also comparable with the rate reported in 2001 (1.7:1).
When compared with previous years, the percentage of cases
born outside Ireland increased in 2002. One hundred and
twenty three cases (30.1%) were born outside Ireland,
compared to 63 cases (16.5%) in 2001, 45 cases (11.1%) in
2000 and 65 cases (13.9%) in 1999. However, this percentage
remains comparable with other western European countries.
In 2001, among the 21 countries in Western Europe who
reported data to the EuroTB network, 32% of notifications
were in foreign born patients.4 For example, in the United
Kingdom, France and Germany, all of whom have similar
notification rates to Ireland (9.2-11.8/100,000), the
percentage of foreign-born patients ranged from 35.7% to
51.1% in 2001.4
The number of cases with outcome data in 2002 was 77.2%.
This is an increase of 17% on percentage of outcome data
available in 2001 and 2000. This increase may partly be due
to the fact that 2002 was the first year where data were
collected using the Epi2000 system. This windows-based
system is more user friendly than the previous Epi6 system. In
the short term, NTBSS will continue to run on the current
Epi2000 system. It is critical to TB control in Ireland that
surveillance of TB be maintained at a high level, particularly in
monitoring multi-drug resistant tuberculosis. Although there
were no cases of MDR-TB notified in Ireland in 2002, 1.6% of
new cases of TB in 2001 in Western Europe were multi-drug
resistant.4
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Table 4. Summary of epidemiology of TB in Ireland, 2000 – 2002
  2000 2001 2002
Total number of cases 395 381 408
Notification rate per 100,000 population 10.1 9.7 10.4
Foreign born TB patients 44 63 123
% culture positive patients 58 58.8 61
M. tuberculosis 222 204 234
M. bovis  2 7 5
M. africanum 3 1 0
% smear positive pulmonary cases 47.2 44.4 38.4
Monoresistance to isoniazid 2 4 8
Monoresistance to streptomycin 1 3 1
Monoresistance to pyrizinamide 1 1 0
Multi-drug resistant cases  2 2 0
Deaths attributed to TB 6 5 5
 Table 3: Diagnostic categories of TB cases notified in 2002, by health board
Health Board  Pulmonary Extrapulmonary P+E Unknown Total
ERHA  109 36 17 0 162
MHB 12 4 0 3 19
MWHB 15 12 4 1 32
NEHB 11 5 4 4 24
NWHB 10 1 1 0 12
SEHB 33 10 6 0 49
SHB 54 20 3 0 77
WHB 24 7 2 0 33
Total 268 95 37 8 408
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Key Points
• During 2003, there were 399 newly diagnosed cases of
HIV infection, a 10% increase in the number of cases
diagnosed in 2002 
• The cumulative total of HIV infections reported in
Ireland to the end of December 2003 is 3,408
• Of the 399 cases, 221 were heterosexually acquired, 75
were among men who have sex with men (MSM) and 47
were among injecting drug users (IDUs) 
• During 2003, almost 80% of the cases were between 20
and 40 years of age and the mean age was 30.8 years 
• Of the 399 cases diagnosed in 2002, 202 (51%) were
male and 196 (49%) were female. The mean age at HIV
diagnosis was 33.4 years in males and 27.7 years in
females, a difference of 5.7 years 
• One hundred and thirty three of the newly diagnosed
cases in 2003 were born in Ireland and 198 were born in
sub-Saharan Africa 
Introduction
During 2003, an estimated 4.8 million people became newly
infected with HIV worldwide.1 This is the largest number in a
single year since the epidemic began.1 Today, an estimated
37.8 million people are living with HIV and the epidemic has
killed over 20 million people since the first cases of AIDS were
identified in 1981.1 Sub-Saharan Africa is the most severely
affected region of the world. An estimated three million
people were newly infected in sub-Saharan Africa in 2003,
representing over 60% of new infections globally.1
Increasing numbers of people newly diagnosed with HIV have
been seen in Ireland since the late 1990s. National HIV case
based reporting was introduced in Ireland in July 2001 on a
recommendation of the National AIDS Strategy Committee
(NASC).2 The system aims to ensure the collection of timely
data on the distribution and mode of transmission of HIV
infection, accurately monitor trends in the epidemic, and
enable linkage between reports of HIV infection and AIDS. A
report on newly diagnosed HIV infections in Ireland in 2003
was recently published and is available on the NDSC website.3
This is the second annual report published since the
introduction of HIV case based reporting in Ireland.
Methods
All positive HIV samples are sent to the NVRL for
confirmation. For every newly confirmed HIV diagnosis, the
laboratory sends a HIV/AIDS surveillance report form to the
clinician who requested the confirmatory HIV test. The
HIV in Ireland, 2003
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laboratory generates a soundex code, which is used as an
identifier on the HIV/AIDS surveillance report form. Soundex
coding adds an extra layer of confidentiality to HIV/AIDS
surveillance report forms and allows patient names to be
coded in a way that makes it impossible to decode it to an
unequivocal form of the actual name. A copy of the form is
also sent to the Director of Public Health (or nominee on
his/her behalf) in the health board where the patient resides
to alert them to the newly diagnosed case. The clinician is
requested to complete the form and return it to the relevant
Director of Public Health. The forms are then forwarded to the
NDSC where national figures are collated. Analysis of HIV
data is carried out by the NDSC every six months and a
report is published on the NDSC website and sent to people
on  a large mailing list including clinicians, microbiologists,
public health personnel, DoHC, non-governmental
organizations (NGOs) and other interested parties. In
addition, twice yearly, a summary of the data is forwarded to
the European Centre for the Epidemiological Monitoring of
AIDS (EuroHIV). Clinicians are also asked to report all cases of
AIDS to NDSC using the HIV/AIDS surveillance report forms. A
summary of the AIDS data is also reported to EuroHIV on a
twice-yearly basis.
Results
There were 399 newly diagnosed HIV infections in Ireland in
2003. This compares to 364 cases diagnosed in 2002, and
represents a 10% increase. The rate of newly diagnosed HIV
infection in Ireland in 2003 was 101.9 per million population.
Exposure category 
A breakdown by exposure category in 2003 can be seen in
table 1. This is compared to the breakdown by exposure
category in 2002. Figure 1 shows the trends in newly
diagnosed cases among the three major risk groups
(heterosexuals, MSM and IDUs) from 1994 to 2003.
Of the 399 newly diagnosed cases, 221 were heterosexually
acquired. This compares to 232 in 2002 and 173 in 2001.
There were 75 new diagnoses among MSM during 2003
compared with 46 in 2002 and 71 in 2001. There were 47
new diagnoses among IDUs during 2003 compared with 50 in
2002 and 38 in 2001. The exposure category was not reported
for 39 of the newly diagnosed infections in 2003.
HIV infection was newly diagnosed in 14 children during
2003. Of the 14 children, 12 (including 5 infants) were known
to be infected through mother-to-child transmission (MCT). A
total of 150 babies were born to HIV infected mothers in
2003. Of these 5 (see above) were diagnosed with HIV
infection and the status of the remaining 145 is
indeterminate (i.e. they do not meet the criteria for HIV
infection and were <18 months at time of test or they were
born to a HIV infected mother but their antibody status is
unknown).
Sex and age distribution
Of the 399 newly diagnosed cases, 202 (51%) were male and
196 (49%) were female. Information on gender was
unavailable for one of the new cases. The majority of
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Figure 1: Newly diagnosed HIV infections in Ireland among heterosexuals, 
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Table 1: Newly diagnosed HIV infections in Ireland by exposure category (2002 and 2003) 
Exposure category    2002 2003
 Number % Number %
Heterosexual 232 63.7 221 55.4
MSM 46 12.6 75 18.8
IDU 50 13.7 47 11.8
Mother to Child transmission (MCT) 8 2.2 12 3.0
Other 5 1.4 5 1.3
Unknown 23 6.3 39 9.8
Total 364 100.0 399 100.0
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heterosexuals (66.5%) were female and the majority of IDUs
(63.8%) were male. Of the 196 females with newly diagnosed
HIV infection in 2003, 81 were pregnant at the time of HIV
diagnosis. Information relating to pregnancy status is
unavailable for 30 of the female cases.
A breakdown of cases by exposure category and age group is
shown in table 2. Almost 80% were between 20 and 40 years
of age and the mean age was 30.8 years. The mean age at HIV
diagnosis was 27.7 years in females and 33.4 years in males, a
difference of 5.7 years. The mean age at HIV diagnosis was 29.0
years in IDUs, 30.2 years in heterosexuals and 36.7 years in
MSM.
Geographic origin
Analysis of 2003 cases by geographic origin is presented in
figure 2. Classification by geographic origin is as used by
EuroHIV. Geographic origin is based on the country of birth
for adults and the country of birth of the mother for children.
Of the 399 cases diagnosed in 2003, 133 were born in Ireland
and 198 were born in sub-Saharan Africa. Information on
geographic origin is unavailable for 41 of the newly diagnosed
cases. Of the reported heterosexual cases, 82% were born in
sub-Saharan Africa and 14% were born in Ireland. Seventy five
percent of the newly diagnosed cases reported among MSM
and 96% of the newly diagnosed cases reported among IDUs
were born in Ireland.
Area of residence
Of the 399 cases newly diagnosed in 2003, 231 were resident
in the ERHA area and 125 were resident outside the ERHA at
the time of HIV diagnosis. Information on area of residence is
unavailable for 43 of the 399 cases. By exposure category,
92% of IDUs, 62% of heterosexuals and 56% of MSM were
resident in the ERHA area at HIV diagnosis.
Cumulative Total 
The cumulative total of HIV cases reported in Ireland to
December 2003 to 3,408. A breakdown of the cumulative
cases can be seen in table 3.
AIDS cases and AIDS-related deaths
The total number of AIDS cases reported to the end of 2002
is 731 and the total number of AIDS-related deaths reported
to the end of 2002 is 369. Information on AIDS and AIDS-
related deaths reported during 2003 is currently being
collated and will be published on the NDSC website.
Discussion
Between 1998 and 2003, there was a 243% increase in the
number of HIV infections diagnosed annually in Ireland. This
increase can largely be explained by a substantial rise in the
number of heterosexually acquired cases, which increased
from 47 new diagnoses in 1998 to 221 new diagnoses in
2003. Of the heterosexually acquired cases diagnosed in
2003, the majority were born in sub-Saharan Africa. A similar 
Table 2: Newly diagnosed HIV infections in Ireland by exposure category and age group (2003)
Age group (years)              Exposure Category
 Heterosexual  MSM  IDU MCT Other  Unknown Total
0-9 - - - 10 - - 10
10-19 13 1 2 2 2 1 21
20-29 92 15 23 - 2 16 148
30-39 95 36 18 - 1 15 165
40-49 16 16 4 - - 6 42
50-59 5 5 - - - - 10
60-69 - 1 - - - 1 2
70-79 - 1 - - - - 1
Total 221 75 47 12 5 39 399
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Figure 2: Newly diagnosed HIV infections in Ireland by exposure category and geographic 
origin (2003). (Geographic origin is based on country of birth for adults and country of 
birth of mother for children.)
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situation is evident in many other western European countries
where persons originating from sub-Saharan Africa bear a
disproportionate share of the burden of the epidemic.
4
This is
not surprising given that sub-Saharan Africa is the area of the
world that is most severely affected by the global pandemic.1
The number of cases of HIV infection for which the exposure
category is not reported has increased in recent years from 7
(2.3%) in 2001, to 23 (6.3%) in 2002 to 39 (9.8%) in 2003.
This makes the analysis of data and interpretation of trends
difficult. Neither HIV nor AIDS are currently statutorily
notifiable in Ireland and the present HIV case based reporting
system and AIDS reporting systems operate on a voluntary
basis. The report, A Review of Notifiable Diseases and the
Process of Notification, from the Notifiable Diseases
Subcommittee of the Scientific Advisory Committee of the
National Disease Surveillance Centre, in February 2001,
recommended that HIV/AIDS should be a statutorily
notifiable.5 In order to bring this about, a change in legislation
would be required. The issue of incomplete reporting and
statutory notification of HIV/AIDS is currently under review
by the National AIDS Strategy Committee.
The increase in HIV infections diagnosed among MSM in
Ireland may be a reflection of increasing risky sexual
behaviour in this group. Recent increases in rates of syphilis
and gonorrhoea and rises in HIV-related risk behaviours
among MSM have been reported in Western Europe.6 Concern 
has also been raised in the United States over a resurgence of
risky sexual behaviours and infections among MSM.7 In 2000,
a syphilis outbreak was identified in Ireland, which occurred
mainly among MSM in Dublin.8 Because syphilis infection
facilitates acquisition and transmission of HIV, this recent
outbreak of syphilis among MSM in Dublin raises concerns
about potential increases in HIV transmission in this group.
It has been clearly shown that transmission of the HIV virus
from mother to child can be dramatically reduced or prevented
by antenatal screening and treatment of HIV positive women
with antiretroviral drugs and by careful management of the
delivery.9 In April 1999, the Department of Health and
Children officially launched the national linked antenatal HIV
screening programme in Ireland. This programme recommends
that HIV testing be offered to all women who attend for
antenatal care. The NDSC collects data on the linked antenatal
HIV testing programme from maternity units/hospitals on a
quarterly basis and provisional data for 2002 are published on
the NDSC website.10 Data are available in respect of 53,929
women who were offered the antenatal HIV test in 2002. Of
these 53,929 women, 51,144 availed of the test (an uptake
rate of 94.8%). Of the 51,144 women tested, 156 were
identified as HIV positive. Of these, 113 (72.4%) were new
diagnoses, that is, they had not been previously aware of their
HIV status. Once diagnosed, these women have the
opportunity to avail of treatment, which will dramatically 
reduce or even prevent the transmission of HIV to their babies.
Table 3: Cumulative total HIV infections diagnosed in Ireland by exposure category 
(to end of December 2003) 
Exposure category             Cumulative Total to end of Dec 2003
 Number %
IDU 1131 33.2
Heterosexual 1164 34.2
MSM 764 22.4
Haemophiliac 106 3.1
Children 75 2.2
Prisoner  39 1.1
Blood Donor† 30 0.9
Transfusion Recipient 8 0.2
Occupational 6 0.2
Haemophiliac contact 4 0.1
Other  11 0.3
Unknown 70 2.0
Total 3408 100.0
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These provisional data highlight the effectiveness of the
antenatal HIV testing programme in Ireland.
The majority of people diagnosed with HIV infection in 2003
were aged between 20 and 40 years. There was a notable
difference in age distribution between the sexes and females
were younger at HIV diagnosis then males. This trend has
been seen worldwide and it has been suggested that women
may be at risk for infection at an earlier age due to infection
by older sexual partners.1 The availability of routine antenatal
HIV screening in Ireland and differences in health seeking
behaviour may result in women being diagnosed at an earlier
stage than their male counterparts.
A disproportionately high number of newly diagnosed HIV
infections were resident in the ERHA area at time of HIV
diagnosis. In 2003, the rate in the ERHA was 164.8 per million
population compared to 49.7 per million population in the
rest of the country. In particular, the rate of newly diagnosed
HIV in the ERHA among those whose probable route of HIV
transmission was IDU was 30.7 per million population
compared to 1.6 per million population in the rest of the
country.
It is important to note that the data presented does not
represent HIV incidence but reflects the number of new
diagnoses in a given time period, which is dependent on
uptake of HIV testing. In the UK, it is estimated that 31% of
HIV infected people remain unaware of their HIV status.4
This report highlights the continued increase in the annual
number of newly diagnosed HIV infections in Ireland and
emphasises the ongoing need for appropriate prevention 
and treatment and care programmes for all risk groups in
Ireland.
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Sexually Transmitted Infections 
in Ireland
Key Points
Quarterly STI data (2002)
• Total number of notified STIs increased by 8% in 2002,
compared to 2001
• Three most commonly notified STIs in 2002 were ano-
genital warts, non-specific urethritis and Chlamydia
trachomatis
• Largest increases during 2002, compared to 2001, were
observed for infectious hepatitis B, molluscum contagiosum
and non-specific urethritis 
• Gonorrhoea notifications decreased by 39% during 2002,
compared to 2001
Syphilis enhanced surveillance data (2000-2003)
• Following the syphilis outbreak that occurred between 2000
and 2002, there remains a high level of endemic syphilis in
2003
Introduction
During 2002, 14 sexually transmitted infections (STIs) were
legally notifiable in Ireland: ano-genital warts, candidiasis,
chancroid, Chlamydia trachomatis, genital herpes simplex,
gonorrhoea, granuloma inguinale, infectious hepatitis B,
lymphogranuloma venereum, molluscum contagiosum, non-
specific urethritis, Pediculosis pubis, syphilis and
trichomoniasis. This list of notifiable STIs was updated in
January 2004 (Infectious Diseases (Amendment) (No. 3)
Regulations 2003, S.I. No. 707 of 2003), however this report
details the 14 STIs that were notifiable during 2002.
Aggregate data on the number of notified STIs from
Departments of Public Health is collated quarterly.
Departments of Public Health are notified of STIs mostly from
STI clinics and some GPs. The number of STIs notified by
quarter, health board, age group and gender for 2002 are
presented in this report. Rates per 100,000 population are
based on the 2002 population census, unless otherwise
stated. It should be noted that cases of infectious hepatitis B
that are sexually transmitted may also be reported through
the weekly infectious disease notification system. Please note
that quarterly STI data is only available from Q1 1995 &
annual STI data is only available from 1989. This report also
briefly summarises provisional syphilis data reported through
the enhanced syphilis surveillance system between January
2000 and December 2003.
During 2002, the total number of notified STIs increased by
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7.9%, when compared to 2001. A comprehensive report on
STIs notified in Ireland in 2002 is available on the NDSC
website.1, 2  During 2003, a high level of endemic syphilis was
identified through the syphilis enhanced surveillance system.
Materials and methods
Aggregate STI data is collated quarterly from STI clinics
including age group, gender and diagnosis. Rates per 100,000
population for 1989 to 1993 are based on the 1991
population census; rates for 1994 to 1999 are based on the
1996 population census and rates for 2000 to 2002 are based
on the 2002 population census.
The enhanced syphilis surveillance system was set up to
capture data on all syphilis cases from January 2000 including
age, gender, country of birth and health board of diagnosing
clinic. Clinical details and at risk behaviour data were also
collected.
Results
Notified STIs between 1989 and 2002
During 2002, 10471 STIs were notified compared to 9703 in
2001, a 7.9% increase (table 1). Notified STIs have been
increasing steadily each year since 1994, increasing by
157.1% between 1994 and 2002 and by 370.0% between
1989 and 2002. The number of STIs notified in 2002 is the
highest number reported in any year on record. Notified cases
of candidiasis, C. trachomatis, genital herpes simplex,
infectious hepatitis B, lymphogranuloma venereum,
molluscum contagiosum, non-specific urethritis, syphilis and
trichomoniasis all increased during 2002, compared to 2001.
Ano-genital warts, gonorrhoea and P. pubis notifications all
decreased in 2002, compared to 2001. Significantly, notified
cases of infectious hepatitis B increased by 46.2% and
gonorrhoea decreased by 38.7%. No cases of granuloma
inguinale were notified in 2002 or 2001. Notifications of
chancroid remained constant. The cumulative rate per
100,000 population for all notified STIs increased in 2002 to
267.3 per 100,000 population; compared to a rate of 247.7
per 100,000 in 2001. Annual trends for ano-genital warts,
non-specific urethritis, C. trachomatis, genital herpes simplex,
gonorrhoea, syphilis and infectious hepatitis B are presented
in figure 1.
Notified STIs by quarter, 2002
The total number of notified STIs in 2002 peaked during Q2
(table 2). Syphilis peaked during Q1 and ano-genital warts,
candidiasis, genital herpes simplex, gonorrhoea,
lymphogranuloma venereum, molluscum contagiosum and
trichomoniasis peaked during Q2 2002. Chancroid and non-
specific urethritis peaked during Q3 2002. C. trachomatis and
P. pubis reached their highest numbers for 2002 during Q4.
Infectious hepatitis B peaked during quarters 3 and 4 in 2002.
Notified STIs by health board, 2002
During 2002, 42.4% (4434) of all STI notifications were from
the ERHA, 16.4% (1721) from the MWHB, 15.4% (1617) from
the SHB, 11.0% (1147) from the WHB, 8.7% (906) from the
Table 1: Notified sexually transmitted infections for 2002 and 2001
Sexually Transmitted Infection  2002 2001 Increase  % Increase
Ano-Genital Warts 3932 3993 -61 -1.53
Candidiasis 1351 1150 201 17.48
Chancroid 1 1 0 0.00
Chlamydia Trachomatis 1922 1649 273 16.56
Genital Herpes Simplex 358 331 27 8.16
Gonorrhoea 214 349 -135 -38.68
Granuloma Inguinale 0 0 0 0.00
Infectious Hepatitis B 57 39 18 46.15
Lymphogranuloma Venereum 1 0 1 -
Molluscum Contagiosum 150 111 39 35.14
Non-Specific Urethritis 2025 1634 391 23.93
Pediculosis Pubis 84 103 -19 -18.45
Syphilis 303 279 24 8.60
Trichomoniasis 73 64 9 14.06
Total 10471 9703 768 7.92
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Figure 1: Number of notifications of ano-genital warts, non-specific urethritis, C. trachomatis, 
genital herpes simplex, gonorrhoea, syphilis & infectious hepatitis B, by year between 1989 
and 2002.
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SEHB, 6.1% (637) from the NWHB, 0.07% (7) from the MHB
and 0.02% (2) from the NEHB (table 3). It is important to
note that STI surveillance is mainly clinic based and there are
currently no STI clinics in the MHB and NEHB. The majority of
all notifiable STIs in 2002 were notified from the ERHA:
chancroid (n=1; 100.0%), lymphogranuloma venereum (n=1;
100.0%), syphilis (n=243; 80.2%), trichomoniasis (n=49;
67.1%), genital herpes simplex (n=220; 61.5%), gonorrhoea
(n=120; 56.1%), infectious hepatitis B (n=30; 52.6%),
molluscum contagiosum (n=72; 48.0%), C. trachomatis
(n=910; 47.4%), candidiasis (n=546; 40.4%), ano-genital
warts (n=1588; 40.4%) and P. pubis (n=24, 28.6%). The
majority of notifications of non-specific urethritis (n=691;
34.1%) in 2002 were from the MWHB. STI notifications have
increased in all health boards in 2002, compared to 2001,
with the exception of the ERHA, where notifications
decreased by 9.9%.
Notified STIs by age group and gender, 2002
Where the age group was known (n=6013, 57.4%), 12.2%
(736) of notified STIs were 0 to 19 years old, 61.3% (3683)
were 20 to 29, 18.3% (1099) were 30 to 39 and 8.2% (495)
were aged 40 years of age or older, in 2002. For all STIs, the
20-29 year age group represented the largest age group, with
the exception of syphilis and lymphogranuloma venereum
where the majority of cases were aged between 30 and 39
years of age (table 4).
Forty-eight percent (5066) of all notified STIs were amongst
males during 2002, whilst 50.6% (5298) were amongst
females (table 4). Gender data was not reported for 107
(1.0%) notifications. The majority of cases of
lymphogranuloma venereum (100.0%), syphilis (71.0%),
trichomoniasis (61.6%), non-specific urethritis (58.9%), P.
pubis (58.3%) and molluscum contagiosum (50.7%) were
amongst males. The majority of notifications of chancroid
(100.0%), infectious hepatitis B (68.4%), genital herpes
simplex (57.8%), gonorrhoea (57.0%), candidiasis (55.9%),
ano-genital warts (53.5%) and C. trachomatis (53.0%) were
amongst females.
STI notifications: disease-specific trends, 2002
Ano-genital warts
In 1989, 505 (14.3/100,000) ano-genital warts cases were
notified, increasing to 1066 (30.2/100,000) in 1992.
Notifications have increased each year since 1992, reaching
3993 (101.9/100,000) in 2001. In 2002 (n=3932),
notifications decreased slightly by 1.5%, compared to 2001.
From Q1 2001 to Q4 2002, notified cases of ano-genital
warts have remained stable, with a mean of 991 cases per
quarter. In 2002, males accounted for 44.8% of cases and
females for 53.5% of cases (gender was not reported for 1.7%
cases). Where the age group was known (in 55.2% of cases),
0-19 year olds accounted for 13.9% of cases, 65.6% of cases
were 20-29, 15.2% were 30-39 and 5.3% were aged 40 years
or older. Ano-genital warts accounted for the majority
(37.6%) of all STI notifications in 2002.
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Candidiasis
Between 1990 and 1997, the mean number of notified
candidiasis cases was 1293 per year, peaking in 1997 at 1521
cases (42.0/100,000). Notified cases decreased each year
between 1997 and 2000, reaching 1095 in 2000
(28.0/100,000). During 2001 & 2002, this decreasing trend
was reversed, with 1150 (29.4/100,000) and 1351
(34.5/100,000) candidiasis cases notified, respectively.
Candidiasis accounted for 12.9% of all STI notifications in
2002. In 2002, 34.5 candidiasis cases per 100,000 population
were notified, a decrease from the rate of 29.4 per 100,000 in
2001. During 2002, the number of male cases increased by
246.5% and the number of female cases decreased by 29.5%,
compared to 2001. In 2002, males accounted for 43.6% of
cases and females for 55.9% (gender was not reported for 7
cases). Where the age group was known (in 60.8% of cases) in
2002, 0-19 year olds accounted for 11.7% of cases, 20-29
year olds for 55.5%, 30-39 year olds for 20.6% and 12.2%
were aged 40 years or older.
Chancroid
One case of chancroid was notified during 2002, in Q3 2002.
With the exception of the year 2000 (when 16 cases were
notified), between 0 and 3 cases of chancroid were notified
each year between 1989 and 2002.
Chlamydia trachomatis
From 1989 to 1995, the number of notified cases of C.
trachomatis generally remained stable fluctuating around a
mean of 205 per year. In 1995 there was a marked increase of
84.2% on the previous year (from 133 cases, 3.7/100,000 to
245 cases, 6.8/100,000). Since 1995 there has been an
increasing number of cases reported each year reaching 1922
in 2002 (49.1/100,000). Notified cases have increased by
684.5% between 1995 and 2002 and by 16.6% between
2001 and 2002. During Q4 2002, 546 (13.9/100,000) cases of
C. trachomatis were notified, the highest number notified in
any one quarter on record. The number of male and female
notifications increased by 15.0% and 16.7%, respectively, in
2002, compared to 2001. Fifty-three percent of cases were
female and 45.8% were male (gender was not reported in 24
cases) in 2002. Where the age group was known (in only
49.2% of cases), 0-19 year olds accounted for 16.0% of cases,
20-29 year olds for 68.0%, 30-39 year olds for 12.8% and
3.2% were 40 years of age or older in 2002.
Genital herpes simplex
Genital herpes simplex notifications have been increasing
gradually since 1989, with 78 (2.2/100,000) cases notified in
1989 and 358 (9.1/100,000) in 2002. During 2002, there was
an increase of 8.2% in the number of notified cases,
compared to 2001. During 2002, the number of male cases
increased by 24.2% and the number of female cases increased
by 0.5%, when compared to 2001. In 2002, where the age
group was known (in 41.9% of cases), 0-19 year olds
accounted for 12.0% of cases, 20-29 year olds for 58.7%, 30-
39 year olds for 23.3% and 6.0% were 40 years of age or
older.
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Infectious Hepatitis B
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Table 2: Notified sexually transmitted infections by quarter from Q1 1999 to Q4 2002
Sexually Transmitted Infection 1999 2000 2001 2002
 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
  Ano-Genital Warts 762 905 671 711 953 952 832 998 1060 1025 974 934 1017 1027 939 949
 Candidiasis 269 263 273 300 317 262 272 244 222 282 347 299 324 383 311 333
 Chancroid 0 0 0 1 0 3 5 8 1 0 0 0 0 0 1 0
 Chlamydia Trachomatis 169 295 152 253 309 346 310 378 375 379 441 454 433 460 483 546
 Genital Herpes Simplex 94 53 38 90 75 50 74 70 97 73 72 89 84 103 90 81
 Gonorrhoea 21 55 59 40 54 50 96 90 86 100 89 74 48 60 59 47
 Granuloma Inguinale 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0
 Infectious Hepatitis B 2 0 0 0 0 0 5 10 7 10 9 13 10 13 17 17
 Lymphogranuloma Venereum 0 0 2 0 0 0 0 0 0 0 0 0 0 1 0 0
 Molluscum Contagiosum 23 29 10 21 33 37 21 27 35 38 19 19 34 49 40 27
 Non-Specific Urethritis 243 389 304 329 425 385 404 512 400 421 407 406 470 497 530 528
 Pediculosis Pubis 35 25 21 32 37 38 25 38 30 30 19 24 23 18 17 26
 Syphilis 2 1 1 2 2 7 21 16 49 72 87 71 85 64 82 72
 Trichomoniasis 10 15 9 13 18 15 27 18 15 11 16 22 13 31 14 15
 Total 1630 2030 1541 1792 2223 2145 2092 2409 2377 2441 2480 2405 2541 2706 2583 2641
Gonorrhoea
Two hundred and fourteen gonorrhoea cases were notified in
2002. The total number of gonorrhoea notifications decreased
by 38.7% in 2002, compared to 2001. During 2002, the
number of male cases decreased by 66.0% and the number of
female cases increased by 48.8%, when compared to 2001.
Where the age group was known (in 52.8%), 0-19 year olds
accounted for 11.5% of cases, 20-29 year olds for 60.2%, 30-
39 year olds for 17.7% and those aged 40 years or older for
10.6% of cases in 2002. Prior to the recent quarterly
decreases in gonorrhoea notifications (in Q4 2001 & in 2002),
reported notifications of gonorrhoea increased consistently
between 1996 and 2001, increasing from 83 (2.3/100,000) in
1996 to 349 (8.9/100,000) in 2001.
Granuloma Inguinale
No cases of granuloma inguinale were notified during 2002.
The number of cases of granuloma inguinale has ranged from
0 to 6 cases per year, between 1989 and 2002.
Infectious Hepatitis B
Between 1989 and 1999, infectious hepatitis B cases reported
through the STI quarterly notification system ranged from 0
to 4 cases per year. Between 1999 and 2000, there was a
650.0% increase in notifications, when 15 cases were notified
in the last 2 quarters of 2000. During 2001, this increase
continued with 39 cases reported, a 160.0% increase on 2000.
Fifty-seven cases were notified in 2002, the highest yearly
total on record, increasing by 46.2%, compared to 2001. The
number of male cases decreased by 40.0% in 2002, compared
to 2001. However, the number of female cases increased
dramatically by 333.3%. Thirty-two percent (31.6%) of cases
notified in 2002 were male and 68.4% were female. Where
the age group was known (in 56.1%), 6.3% of cases were
aged between 0 and 19 years, 20-29 year olds accounted for
53.1%, 28.1% were 30-39 year olds and 12.5% of cases were
aged 40 years or older in 2002.
Lymphogranuloma venereum
Only one case of lymphogranuloma venereum was notified
during 2002, in Q2 2002. The number of notified cases of
lymphogranuloma venereum ranged from 0 to 5 cases per
year, between 1989 and 2002.
Molluscum contagiosum
Notified cases of molluscum contagiosum have increased
gradually between 1989 and 2002, increasing from 31
(0.9/100,000) in 1989 to 150 (3.8/100,000) in 2002.
Following a slight decrease of 5.9% in 2001, notifications of
molluscum contagiosum increased by 35.1% in 2002,
compared to 2001. During 2002, 50.7% of cases were male
and 49.3% were female. Male cases increased by 11.8% in
2002, compared to 2001 and female cases increased by
72.1%. Where the age group was known (in 48.0% of cases),
0-19 year olds accounted for 13.9% of cases, 65.3% were 20-
29, 9.7% were 30-39 and 11.1% were aged 40 years or older
in 2002.
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Table 3: Notified sexually transmitted infections by health board for 2002
Sexually Transmitted Infection  ERHA  MHB  MWHB  NEHB  NWHB  SEHB  SHB  WHB  Total
 Ano-Genital Warts 1588 0 490 0 272 418 703 461 3932
 Candidiasis 546 0 195 1 84 74 182 269 1351
 Chancroid 1 0 0 0 0 0 0 0 1
 Chlamydia Trachomatis 910 1 237 0 49 170 333 222 1922
 Genital Herpes Simplex 220 0 23 0 6 22 48 39 358
 Gonorrhoea 120 0 34 0 5 20 16 19 214
 Granuloma Inguinale 0 0 0 0 0 0 0 0 0
 Infectious Hepatitis B 30 1 17 0 0 1 5 3 57
 Lymphogranuloma Venereum 1 0 0 0 0 0 0 0 1
 Molluscum Contagiosum 72 0 11 0 2 24 31 10 150
 Non-Specific Urethritis 630 0 691 0 205 158 251 90 2025
 Pediculosis Pubis 24 0 9 0 7 10 18 16 84
 Syphilis 243 5 8 1 5 7 20 14 303
 Trichomoniasis 49 0 6 0 2 2 10 4 73
 Total 4434 7 1721 2 637 906 1617 1147 10471
Non-specific urethritis 
Non-specific urethritis notifications fluctuated around a mean
of 640 per year between 1989 and 1994. Between 1994 and
2000 notifications increased steadily each year, from 610 in
1994 to 1726 in 2000, an increase of 183.0%. This steady
increase was followed by a slight dip in 2001 with
notifications decreasing by 5.3%, compared to 2000. This
decrease was reversed in 2002, with notifications increasing
by 23.9%, compared to 2001. During 2002, the number of
female cases increased by 125.8% and the number of male
cases decreased by 5.7%, compared to 2001. Where the age
group was known (in 66.5% of cases), 0-19 year olds
accounted for 9.4% of cases, 60.7% were 20-29, 20.9% were
30-39 and 9.0% were aged 40 years or older in 2002. Non-
specific urethritis accounted for 19.3% of all STI notifications
in 2002.
Pediculosis pubis
P. pubis notifications fluctuated around a mean of 72 cases
per year between 1989 and 1995. Following this, notifications
increased gradually between 1996 and 2000, with 79
(2.2/100,000) cases notified in 1996 and 138 (3.5/100,000)
cases in 2000. This increasing trend was reversed in 2001,
when 103 (2.6/100,000) cases were notified, the lowest
number notified since 1997. The decreasing trend was
continued in 2002, with 84 cases notified, a decrease of
18.5% compared to 2001. During 2002, male cases decreased
by 30.0%, however female cases increased by 12.9%,
compared to 2001. Where the age group was known in 2002
(in 65.5% of cases), 0-19 year olds accounted for 18.2% of
cases, 60.0% were 20-29, 16.4% were 30-39 and 5.5% were
aged 40 years or older.
Syphilis
The data reported in this paragraph refers to syphilis cases
notified through the quarterly STI notification system.
Enhanced syphilis data is detailed elsewhere in this report.
There was a dramatic increase in syphilis amongst men who
have sex with men (MSM) in Dublin beginning in early 2000.3,
4 This was against a low incidence of syphilis nationally
throughout the 1990s, which in 1999 reached its lowest level
in 10 years (6 cases, 0.2/100,000). Between Q2 and Q3 2000,
syphilis notifications increased significantly by 200.0% (from
7, 0.2/100,000 to 21, 0.5/100,000). A total of 46
(1.2/100,000) syphilis cases were notified through the STI
quarterly notification system in 2000, the highest number on
record prior to this. In 2001, 279 (7.1/100,000) syphilis cases
were notified, an increase of 506.5% compared to 2000,
peaking in Q3 2001. Three hundred and three syphilis cases
(7.7/100,000) were notified through the STI quarterly
notification system in 2002. Although, syphilis notifications
increased by 8.6% in 2002, compared to 2001, the steadily
increasing trend observed between Q4 2000 and Q3 2001,
did not continue in 2002, with an undulating pattern being
observed during 2002 (figure 1). During 2002, male cases
decreased by 6.5% and female cases increased by 85.1%,
compared to 2001. Where the age group was known (in
92.4% of cases), 2.1% of cases were aged between 0 and 19
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Table 4: Notified sexually transmitted infections by age group (years) & gender for 2002
Sexually Transmitted Infection  0-19  20-29  30-39  40+  Age unknown Male Female Gender unknown  Total
Ano-Genital Warts 302 1424 330 114 1762 1761 2103 68 3932
Candidiasis 96 456 169 100 530 589 755 7 1351
Chancroid 0 0 0 0 1 0 1 0 1
Chlamydia Trachomatis 151 643 121 30 977 880 1018 24 1922
Genital Herpes Simplex 18 88 35 9 208 149 207 2 358
Gonorrhoea 13 68 20 12 101 90 122 2 214
Granuloma Inguinale 0 0 0 0 0 0 0 0 0
Infectious Hepatitis B 2 17 9 4 25 18 39 0 57
Lymphogranuloma Venereum 0 0 1 0 0 1 0 0 1
Molluscum Contagiosum 10 47 7 8 78 76 74 0 150
Non-Specific Urethritis 127 818 281 121 678 1193 831 1 2025
Pediculosis Pubis 10 33 9 3 29 49 35 0 84
Syphilis 6 74 114 86 23 215 87 1 303
Trichomoniasis 1 15 3 8 46 45 26 2 73
Total 736 3683 1099 495 4458 5066 5298 107 10471
years, 26.4% were 20-29, 40.7% were 30-39 and 30.7% were
aged 40 years or older in 2002. The age group of syphilis cases
is markedly different to most other STIs notified, with the
majority of cases aged between 30 and 39 years of age.
Trichomoniasis
The mean number of trichomoniasis notifications reported per
year between 1989 and 2002 was 68, peaking in 1991 at 163
(4.6/100,000). During 2002, 73 (1.9/100,000) cases were
notified, an increase of 14.1% compared to 2001 when 64
(1.6/100,000) cases were notified. In 2002, male
trichomoniasis notifications increased dramatically by 221.4%,
however female cases decreased by 46.9%, compared to
2001. Where the age group was known (in 37.0% of cases),
3.7% of cases were aged between 0 and 19 years, 55.6% were
20-29, 11.1% were 30-39 and 29.6% were 40 years of age or
older in 2002.
Enhanced surveillance of syphilis (January 2000 to
December 2003, provisional data)
A total of 874 syphilis cases have been reported to NDSC
through the syphilis enhanced surveillance system between
January 2000 and December 2003, peaking in 2001. Of the
total 874 cases reported, 88.7% (775) have been reported
from the ERHA. Sixty-eight percent of the 874 cases were
early (infectious)*syphilis and 32% were late† syphilis cases.
Seventy-two percent of cases were male and 27.8% were
female. The mean age for male and female cases was 36.0 and
29.7 years, respectively. Fifty-nine percent of all syphilis cases
were amongst MSM: 416 were homosexual and 53 were
bisexual. Forty-one percent of cases were heterosexual: 137
male and 194 female. One hundred and forty-four (16.5%)
syphilis cases were HIV positive, 93 of these cases were early
(infectious) syphilis cases and 44 were late syphilis cases. Four
percent of cases were newly diagnosed HIV cases. Twenty-two
percent of early (infectious) syphilis cases had one or more
concurrent STI (excluding HIV). Over, 2% of infectious syphilis
cases had two or more concurrent STIs. One hundred female
cases were identified through antenatal screening, 67.0%
were late syphilis cases, 23.0% were early syphilis cases and
10.0% were of unknown syphilis stage. Seventy-nine cases
identified through antenatal screening were non-nationals,
seven were Irish nationals and 14 were of unknown
nationality. Five of these cases were HIV positive. Six
congenital syphilis cases have been reported to NDSC since
January 2000.
*Early (infectious) syphilis cases refer to primary, secondary and
early latent syphilis cases.
†Late syphilis cases refer to late latent and tertiary syphilis cases
Discussion
The increase in STIs in Ireland during 2002 is likely to be
associated with an increase in unsafe sexual behaviour.
Anecdotal evidence also suggests that improved acceptability
of STI clinic services, greater public and professional
awareness of STIs and improvements in diagnostic tests have
contributed to the increases in identification and reporting 
of STIs.
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Figure 2: Early (infectious) syphilis cases by sexual orientation and quarter and year of diagnosis, as reported through the syphilis enhanced surveillance system. Please note that 2003 
data is provisional and incomplete. 
Homosexual Bisexual Heterosexual
Recently concern has been raised over a resurgence of STIs,
particularly amongst MSM. There was a dramatic increase in
syphilis amongst MSM in Dublin during 2000. This was against
a low incidence of syphilis throughout the 1990s. Syphilis, like
other genital ulcer diseases, increases the risk of transmitting
and acquiring HIV. In response to this increase in syphilis the
Director of Public Health in the ERHA established an outbreak
control team in October 2000. The outbreak amongst MSM in
Dublin peaked in Q3 2001 and there now remains a high level
of endemicity.
3, 4 
The increase observed in female syphilis
cases during 2002 was partly due to cases identified through
antenatal screening, as reported through the syphilis
enhanced surveillance system. The peak in gonorrhoea
notifications observed in 2001, coincided with the outbreak of
syphilis amongst MSM. Gonococcal infections tend to be
concentrated in core risk groups, such as MSM. During 2002,
the decrease in gonorrhoea notifications observed, particularly
amongst men, coincided with the decrease in reported
syphilis cases amongst MSM. Gonorrhoea and syphilis co-
infections were reported through the syphilis enhanced
surveillance system, during the syphilis outbreak. The
decreases in gonorrhoea and syphilis notifications in male
cases in 2002 may have resulted from the interventions put in
place to control the syphilis outbreak.
The true rates of chlamydial infections are likely to be higher
than those presented in this report, due to the pool of
undiagnosed asymptomatic infection. Increased testing for
chlamydial infection and the availability of sensitive and
specific tests using nucleic acid amplification may also have
influenced the increase in C. trachomatis notifications.
The dramatic increase in infectious hepatitis B notifications
since 1999 may reflect the introduction of screening
programmes. Asylum seekers currently undergo voluntary
health screening, which includes testing for hepatitis B
infection. The high proportion of female cases notified may
also be a result of antenatal screening of pregnant women in
some maternity hospitals.5 Information currently reported on
hepatitis B is inadequate. More detailed information (including
risk factor details) gathered through enhanced surveillance is
necessary to monitor and inform prevention and control
strategies and to plan services.
STI surveillance is mainly clinic-based, although some
notifications also come from primary care. The health board
data presented in this report represent the proportion of STIs
notified by each health board and do not necessarily reflect
cases among residents of a particular health board area.
People may travel from their area of residence to STI clinics
outside their area, for example, there are no STI clinics in the
MHB or NEHB and this is reflected in the very small numbers
of STIs reported from these health boards. The decrease in
reported cases from the ERHA may not represent an actual
decline in incidence or diagnosis of STIs in the ERHA but may
reflect incomplete reporting as people may be opting to
attend local services e.g. General Practitioners and cases may
not be reported. Modern STI control and policy-making
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requires behaviourally and geographically targeted
interventions. STI surveillance systems should collect data
from all sites where STIs are identified including general
practice and should include a range of behavioural,
geographical, clinical and microbiological information. A
subcommittee of the Scientific Advisory Committee of NDSC
is currently undertaking a review of STI surveillance in Ireland
and will make recommendations in this regard. 1, 2
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Information and 
Communications Technology 
and Website
NDSC’s information and communication technology activities
continued to grow in 2003. IT staff are responsible for the
management, purchase and support of the following systems
and functions:
• information security
• network systems and infrastructure
• NDSC website
• e-mail system
• telephone system and fax machines
• mobile phones
• mobile computing equipment
• building access control system
• security system
Additional IT systems deployed in 2003 include:
• Blackberry wireless email devices
• Visiontime flexitime software
• monitoring and logging system for internet traffic
• connection to the Government Virtual Private
Network (VPN)
• infrastructure for the CIDR system
Information Governance
During 2003 the NDSC Board agreed funding for the
organisation to work towards attaining certification to the
Information Security standard IS17799/BS7799. The decision
was taken due to the continuing growth of NDSC, increasing
volumes of data and information held by NDSC, and
requirements of the Computerised Infectious Disease
Reporting (CIDR) system.
The standard is very broad based and requires an organisation
to address all aspects of security including physical access to
its facilities, document handling and storage, secure
communication in all formats and security of IT systems.
To comply with the standard NDSC must show that it has
appropriate policies, procedures and equipment in place to
protect its information resources. One of NDSC’s core
activities is the exchange of medical information with partner
organisations. It is therefore vital that NDSC ensures the data
it holds on behalf of others is stored, processed and
transmitted securely.
The National Disease Surveillance Centre became the first
public body in Ireland to be awarded an IS 17799 certificate
for information security in April 2004.
Website
The NDSC website (www.ndsc.ie) continues to be one of the
most important communications tools available to NDSC. A
wide range of information is published on the web site,
including electronic versions of all reports produced by the
NDSC, weekly and annual infectious disease statistics, disease
specific fact sheets, press releases and other general
information.
The level of use of the site increased significantly during the
year. In the last quarter of 2002 the average number of logons
to the site per day was 575 compared with 789 users per day
in the last quarter 2003.
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Key Points
• There was increased measles activity in 2003
• The crude incidence rate of measles per 100,000
population in 2003 was 14.6 compared to 6.2 in 2002
• Ireland has a high measles incidence rate compared to
many other developed countries
• Ireland needs to develop and implement a measles
elimination plan to meet the WHO target of 2010 as the
year for achieving measles elimination in the WHO
European Region
Introduction
Measles is an acute viral infectious disease. The onset of
illness is characterised by high fever, cough, coryza (runny
nose) and conjunctivitis. Approximately two to four days
after onset of illness a rash appears and usually lasts four to
seven days. Complications of measles can occur and include
pneumonia, otitis media and encephalitis. Measles results in
death in approximately one to two cases per 1000 population.
In Ireland three measles deaths were reported during 2000.
Two of these deaths were as a result of pneumonia
complicating measles and one was due to post-measles
encephalitis.
Measles is a highly contagious disease but can be prevented
by vaccination. Measles vaccine in Ireland is currently
available as part of the combined measles-mumps-rubella
(MMR) vaccine. Two doses of MMR are recommended as
approximately two to five percent of children who receive
only one dose fail to respond to it. More than 99% of
individuals who receive two MMR doses (provided the first
dose is given after their first birthday) develop immunity to
measles. In Ireland, vaccination with the first dose of MMR is
recommended at twelve to fifteen months and the second
dose at four to five years.
Measles is a notifiable disease in Ireland and since 2000 is
notified weekly to NDSC. During 2003 measles notifications
more than doubled compared to annual figures for 2001 and
2002.
Materials and methods
Measles data, obtained through the weekly infectious disease
Measles, 2003
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notification system, for 2003 are presented in this report. A
dataset, including identification number, date of birth, age,
sex, date of onset, date of notification/week of notification,
Community Care Area and county, is routinely collected
through the weekly notification system for each case. In
addition, for a number of measles cases in 2003, enhanced
details such as information on vaccination status, laboratory
results and hospitalisation status were reported.
Analysis of measles data was carried out using Microsoft
Access and Excel. Incidence rates were calculated based on
population data taken from the 2002 census.
Results
Incidence
A total of 572 measles cases were notified during 2003 in
Ireland, giving a crude incidence rate of 14.6 per 100,000
population. This rate is more than double the crude incidence
rate of 6.2 per 100,000 population in 2002. The breakdown
of measles cases by health board and the crude incidence
rates by health board during 2002 and 2003 are presented in
table 1. In 2003, the highest numbers of cases were notified
in the ERHA (n=363, 63%) and the MHB (n=123, 22%)
followed by the WHB (n=35, 6%). Compared to 2002 there
was a 6.8 fold increase in measles notifications in the MHB
and a 3.5 fold increase in notifications in the ERHA. The
highest crude incidence rate in 2003 was in the MHB
(54.6/100,000) followed by the ERHA (25.9/100,000) and the
WHB (9.2/100,000).
Sex and age distribution
A breakdown of measles cases by age group and the age
specific incidence rates of measles cases per 100,000
population in 2002 and 2003 are presented in table 2.
Measles cases were reported in both children and adults in
2003. The highest number of cases (n=207, 36%) in 2003
was in the age group 1-2 years while the highest incidence
rates were in the age groups <1 year (200.0/100,000) and 1-2
years (185.3/100,000). Compared to 2002, the largest
increase was seen in the age group five to nine years. Of the
572 measles notifications, 283 were male, 282 were female
while sex was not reported for seven cases.
Seasonality
Measles cases by week of notification are shown in figure 1.
An increase in measles notifications commenced in late
November 2002 (Week 48 2002) peaking in the last week of
January 2003 (Week 5 2003) with 45 cases reported
nationally. It was late July (Week 31 2003) before weekly
measles notifications had dropped to five cases or fewer for
two consecutive weeks. From late November to late July
(Weeks 48 2002-31 2003) 563 measles cases were notified.
The majority of these cases were notified in the ERHA
(n=355, 63%) and MHB (n=127, 23%) followed by the WHB
(n=34, 6%).
Laboratory data
Laboratory results were provided to NDSC for 114 (114/572,
20%) measles notifications. Of these 114 cases, 111 were
reported as laboratory positive while three were negative for
measles. In addition, 69 (69/572, 12%) measles notifications
Table 1.  Numbers of measles notifications and crude incidence rates (CIR) per 
100,000  population by health board in 2002 and 2003 
Health board                      2002                  2003
 Number CIR Number CIR
ERHA 105 7.5 363 25.9
MHB 18 8.0 123 54.6
MWHB 10 2.9 24 7.1
NEHB 41 11.9 15 4.3
NWHB 1 0.5 1 0.5
SEHB 14 3.3 6 1.4
SHB 18 3.1 5 0.9
WHB 36 9.5 35 9.2
Total 243 6.2 572 14.6
Table 2.  Number of measles notifications and rate per 100,000  population by 
age group in 2002 and 2003
Age group (years)        2002                  2003
 Number      Rate Number    Rate
<1 67 123.0 109 200.0
1-2 85 76.1 207 185.3
3-4 27 24.2 61 54.7
5-9 30 11.4 107 40.5
10-14 21 7.4 60 21.0
15-19 5 1.6 6 1.9
20-24 4 1.2 13 4.0
25+ 3 0.1 0 0.0
Unknown 1 - 9 -
Total 243 6.2 572 14.6
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had specimens sent for laboratory testing but the results were
not reported to NDSC.
As measles vaccine induces a positive measles IgM response a
positive IgM test cannot be used to confirm the diagnosis of
measles in individuals who received measles vaccine six to 45
days before rash onset. Of the 111 laboratory positive
measles cases reported 29 had received at least one dose of
vaccine (table 3). The date of vaccination in relation to onset
of disease was not provided for 21 of these cases. Of the
remaining eight cases, six were vaccinated (MMR1) six years
or greater prior to onset while two were vaccinated just
preceding onset (indicating that these two cases were already
incubating measles at the time of vaccination).
Saliva specimens for laboratory testing should be taken
between one and five weeks following the appearance of the
rash. Of the three laboratory negative measles cases, two had
saliva specimens sent for laboratory testing. One of these
negative saliva specimens was taken on the day of rash onset
and, therefore, may be a false negative result. For the second
negative saliva specimen the specimen was taken at an
appropriate time (nearly one month after onset of rash).
Vaccination data
Of the 300 cases where vaccination status was known, 61%
(182/300) were unvaccinated; 82% (149/182) of those
unvaccinated were aged greater than or equal to one year and
therefore, were potentially eligible for vaccination with MMR1
(assuming there were no contraindications to vaccination).
Fifteen percent (45/300) of cases were vaccinated with MMR1
only. Fifty-eight percent (26/45) of these cases were aged
greater than five years and therefore were not age
appropriately vaccinated. Sixteen of the cases vaccinated
with MMR1 were known to have received the vaccine less
than 18 days prior to onset suggesting the possibility they
were already incubating measles at the time of vaccination.
For six cases the date of vaccination in relation to disease
onset was not reported. An additional 66 cases were known
to have received at least one dose of MMR, however, cases
may have received two doses.
Seven cases received MMR2, however, it is important to note
that none of these cases were reported as laboratory
confirmed (table 3). Of the seven cases who received MMR2,
five received MMR2 less than or equal to 14 days prior to
onset of illness while the vaccination date was not reported
for one case. Therefore, none of these seven cases are known
to be or can be classified as vaccine failures based on the data
provided.
Hospitalisation data and complications of measles
Information on hospitalisation status was available for 120
notifications (120/572, 21%). Twelve cases were hospitalised
representing 10% (12/120) of all cases with known
hospitalisation status (table 4). The hospitalised cases were
aged between 10 months and 22 years (mean age, 8 years;
median age, 4 years). Seven of the hospitalised cases were
unvaccinated, six of these were aged greater than 12 months
and, therefore, were potentially eligible for vaccination. Three
had received MMR1 only (2 of these received MMR1 less than
18 days prior to onset of illness), one of these was aged
greater than five years and therefore was not age
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appropriately vaccinated. Vaccination status was not provided
for two cases. Laboratory results were reported to NDSC for
seven of the hospitalised cases, all seven cases were
laboratory confirmed.
Information on measles complications was reported for 10%
(57/572) of cases. Six cases were reported to have a lower
respiratory tract infection while ear infection was reported as
a complication for two cases. No deaths were reported
among the 572 measles notifications.
Discussion
In Ireland, despite the dramatic reduction in measles cases
following the introduction of a measles vaccine in 1985 and
MMR in 1988, measles continues to be a problem with
recurrent outbreaks. Measles outbreaks occurred in 1993 and
2000 with 4328 and 1603 cases notified, respectively.
Measles activity increased again in 2003 with a total of 572
measles cases notified, representing an increase of 135%
compared to 2002. Since the national collation of cohort
based immunisation uptake data commenced in Ireland in
Quarter 1 1999, MMR1 uptake at 24 months has never
reached the WHO target of 95%.1 While the uptake of MMR
remains below the target of 95% required to prevent the
spread of measles outbreaks will continue to occur.
Ireland has a high incidence of measles compared to a
number of other European countries. In 2002, the incidence
of measles in Ireland ranked us seventh highest among 42
regions reporting to WHO Europe.2 The incidence of measles
in Ireland increased in 2003 compared to 2002. In Quarter 1
2003 the incidence of measles in Ireland was the highest
compared to 40 regions reporting to WHO Europe.3
Many countries, including Australia, USA and some European
countries, have implemented measles control strategies with
the aim of eliminating measles. The plan to eliminate
measles in Australia began in 1998 with the Measles Control
Campaign. In Australia, 31 confirmed measles cases were
reported during 2002 giving an incidence rate of 0.2 cases per
100,000 population, the lowest annual rate for Australia since
national surveillance began in 1991.4 In the USA measles
cases have declined since 1993, following elimination efforts,
with a record low of 44 confirmed measles cases in 2002.5
Finland has succeeded in eliminating measles while other
European countries have reported incidence rates of less than
0.1/100,000 indicating they are nearing elimination.6,7
The WHO has targeted 2010 for measles elimination in the
WHO European Region. In order to interrupt indigenous
measles transmission by 2010 and achieve measles
elimination Ireland needs to establish a national plan for
elimination with particular emphasis on improving MMR
uptake rates. Strengthening of measles surveillance in Ireland
is also important, as surveillance is a critical component in the
control and elimination of measles. Measles surveillance is
required to detect cases and to understand the reasons for
the occurrence of the disease so that appropriate and timely
control measures can be implemented. Surveillance also
detects trends and risk factors thereby guiding and monitoring
the effectiveness of control and elimination efforts. One of
the limitations of measles surveillance data provided to NDSC
in 2003 was despite receiving enhanced data on a number of
cases this data was often incomplete. For example, for a
Table 4.  Number of measles cases notified in Ireland by age group and hospitalisation status during 2003       
Age group (years)  Hospitalisation status                    Total
 Hospitalised Not hospitalised Not reported
<1 1 14 94 109
1-2 5 27 175 207
3-4 0 13 48 61
5-9 3 30 74 107
10-14 0 22 38 60
15-19 0 1 5 6
20-24 3 1 9 13
25+ 0 0 0 0
Unknown 0 0 9 9
Total 12 108 452 572   
Table 3.  Laboratory result and vaccination status of measles notifications in Ireland during 2003
Vaccination status  Laboratory Result                    Total
 Positive     Negative Not tested/unknown
MMR1* 29 † 0  82 111 ‡
MMR2§ 0 1  6 7 §
Nil 54 0  128 182
Not Reported 28 2 || 242 272
Total 111 3  458 572
*66 cases known to have at least one dose of MMR, cases may have received two doses     
†21 cases date of vaccination in relation to disease onset not provided, 2 cases vaccinated just preceding onset     
‡68 cases date of vaccination in relation to disease onset not provided, 19 cases were known to be vaccinated <18 days prior to onset     
§5 cases known to be vaccinated <=14 days prior to onset, 1 case vaccination date not provided     
||1 possible false negative as saliva specimen taken on day of rash onset     
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number of cases, where vaccination status was provided, the
date of vaccination in relation to disease onset was not
reported making interpretation of the vaccination data
difficult. Incomplete surveillance data poses problems during
analysis and interpretation. As measles surveillance and data
quality are improved so to will the ability to control and
prevent measles cases thereby aiding elimination.
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The aim of the European Sero-Epidemiology Network 2
(ESEN2) is to co-ordinate and harmonise the serological
surveillance of immunity to communicable disease across
Europe. The ESEN2 network focuses on eight vaccine
preventable diseases in particular: measles, mumps, rubella,
pertussis, diphtheria, varicella zoster, hepatitis A and hepatitis
B. The network expanded in 2003 to include 6 new applicant
states, bringing to 22 the total number of countries
participating in the network (figure 1).
In order to accurately compare results from serological
surveillance across participating countries, each country
tested a set of agreed standards supplied by reference
laboratories throughout Europe. A first round of testing for
these standards was completed in 2003 by the National Virus
Reference Laboratory (NVRL). These standards will be retested
upon completion of the project. In collaboration with the
NDSC and the NVRL, laboratories from six health boards /
authorities completed the collection of samples for the ESEN2
study in 2003. Testing of these samples began in 2003. Key
information on the history and development of vaccination
programmes throughout Europe, collected in 2002 by ESEN2
participants, will be central in analysing the results generated
from this study. This will provide valuable information on the
level of immunity in the Irish population to these serious
preventable diseases as well as aiding in decision and policy
making in Ireland.
Testing for the measles, mumps, rubella, varicella zoster,
hepatitis A and hepatitis B work-packages is being carried out
at the National Virus Reference Laboratory, Dublin while
testing for the diphtheria and pertussis work-packages is
being carried out at the Communicable Disease Surveillance
Centre, Colindale, London. The ESEN2 project is due to be
completed in 2004.
European Sero-Epidemiology
Network 2 (ESEN 2)
Figure 1. Countries participating in ESEN2: Belgium, Bulgaria, Cyprus, Czech Republic, 
Finland, Germany, Greece, Hungary, Ireland, Israel (not shown), Italy, Latvia, Lithuania, 
Luxembourg, Netherlands, Malta, Romania, Slovakia, Slovenia, Spain, Sweden, 
United Kingdom
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Viral Hepatitis, 2003
Key Points
• Viral hepatitis - type A continued to occur at very low
levels, with 25 cases notified in 2003
• There were 547 cases of viral hepatitis - type B notified
in 2003, this was an increase of 19% compared to the
previous year. Little information is currently available
on risk groups and sources of infection
• Most of the notifications made under the category of
viral hepatitis-type unspecified were due to hepatitis C.
Hepatitis C was not a notifiable disease in its own right
in 2003. It has been made notifiable in an amendment
to the Infectious Diseases Regulations implemented on
January 1 2004 and it is hoped that this will improve
the surveillance data available on hepatitis C in Ireland
in the future
• Work is progressing on a national database for people
infected though blood and blood products. It is hoped
that this will provide useful information on hepatitis C
infection in this group of people
Viral hepatitis - type A
Introduction
Hepatitis A virus causes an acute, self-limiting disease. It is
transmitted via the faecal-oral route, and is most common in
areas of the world with poor sanitation. The clinical severity of
hepatitis A infection increases with age. Childhood infection is
usually quite mild, the majority of children under 5 years
showing no symptoms, but people infected as adults can
suffer severe and prolonged illness. Hospitalisation and
mortality rates also increase with age.1 Hepatitis A is
preventable by vaccine. Currently in Ireland vaccination is
recommended for people in certain high risk groups such as
close contacts of known cases, travellers to high endemicity
countries, patients with chronic liver disease and those at
occupational risk.2
Materials and methods
Hepatitis A is a notifiable disease under the Infectious
Diseases Regulations 1981. Aggregate data on notifications
are available from 1982 and disaggregate data (including age
and sex) since mid-2000.
Results
There were 25 cases of hepatitis A notified in 2003 (figure 1),
giving an incidence rate of 0.6 cases/100,000 population. The
incidence rates varied between health boards, from no cases
in the NWHB to 1.8 cases/100,000 in the MHB (figure 2).
The majority of cases of hepatitis A notified in 2003 were
male (n=16). This was in contrast to 2002 when most cases
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were female. The mean age of cases was 26 years (ranging
from <1 year to 91 years).
Discussion
Hepatitis A continued to occur at a low rate in 2003, with less
than one case notified per 100,000 population. However, the
incidence of hepatitis can vary greatly from year to year
(figure 1). Hepatitis A has the potential to cause large scale
community outbreaks in susceptible populations. While
foodborne outbreaks continue to occur3, 4 outbreaks of
hepatitis A are also being described in risk groups such as men
who have sex with men (MSMs)
5, 6 
and injecting drug users
(IDUs).7 The burden of illness associated with hepatitis A can
be high, especially those infected as adults.
Risk factor information is not collected at a national level in
Ireland. More detailed information, including risk factor
details, is required to monitor and inform prevention and
control strategies and to plan services.
Viral hepatitis – type B
Introduction
Hepatitis B virus is spread via infected body fluids including
blood. Only a small proportion of acute hepatitis B cases
(10% children and 30-50% of adults) develop clinical
symptoms. Chronic infection can occur and is associated with
an increased risk of developing chronic liver disease and liver
cancer. The proportion of cases who develop chronic infection
decreases with age at infection, from 90% of babies infected
at birth to around 10% of people infected as adults.1 In
Ireland hepatitis B infection is known to be prevalent in
certain populations such as IDUs,8 prisoners,9 and immigrants
from high endemicity countries.10, 11 A vaccine is available for
the prevention of hepatitis B infection. Currently
immunisation is recommended for individuals who are at
increased risk of infection because of their occupation,
lifestyle or other factors.2
Materials and methods
The Infectious Diseases Regulations 1981 specify hepatitis B
as a notifiable disease. Up to the end of 2003 no case
definitions existed for any of the notifiable diseases, and there
was therefore no requirement in the notification process to
distinguish between cases of acute and chronic hepatitis B. An
amendment to the regulations implemented on 1st January
2004 (S.I. 707 of 2003) introduced case definitions and
differentiated between notifications of acute hepatitis B and
chronic hepatitis B for the first time. In addition, laboratory
directors are now required to report cases of notifiable
diseases they identify.
The National Virus Reference Laboratory (NVRL) provided
data on the number of new hepatitis B surface antigen
(HBsAg) positive samples identified by them between 1990
and 2003.
Results
The increase in hepatitis B notifications seen in recent years
continued in 2003, with a total of 547 cases being notified
(figure 3). In 2003 for the first time there were fewer new
HBsAg positive samples identified by the NVRL than clinical
notifications made. The national notification rate was
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14/100,000 population, with the highest rates being reported
by the SHB (figure 4).
There were slightly more female than male cases notified
(259 male, 275 female). The mean age of cases was 29 years
(ranging from <1 year to 58 years). Just over half (52%) of all
notified cases were between the ages of 25 and 34 years. The
largest increases compared to 2002 occurred in the 15-19
year and 25-34 year age groups (table 1).
In addition to these notifications, it is likely that some
hepatitis B cases in 2003 will have been notified as sexually
transmitted infections (STIs). STIs are notified separately to
the weekly notifications, in aggregate form on a quarterly
basis. Unfortunately the STI reporting system is not as timely
as the weekly notification system and the hepatitis B STI data
for 2003 are not currently available. While the cases of
hepatitis B notified through this system may be duplicates of
cases reported through the weekly notification system, it is
more likely that they are new cases as they would have been
identified through a different route (i.e. identified in STI
clinics). The number of cases of hepatitis B notified through
this system has increased in recent years. 12
Discussion
Although Ireland is considered a low endemicity country,
hepatitis B notifications have increased substantially in recent
years. This increase may reflect the introduction of screening
programmes or it may reflect improved notification. Many of
the notified cases are likely to be chronically infected asylum
seekers. Asylum seekers currently undergo voluntary health
screening, which includes testing for hepatitis B infection. The
high proportion of female cases notified might also be a result
of antenatal screening of pregnant women which now takes
place routinely in many maternity hospitals, although it has
not been implemented as a national programme.
Information on hepatitis B in Ireland is poor. Prior to the
introduction of the amendment to the Infectious Diseases
Regulations on 1 January 2004, the only data routinely
available were those from clinical notifications. Surveillance
data should improve now with the requirement on
laboratories to notify and with the introduction of case
definitions. However, this will not provide risk factor
information. This information is essential in order to identify
risk groups and sources of infection. It is impossible to plan or
evaluate prevention and control activities without having this
information. This can only be achieved by the introduction of
an enhanced surveillance system for all cases of acute and
chronic hepatitis B throughout the country. There is also a
need for ongoing seroprevalence surveys to track the
epidemiology of hepatitis B in Ireland.
In 1992 the WHO recommended that hepatitis B vaccine
should be integrated into national immunisation programmes
of all countries by 1997. In Ireland the current guideline
recommends hepatitis B vaccination for high groups only.2
Until better information is available on the epidemiology of
hepatitis B in Ireland it is not possible to accurately assess
whether universal childhood hepatitis B vaccination should be
introduced.
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Figure 3. Number of cases of hepatitis B notified to health boards, and HBsAg positive samples identified by the NVRL, 1990-2003. 
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Viral hepatitis-type unspecified
Introduction
Up to the end of 2003 the third category of viral hepatitis
notifiable under Infectious Diseases Regulations 1981 was
“viral hepatitis, type unspecified”. Most cases notified under
this category in recent years are likely to have been hepatitis
C. Hepatitis C is spread via infected body fluids. Initial
infection is mainly asymptomatic (around 90% of cases).
However, between 50% and 80% of cases go on to develop
chronic infection.1 It is likely that approximately half of
chronically infected people eventually develop cirrhosis or
liver cancer. There is no vaccine currently available for the
prevention of hepatitis C.
Materials and methods
Hepatitis C was made a notifiable disease by the Infectious
Diseases Regulations amendment introduced on the 1 January
2004 (S.I. 707 of 2003). Previously hepatitis C could have
been notified under the category “viral hepatitis, type
unspecified”, but was not a notifiable disease in its own right.
Since the NDSC started collecting disaggregate data in mid-
2000, many of the notifications of viral hepatitis type
unspecified have included information on the cause of the
hepatitis, most of these being hepatitis C.
Results
There were 85 cases of unspecified viral hepatitis notified in
2003. This was slightly fewer than the number notified in
2002 (n=89). Ninety one percent of the viral hepatitis, type
unspecified notifications in 2003 were identified as hepatitis
C. There was one case of hepatitis E notified in 2003.
The notification rate of viral hepatitis type unspecified in
2003 was 2.2 cases/100,000 population. Although the SEHB
continued to have the highest rate of viral hepatitis type
unspecified, its rate had decreased compared to previous years
(figure 5).
Age and sex were reported for most cases (96% and 93%
respectively). There were more male than female cases
notified (49 male, 30 female). The mean age of cases was 32
years (ranging from 17 years to 62 years). The age specific
rates of notified cases can be seen in table 2.
Discussion
Up to now there has been little routine information available
on hepatitis C in Ireland. With the introduction of the
amendment to the Infectious Diseases Regulations on 1
January 2004 the specification of hepatitis C as a notifiable
disease and the introduction of laboratory reporting should
greatly improve the quality of routine information on
hepatitis C. Enhanced surveillance is also needed to enable
identification of risk factors, and this information could be
used to monitor and inform prevention and control strategies
and to plan services.
National hepatitis C database
The Consultative Council on Hepatitis C commissioned a
review of health services available for people infected with
hepatitis C through the administration in this state of blood
Table 1. Notified cases of hepatitis B, number and notification rate/100,000 
population by age group, 2002 and 2003
 2002 2003
Age group (years) Number  Rate/100,000  Number  Rate/100,000
0-4 6 2.2 8 2.9
5-9 4 1.5 4 1.5
10-14 5 1.8 12 4.2
15-19 23 7.3 43 13.7
20-24 65 19.8 69 21.0
25-34 241 39.0 282 45.7
35-44 88 15.6 84 14.9
45-54 14 2.9 26 5.4
55-64 2 0.6 8 2.3
65+ 0 0 0 0
Total* 458 11.7 547 14.0
* Total includes cases of unknown age
Table 2. Notified cases of viral hepatitis type unspecified, number and notification 
rate/100,000 population by age group, 2002 and 2003
 2002 2003
Age group (years) Number  Rate/100,000  Number  Rate/100,000
0-4 4 1.4 0 0.0
5-9 1 0.4 0 0.0
10-14 0 0.0 0 0.0
15-19 2 0.6 2 0.6
20-24 15 4.6 19 5.8
25-34 36 5.8 36 5.8
35-44 17 3.0 18 3.2
45-54 8 1.7 6 1.2
55-64 3 0.9 2 0.6
65+ 3 0.7 0 0.0
Total* 89 2.3 85 2.2
* Total includes cases of unknown age
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and blood products. One of the recommendations of the
review was that a national database of people infected with
hepatitis C through the administration of blood or blood
products within the state be established for research purposes
at an independent coordinating agency and run in association
with relevant groupings.13 There was consensus that a unique
opportunity exists for internationally significant research
which can inform both treatment and understanding of the
nature of the hepatitis C process, and there was agreement
that hepatitis C research in Ireland would be greatly advanced
by the availability of a national database of those affected by
the virus.
The NDSC was asked to set up this database, and the
preparatory work was started in 2002 and continued in 2003.
The objectives of the database are:
• To follow the natural history of infection in this group of
people
• To evaluate the impact of various host factors on the
progression of the disease 
• To evaluate the outcomes of treatment
• To monitor the uptake of services
• To provide information for the planning and evaluation of
health services.
• To serve as a resource for future research into hepatitis C
Any person who has contracted hepatitis C infection through
the administration of blood or blood products within the
State is eligible to be included in the database. For the
purpose of this database, hepatitis C infection is defined as
the detection of HCV specific antibodies or the detection of
HCV nucleic acid. It is estimated that about 1,600 persons
have been infected with hepatitis C through the
administration of blood and blood products in Ireland. These
include women infected through anti-D immune globulin,
persons with haemophilia, recipients of blood transfusion and
persons who received treatment for renal disease.
The source of the information for the database will be the
medical records of patients who have attended any of the
eight designated hepatology units (Beaumont Hospital, the
Mater Misericordiae University Hospital, St Vincent’s
University Hospital, St James’s Hospital and Our Lady’s
Hospital for Sick Children in Dublin, St Luke’s General Hospital
in Kilkenny, Cork University Hospital and University Hospital,
Galway). Patients will only be included on the database if they
give their consent. The database will not contain names or
addresses; initials and dates of birth will be collected to allow
for identification of duplicates. Ethical approval for the
database has been received from the ethics committees of
the eight hospitals.
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Figure 5. Rate of notifications of viral hepatitis type unspecified per 100,000 population by health board, 2001-2003
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Key Points 
• Severe Acute Respiratory Syndrome (SARS) is considered
to be the “first severe and readily transmissible new
disease to emerge in the twenty first century”
• SARS placed unprecedented demands on public health
systems challenging their capacity for surveillance,
outbreak containment, infection control and information
management at global, national and regional level
• SARS is less infectious but more virulent than most
acute respiratory infections e.g. influenza
• The overall global case fatality from SARS was
approximately 9.6% but was higher in older age groups
(50% if aged over 65 years)
• In Ireland, one probable case of SARS (who was infected
overseas) was notified
• Globally, 21% of documented SARS cases occurred in
health care workers 
Introduction 
Severe Acute Respiratory Syndrome (SARS) is considered to be
the “first severe and readily transmissible new disease to
emerge in the twenty first century”.1 Between March and July
2003, over 8,000 probable cases of SARS and 900 deaths from
SARS were reported in approximately 30 countries. The main
countries affected by the SARS outbreak were China,
Southeast Asia and Canada.
2 
The outbreak was successfully
contained within five months and on July 5th 2003, the World
Health Organisation (WHO) announced that the last human
chain of transmission of SARS had been broken.
The overall case fatality from SARS is approximately 9.6%,
ranging from less than 1% in those aged 24 years or under, to
15% in persons aged 45 to 64 years and in persons aged over
65 it can exceed 50%.3 SARS is a droplet spread viral
infection caused by a novel coronavirus known as SARS-CoV.
It is likely that SARS originated in the Guangdong Province in
China in November 2002 and preliminary animal studies have
isolated the SARS-CoV virus in wild animals native to this
Province and to other parts of China.4 Globally, 21% of
documented SARS cases occurred in health care workers.5
Currently, there is no vaccine against SARS. In addition, SARS
remains a challenge for clinical diagnosis and management
because of its non-specific clinical features, which resemble
those of other respiratory infections and the lack of both
specific antiviral therapy and a rapid diagnostic test that can
reliably detect SARS-CoV in the first few days of illness.
During the outbreak period, the WHO case definitions relied
heavily on epidemiological criteria such as locations of SARS
Severe Acute Respiratory Syndrome
(SARS)
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outbreaks to increase the specificity of syndromic clinical
criteria for atypical pneumonia or respiratory distress
syndrome (RDS). However, epidemiological links to cases of
SARS and areas reporting recent local transmission are no
longer of use in helping to define incident cases. This presents
a challenge for the surveillance of SARS   
While much has been learned about SARS including its
causation (SARS-CoV), we still have limited knowledge about
the epidemiology and ecology of SARS coronavirus infection
and its potential to re-emerge has not been ruled out. In
view of this, in the post outbreak period, it is imperative that
all countries remain alert for the recurrence of SARS and
increase their capacity to detect and respond to SARS should
resurgence occur.6 Further information on SARS including
guidelines is available at http://www.ndsc.ie/DiseaseTopicsA-
Z/SevereAcuteRespiratorySyndrome.
Materials and methods
During the SARS outbreak in 2003, a dataset was agreed for
reporting of all suspect and probable SARS cases. The agreed
dataset for each case included demographic details (including
occupation), clinical details, laboratory investigations and
results and travel history. See (http://www.ndsc.ie/Disease
TopicsAZ/SevereAcuteRespiratorySyndrome/HealthcareProfess
ionals/d891.PDF) for reporting forms. This information was
entered and stored on a Microsoft Access Database.
Results 
One probable case of SARS was notified in March 2003. The
patient, who became ill after a visit to Hong Kong,
subsequently made a full recovery. Although meeting the
WHO case definition for a probable SARS case, this case was
not confirmed microbiologically with negative convalescent
serology at 28 days. Fifty possible cases of SARS were
investigated of whom 17 met the WHO case definition for a
probable or suspect case of SARS. See http://www.ndsc.ie/
DiseaseTopicsAZ/SevereAcuteRespiratorySyndrome/Healthcare
Professionals/d891.PDF for case definitions. Of the 50 cases
investigated, there was one probable case and 16 suspect
cases. Of these cases, 60% occurred in males and the age
range of cases was between 1 to 77 years, with a median age
of 45 years and mean age of 43 years. All cases had travelled
abroad. Table 1 outlines the countries visited by cases.
Of the 16 suspect cases, eight had alternative diagnoses,
which included:
• Influenza A (2)
• Influenza B (1)
• Respiratory Syncytial Virus  (1)
• Acute Bacterial Pneumonia (2)
• Exacerbation of Chronic Obstructive Pulmonary Disease (1)
• Atypical Pneumonia (1)-No organism isolated.
Discussion
The most significant global threat to public health in 2003
was the outbreak of SARS. It not only had consequences for
public health but also had an immense economic and social
impact on the affected areas. SARS also demonstrated the
impact of globalisation and the pivotal role travel plays in the
rapid dissemination of infectious diseases. Human migration
has been a key means of infectious disease transmission
Table 1: Countries visited by Probable and Suspect Cases of SARS 
Country visited Probable case Suspect case Total for destination
Hong Kong  1 2 3
Hong Kong and China  0 2 2
Hong Kong and Thailand  0 1 1
Toronto 0 2 2
Singapore  0 5 5
Singapore and Thailand  0 1 1
China (Guangdong) 0 2 2
Unknown 0 1 1
Total no of cases  1 16 17
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throughout recorded history. However the volume, speed and
reach of travel today have accelerated the spread of infectious
disease. 7
SARS posed a considerable challenge to global and national
public health due to the following factors: it was a new
disease of unknown aetiology with rapid transmission rates,
no specific treatment or vaccine and a high case fatality ratio.7
Implementing effective “traditional” public health measures
before the aetiological agent was known effectively contained
SARS. This included rapid detection and isolation of cases,
institution of stringent infection control measures including
personal protective equipment (PPE), vigorous contact tracing,
effective risk communication and applied research which
involved international and technical collaboration. Health
Canada’s review of the SARS outbreak emphasises this by
stating that “SARS has been contained, at least temporarily, not
by the genomic revolution, not by advanced pharmaceuticals,
but by old fashioned public health measures like handwashing,
infection control procedures, isolation of cases and tracing and
quarantine of contacts”. 2
Resurgence of SARS remains a distinct possibility and does
not allow for complacency.6 It is likely that SARS will re-
emerge, however it will most likely recur outside Ireland.
Potential sources of re-emergence of SARS include: the animal
reservoir in Southern China which may reseed the human
population, as illustrated by four isolated cases in Guangdong
in January 2004 for which no source was isolated.8 Another
potential source of re-emergence may be laboratory exposure
as demonstrated by episodes in Singapore, Taiwan and 
China.9 10 11 In addition, human-to-human transmission may
initiate re-emergence as seen in the 2003 outbreak. In order
to ensure timely recognition of initial cases and rigorous
follow-up of contacts, well-established, robust global and
national surveillance systems are crucial.
Strengthening of the following areas needs to be prioritised to
ensure an effective response to any future SARS outbreak or
similar public health threat:
1. Enhanced surveillance mechanisms to ensure early
detection of public health threats e.g. SARS, Influenza
Pandemic
2. Improved integration of clinical, laboratory and
epidemiological data which will be facilitated by
Computerised Infectious Disease Reporting (CIDR)
3. An effective alert and response system in all countries
which includes integrating and strengthening existing early
warning systems 
4. National capacity (including a 24/7 response) in outbreak
investigation and prevention and disease control 
5. Co-ordination of outbreak control at national and regional
level and between public health and healthcare providers
6. National and international co-ordination
7. Improved public communication strategies
8. Effective communication procedures and pathways
including command and control structures across the health
services and with other relevant sectors
9. Investment in infection control in acute and primary care
settings in terms of facilities, practice, manpower and
training
10. Research and training in the management of new and
emerging diseases 
The lessons learned from SARS are critical in determining the
improvements needed in the public health infrastructure at
global, national, regional and local level. Without these
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improvements, an effective response to any future threat to
public health will not be optimal. Planning and preparedness
are key to increasing the public health capacity and capability
to respond to SARS or any future threats and to mitigate the
impact on individuals and communities.12 Contingency plans
for responding to public health emergencies must be flexible
and have a multisectoral, multidisciplinary and multilevel
approach.
Finally, SARS has demonstrated the speed with which a
dangerous new disease can emerge and spread throughout
the world. The seriousness of the outbreak and the
challenges, which arose in containing SARS, are regarded as
signposts for the need to strengthen public health
infrastructure and systems globally.
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Key Points
• The incidence of human salmonellosis increased in 2003
with a crude incidence rate (per 100,000 pop.) of 11.5 in
2003, compared to 9.4 in 2002 (clinical notification
data)
• The highest rate was seen in children under 5 years
of age
• In 2003, there were 486 clinical isolates of Salmonella
enterica referred to the National Salmonella Reference
Laboratory (NSRL) for serotyping, phage typing and
antimicrobial sensitivity tests
• 15% of cases were reported to be associated with travel
outside of Ireland in 2003
Introduction
Salmonella is a bacterial zoonotic pathogen that is a relatively
common cause of foodborne illness in Ireland and worldwide.
At present there are over 2,500 known serotypes of
Salmonella. In recent years, two serotypes, namely, S. enterica
serotype Enteritidis and S. enterica serotype Typhimurium
have accounted for the majority of cases of human
salmonellosis.
Salmonellosis presents as an acute enterocolitis, with sudden
onset of headache, abdominal pain, diarrhoea, nausea and
occasionally vomiting. Fever is almost always present.
Dehydration, especially amongst vulnerable populations such
as infants, the immunocompromised and the elderly, may be
severe. S. Typhi and S. Paratyphi can cause enteric fever, a
severe systemic life threatening condition, but this is very rare
in Ireland and mainly travel-associated.
A wide range of domestic and wild animals, as well as humans
can act as the reservoir for this pathogen, although chronic
carriage is rare in humans.
Prevention, surveillance and control of Salmonella infections is
of major public health importance. Measures have been
implemented from farm to fork in an attempt to control
spread of this zoonotic agent.
Materials and methods
The National Salmonella Reference Laboratory (NSRL) was
established in 2000 in the Department of Medical
Microbiology, University College Hospital, Galway. This
laboratory accepts S. enterica isolates from all clinical and
Salmonella in Ireland, 2003
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food laboratories for serotyping, phage typing and
antimicrobial sensitivity testing.
This report reviews data available from the National
Salmonella Reference Laboratory (NSRL) and weekly clinical
notifications for the year 2003. These data enable us to
provide an overview of the epidemiology and burden of
disease caused by Salmonella infections in Ireland today.
Results
Demographic information
There were 486 clinical isolates of S. enterica referred to NSRL
in 2003. The male: female ratio was 1:1. The age groups and
sex of those affected are shown in Table 1. The highest
number of cases in seen in children under five years of age.
However, when age-specific incidence rates are calculated
(figure 1), the burden of illness in this age group is even more
evident.
Seasonality
There was a marked seasonal pattern seen in the number of
clinical salmonellosis cases reported through the weekly
notification system in 2003, with a sharp peak seen in week
number 36 (figure 2).
Serotyping, phage typing and antibiotic susceptibility
results from NSRL
Serotyping
The breakdown of Salmonella serotypes by health board is
shown in Table 2. It should be noted however that for the
NSRL data, health board location refers to the location of the
clinical laboratory that the isolate was originally sent to, and
may not always correspond with the geographic location of
the case.
The predominant serotype causing human illness was S.
Enteritidis (42% of isolates) followed by S. Typhimurium
(28%). Table 3 demonstrates the shift between these two
serotypes in the past number of years. The next most
commonly isolated serotypes in 2003 were S. Hadar (n=21),
S. Virchow (n=10) and S. Kentucky (n=10). There were nine
cases of S. Typhi detected in 2003, which is an increase on
2002 when there were five cases reported.
Phage typing
The predominant phage types of S. Typhimurium and S.
Enteritidis are summarised in Tables 4 and 5.
The incidence of S. Typhimurium DT104b has increased in
recent years and it represented 50% of all Typhimurium
isolates tested in 2003. PT4 has been the predominant phage
type in Enteritidis isolates since 1998 (comprised 28% of all
Enteritidis isolates in 2003), however the incidence of PT1
appears to be on the increase (26% of all Enteritidis isolates
in 2003).
Travel-association
72 isolates (14.8%) reported to NSRL in 2003 were found to
be associated with travel outside of Ireland. The majority of
these cases were associated with travel to Spain (n=26). The
next most common countries reported were Portugal (n=6)
and Thailand (n=6), followed by Pakistan (n=5), India (n=3)
and the UK (n=3).
Table 1. Analysis of clinical isolates of S. enterica (n=416) referred to NSRL,
(2003) by age-group and gender.
Age group (years)  No. of isolates (%)  Male  Female  Unknown
0-4 81 (17) 43 29 9
5-9 32 (7) 20 10 2
10-14 24 (5) 12 12 -
15-19 29 (6) 11 18 -
20-24 52 (10) 19 30 3
25-34 80 (16) 36 42 2
35-44 58 (12) 32 25 1
45-54 49 (10) 22 27 -
55-64 22 (5) 15 7 -
65+ 41 (8) 17 24 -
Unknown 18 (4) 8 9 1
Total 486 235 233 18
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 Figure 1. Age-specific incidence rate of human salmonellosis in Ireland, 2003.
0-4 65+55-64
45-
54
35-
44
25-
34
20-
24
15-
195-9
10-
14
NDSC Annual Report 200358
Table 2.  Serotypes of Salmonella enterica by health board, 2003.
Serotype  ERHA MHB MWHB NEHB NWHB SEHB SHB WHB Total
Agbeni 1 0 0 0 0 0 0 0 1
Agona 4 0 0 0 0 0 0 1 5
Anatum 4 0 0 0 0 0 0 1 5
Blockley 1 0 0 0 0 1 0 0 2
Bovismorbificans 0 0 0 1 0 0 0 0 1
Braenderup 2 1 0 0 0 0 0 0 3
Brandenburg 1 0 0 0 0 0 1 0 2
Bredeney 2 0 1 0 0 0 0 0 3
Cerro 0 0 0 0 0 1 0 0 1
Corvallis 1 0 0 0 0 0 1 1 3
Cotham 1 0 0 0 0 0 0 0 1
Derby 0 0 0 0 0 0 0 1 1
Dublin 0 0 2 1 0 0 0 2 5
Enteritidis 65 17 9 15 9 37 34 19 205
Hadar 2 0 3 13 1 1 1 0 21
Havana 0 0 1 0 0 0 0 0 1
Heidelberg 1 0 0 0 0 0 0 0 1
Indiana 0 0 0 0 0 1 0 0 1
Infantis 2 0 0 0 0 0 0 2 4
Java 0 0 0 0 0 0 1 0 1
Javiana 1 0 0 0 0 0 0 0 1
Kentucky 3 0 1 1 0 5 0 0 10
Kottbus 1 1 0 0 0 1 0 2 5
Litchfield 1 0 0 0 0 0 0 0 1
Manhattan 0 0 1 0 0 0 0 0 1
Mbandaka 1 0 0 0 1 0 0 1 3
Muenchen 1 0 0 0 0 0 1 0 2
Newport 2 1 0 0 0 0 0 2 5
Ohio 0 0 0 0 1 0 0 0 1
Ohlstedt 0 0 0 0 0 0 1 0 1
Panama 0 0 0 0 0 0 0 1 1
Paratyphi A 1 0 0 3 0 0 1 1 6
Paratyphi B 0 0 0 0 0 0 1 0 1
Poona 1 0 0 0 0 0 0 0 1
Reading 2 0 0 0 0 0 0 0 2
Rissen 0 0 0 0 0 0 1 0 1
Saintpaul 1 1 0 0 0 0 1 1 4
Sandiego 1 0 0 0 0 0 1 0 2
Senftenberg 1 0 0 0 0 0 0 0 1
Stanley 3 0 0 1 0 0 0 0 4
Tennessee 0 0 0 0 0 1 0 0 1
Typhi 3 0 2 0 2 0 2 0 9
Typhimurium 54 10 4 5 20 15 13 14 135
Virchow 3 1 1 1 2 1 0 1 10
Wangata 1 0 0 0 0 0 0 0 1
Welikade 1 0 0 0 0 0 0 0 1
Weltevreden 1 0 0 0 0 0 0 0 1
Unknown 4 1 0 1 1 0 0 1 8
Total 174 33 25 42 37 64 60 51 486
CIR 12.4 14.6 7.4 12.2 16.7 15.1 10.3 13.4 12.4
*CIR = Crude incidence rate / 100,000 population
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 Figure 2. Number of salmonellosis notifications by week, 2003 (NDSC).
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Six of the nine isolates of S. Typhi received by NSRL in 2003
were reported to be travel-associated. Three of these were
associated with travel to Pakistan; two with travel to India and
one was unknown.
Antimicrobial resistance
The antimicrobial susceptibility patterns of the most
commonly isolated serotypes in 2003 are presented in Table
6. The same trend that was noted in previous years with high
levels of resistance found amongst S. Typhimurium isolates,
particularly S. Typhimurium DT104 was again found in the
2003 data. Many of these isolates were found to have the
penta resistance phenotype (ACSSuT) that was also reported
in previous years.
Clinical notification data
Salmonellosis is a notifiable disease. Medical practitioners
have a statutory obligation to report all suspected cases.
Information on trends in salmonellosis notifications shows
that the crude incidence rate rose in the 1990s to peak in
1998, decreased until 2002 but an increase was again seen in
2003 (figure 3). The total number of notifications in 2003
was 449.
Discussion 
The significant burden of human illness caused by Salmonella
enterica is evident from the data presented in this review of
the epidemiology of salmonellosis in Ireland in 2003. Of
particular note is that the incidence of disease of human
salmonellosis in Ireland was seen to increase in 2003 (CIR
11.5 per 100,000 population) for the first time since 1998.
The highest incidence was reported in the North-Western
health board region. Higher rates were seen for the same
period in Northern Ireland1 (12.4), England and Wales2 (28.3)
and Scotland3 (24.8).
Similar trends regarding the epidemiology of this pathogen
were noted in 2003 as in previous years. All age-groups were
seen to be affected but the highest incidence was again noted
in children under five years of age. It is likely that more
specimens are submitted for testing from this age-group, so
this should be borne in mind when interpreting these data.
Males and females were equally affected.
Salmonella has a well characterised seasonal distribution and
a sharp rise in cases was noted in week 36 in 2003. A Europe-
wide study has been undertaken by the WHO European
Centre for Environment and Health (ECEH) to examine the
effects of global climate change on a number of gastroenteric
pathogens including Salmonella spp. The first results from this
study examining the effect of temperature on the incidence
of salmonellosis were published in 2004.4
The detailed typing methods being employed by the National
Salmonella Reference Laboratory are dramatically improving
our ability to monitor epidemiological trends, identify clusters
and outbreaks, and assist in trace back through the food
chain.
Analyses of the serotyping results revealed that in 2003,
S. Enteritidis still remained the predominant serotype,
followed by S. Typhimurium. These two serotypes represent
70% of the total salmonellas affecting humans. A diverse
number of other serotypes comprise the remaining 30% of
Table 5. Phage types of S. Enteritidis 
in human isolates (2003) 
Phage type No. of isolates (%)
PT4 58 (28)
PT1 53 (26)
PT21 21 (10)
PT6 13 (6)
PT6a 11 (5)
PT8 10 (5)
PT14b 7 (3)
PT5c 6 (3)
PT13a 5 (2)
Others 18
No type 3
Total 205
Table 3. Serotypes of S. enterica referred to NSRL (1998-2003) (%). 
Serotype 1998  1999  2000  2001 2002 2003
S. Enteritidis 60 (8) 155 (33) 239 (36) 248 (46) 165 (40) 205 (42)
S. Typhimurium 578 (80) 200 (42) 286 (43) 165 (30) 140 (34) 135 (28)
S. Bredeney 15 (2) 55 (12) 24 (4) 11 (2)   2 (0.5) 3 (1)
S. Kentucky 14 (2) 12 (3) 15 (3) 4 (1) 1 (0.2) 10 (2)
All other serotypes 54 (7) 52 (11) 101 (15) 115 (21) 108 (26) 133 (27)
Total 721 474 665 543 416 486
    Table 4. Phage types of S. Typhimurium in human isolates (2003) 
Phage type No. of isolates (%)
DT104b 67 (50)
DT104 22 (16)
DT12 8 (6)
U302 8 (6)
U310 6 (4)
DT193 4 (3)
U311 3 (2)
Others 12 (9)
No type 5 (4)
Total 135
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human isolates, with forty-five serotypes other than
Enteritidis or Typhimurium detected by NSRL in 2003.
Phage typing provides an additional level of sub-typing detail.
The trends in Enteritidis and Typhimurium isolates are
particularly interesting (tables 4 and 5). DT104b has taken
over from DT104 as the predominant Typhimurium phage
type in humans. A decrease has been seen in S. Enteritidis
PT4 across Europe in recent years5. In Ireland, as a percentage
of all S. Enteritidis isolates, PT4 decreased from 85% in 1998
to 28% in 2003. However, a corresponding increase has been
seen of PT1, which comprised 26% of Enteritidis isolates in
2003.
When the AMR (antimicrobial resistance) patterns of the
various Salmonella serotypes were examined, the trend that
has been reported over the past number of years of high
levels of resistance among S. Typhimurium DT104 isolates,
was again seen in 2003. This continues to be cause for
concern.
In 2003, the use of the Enter-net network and hub again
proved to be extremely beneficial for sharing knowledge and
expertise in the area of surveillance and control of
gastrointestinal disease, and as a particularly efficient alert
system to aid in the investigation of clusters and epidemics of
Salmonella and VTEC E. coli.
Finally, analyses of the 2003 data reveal that it is becoming
evident that an increasing number of cases of illness of
salmonellosis are linked to travel outside of Ireland, with 15%
of cases in 2003 being reported as travel-associated. It is
quite likely that many of the ‘unusual’ serotypes that we are
seeing each year are acquired abroad. Of particular note in
2003 was the increase in the number of typhoid cases seen
(n=9) compared to five isolates in 2002. This highlights the
need for reinforcing awareness amongst travellers to endemic
countries.
It is evident from the data presented in this review that
Salmonella continues to be an extremely significant public
health problem, and especially in light of the increase in cases
seen in 2003, control measures must be enforced throughout
the food chain to help to reduce this burden of disease.
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Figure 3.  Crude rate of Salmonellosis in Ireland per 100,000 population 1982-2003.
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Table 6. Antimicrobial susceptibilities of human Salmonella enterica serotypes 
isolated in Ireland in 2003.
        % Resistance
Serotype (Number)   Amp  Chl  Strep  Sulph  Tet  Trim  Nal
S. Enteritidis (205) 8 0 3 4 4 1 33
S. Typhimurium (135) 77 58 66 79 76 21 3
S. Hadar (21) 81 0 95 0 81 0 100
S. Virchow (10) 30 0 0 30 2 20 90
S. Kentucky (10) 50 10 50 60 5 20 70
S. Typhi  (9) 11 11 11 11 11 11 44
S. Dublin (5) 0 0 0 0 0 0 0
S. Stanley (4) 25 25 50 50 50 0 25
S. Bredeney (3) 33 0 0 33 0 0 0
Amp = Ampicillin, Chl = Chloramphenicol, Strep = Streptomycin, Sulph = Sulphonamide,
Tet = Tetracycline, Trim = Trimethoprim, Nal = Naladixic acid
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Campylobacteriosis in Ireland,
2002
Key Points
• Campylobacter is the most common bacterial cause of
gastroenteritis in Ireland
• In 2002, there were 1336 cases of confirmed
campylobacteriosis reported, which was an increase on
the previous year (1286 cases in 2001)
• The crude incidence rate in 2002 was 34.0 per 100,000
persons
• The highest burden of illness is in children under 5 years
of age
• There are slightly more males affected than females
Introduction
Infections due to Campylobacter spp are the most commonly
isolated bacterial cause of human gastrointestinal illness in
Ireland, the UK and many countries globally with temperate
climates. Campylobacter jejuni is the predominant species
associated with human illness, with the remainder mostly
being C. coli and C. lari.
Campylobacteriosis presents as a diarrhoeal illness. The
diarrhoea is often bloody and is frequently associated with
acute abdominal pain. Symptoms may subside after a number
of days or may persist for weeks. Rarely, some long-term
sequelae may develop such as arthritis and approximately one
in every 1000 cases leads to a severe neurological disorder
called Guillain-Barré Syndrome (GBS).
This review presents data from the fourth year of the NDSC
national survey of the incidence of human campylobacteriosis
in Ireland.
Methods
NDSC requested public health doctors and laboratories to
provide disaggregated information on all laboratory-confirmed
cases of campylobacteriosis diagnosed in 2002.
The following minimum dataset was requested: identifier, date
of birth/age, sex, address and date of onset/isolation/
reporting. In regions where laboratory surveillance systems
were in place, this information was requested from their
databases. Duplicates were removed where detected. Data
were assigned a health board and a county where address was
supplied. Analyses were carried out using MS Access and
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SPSS. Direct methods of standardisation were applied using
the Irish population as the standard population. Population
data were taken from the 2002 census. Species differentiation
of isolates was not requested.
Results
Information on Campylobacter was obtained from all Health
Boards. Information on age was missing in 2.3% of cases and
information on sex was incomplete in 3.7% of cases. Those
data without age were not presented in age standardised
charts.
Incidence
In total, 1336 cases of laboratory-confirmed
campylobacteriosis were reported in 2002 in Ireland
(including five cases in non-residents). This gives a crude
incidence rate (CIR) of 34.0 per 100,000 population (table 1).
This compared with a CIR of 32.8 per 100,000 in 2001 (based
on 2002 census data). The number of cases by year is shown
in figure 1. Crude rates by health board for 2002 are
presented graphically in figure 2.
Sex
Males accounted for 51.0% of cases and females 45.3% (with
3.7% of cases missing data on gender) as shown in table 2. A
similar ratio was reported in previous years. The gender
distribution by health board is shown in table 2.
Seasonality
The distribution of cases by week is shown in figure 3. A peak
was seen in week number 22 in 2002. Campylobacter is
known to have a well characterised seasonal distribution with
a peak seen in early summer each year. The seasonal pattern
broken down by health board is shown in Table 3.
Age
Age standardised rates were calculated to allow comparisons
to be made between health board regions without the
confounding effects of age (Figure 4). In 2002, the highest
incidence was recorded in the WHB (48.9) followed by the
SEHB (48.6), with the lowest incidence rate seen in the NEHB
(14.0).
Table 4 depicts crude incidence rates (CIR) and age
standardised incidence rates (ASIR) (per 100,000 population)
by health board in 2002.
The age-standardised data are mapped and presented in
figure 5.
Table 5 shows the breakdown of cases in each age group by
health board in Ireland.
Figure 6 graphs the breakdown of cases by age-group. This
demonstrates that there is a large burden of illness in children
under 5 years of age, and mirrors the results consistently
found since 1999. When we examine age specific incidence
rates for each age group, the burden of illness in this age
group is even more evident (figure 7).
Gender distribution
The variance in gender distribution that has been noted since
1999 was again evident from analysis of the data in 2002. In
every age-group except 15-19 years there was a
Table 1: Number of cases and CIR of human campylobacteriosis in Ireland by 
health board and year, 2002. (Excluding non-resident cases). 
Health Board No of cases CIR - (incl. 95% C.I.)
ERHA 467 33.3 [30.3 - 36.3]
Midland 90 39.9 [31.7 - 48.2]
Mid-Western 71 20.9 [16.0 - 25.8]
North Eastern 50 14.5 [10.5 - 18.5]
North Western 87 39.3 [31.0 - 47.5]
South Eastern 208 49.1 [42.4 - 55.8]
Southern 173 29.8 [25.4 - 34.3]
Western 185 48.6 [41.6 - 55.7]
Ireland 1331 34.0
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Figure 1. Number of laboratory confirmed cases of Campylobacteriosis in Ireland, 1999-2002
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Figure 2.  Crude incidence rates per 100,000 population for human 
campylobacteriosis by health board in Ireland in 2002
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predominance of male cases. This is shown in Figure 8 when
the data are adjusted for age and sex.
Outbreak data
There was one outbreak of Campylobacter jejuni reported to
NDSC in 2002. It occurred in a restaurant and was
responsible for seven persons being ill. The mode of
transmission was suspected to be foodborne although no
implicated food item was identified during the course of the
investigation.
Discussion
This paper presents data from the fourth year of the national
survey of incidence of human campylobacteriosis in Ireland
and has provided valuable information regarding the
epidemiology of this pathogen. It is evident that
campylobacteriosis remains the single biggest cause of
bacterial gastroenteric infection in Ireland (greater than three
times the number of salmonellosis cases reported in 2002). It
should also be noted that these are laboratory confirmed
cases and the true burden of illness is probably much higher.
The crude incidence rate (CIR) was seen to increase in 2002
(34.0 cases/100,000 persons) compared to 2001 (32.8/
100,000). The increase was most notable in the South-
Eastern and Midland health board regions. The Western
health board however has consistently the highest incidence
rate over the past number of years when the data are
standardised for age (ASIR =48.9/100,000). Higher rates were
seen in 2002 for Northern Ireland1 (48.2/100,000), England
and Wales2 (90.7/100,000) and Scotland3 (101.3/100,000).
Many of the epidemiological trends noted since this annual
survey began in 1999, have been found again on examination
of the 2002 data. The incidence rate of this pathogen is
consistently higher in young children and there is a bias
towards male cases in almost all age-groups. It was
recognised that research was needed in Ireland to provide
answers to some of these epidemiological questions, and
hence to address this, a matched case-control study was
initiated in the ERHA region in 2003. The objective is to
identify and assess risk factors for sporadic cases of
campylobacter in Ireland. The study is being carried out by
the Department of Public Health in the ERHA and the NDSC,
and is expected to be completed by the end of 2004, after
which the results will be disseminated.
Another notable feature of this organism is the seasonal
pattern of infection seen each year. In 2002 a sharp peak in
cases was seen in week 22 (Figure 3). An international study,
of which Ireland was involved, has been undertaken by the
WHO European Centre for Environment and Health (ECEH) to
examine the effects of global climate change on a number of
gastroenteric pathogens including Campylobacter spp.4 The
role of climate variability on laboratory-confirmed cases of
campylobacter infections from Europe, Canada, Australia and
New Zealand was examined. The findings of this important
study are due to be published shortly.
There are still many questions that remain unanswered
regarding this pathogen. The lack of typing data on all
isolates often hinders public health investigations, particularly
in trace back through the food chain to find the source of
infection. Detailed antimicrobial resistance profiling of
Table 2.  Number of cases by health board and sex, 2002
Health Board  Total Males  Females Unknown
ERHA 467 243 219 5
MHB 90 44 39 7
MWHB 71 41 30 0
NEHB 50 29 20 1
NWHB 87 43 42 2
SEHB 208 101 103 4
SHB 173 83 80 10
WHB 185 94 72 19
Non Irish Residents 5 4 0 1
Ireland 1336 682 605 49
Table 3.  Cases by month (2002) for each health board in Ireland
 E  M  MW  NE  NW  SE  S  W  N.r.* Total
Jan 13 7 3 3 6 11 13 13 0 69
Feb 19 3 2 4 3 9 13 12 0 65
Mar 28 4 6 2 7 7 9 10 0 73
Apr 42 7 5 1 6 24 11 13 0 109
May 54 7 7 8 8 22 26 18 0 150
Jun 58 16 10 6 9 34 11 32 4 180
Jul 42 10 1 4 7 23 16 17 1 121
Aug 48 7 5 4 12 14 19 14 0 123
Sep 37 5 8 4 7 14 8 11 0 94
Oct 46 10 7 6 9 21 15 7 0 121
Nov 47 5 11 5 7 13 16 23 0 127
Dec 33 8 6 3 6 16 16 14 0 102
NK 0 1 0 0 0 0 0 1 0 2
Total 467 90 71 50 87 208 173 185 5 1336
*Non resident
NDSC Annual Report 2003 65
N
um
be
r 
of
 c
as
es
Week number
 Figure 3: Total cases of campylobacteriosis by week of notification (2002)
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Figure 4: Age standardised incidence rates (ASIR) compared to crude 
incidence rates (CIR) in each health board, 2002.
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Figure 5. Age-standardised rates of campylobacteriosis in Ireland by health board, 2002.
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Figure 6. Cases of campylobacteriosis by age group for Ireland in 2002
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isolates is also essential to monitor trends that have been
highlighted in recent years such as the emergence of
quinolone-resistant Campylobacter spp isolates.5
This review again highlights the significance of this
gastroenteric pathogen and the considerable public health
burden it constitutes. Emphasis must be placed on control
measures throughout the food chain in order to attempt to
reduce the incidence of human disease caused by this
organism.
Acknowledgements
NDSC sincerely acknowledges all those who provided information for the
fourth year of this report on the epidemiology of campylobacteriosis in
Ireland, in particular, public health doctors, surveillance scientists, medical
microbiologists, medical laboratory scientists and environmental health
officers.
References
1. Communicable Disease Surveillance Centre - Northern Ireland.
http://www.cdscni.org.uk/
2. Health Protection Agency – CDSC.
http://www.hpa.org.uk/infections/topics_az/topics.asp?category=a
3. SCIEH. http://www.show.scot.nhs.uk/scieh/
4. Climate Change and Adaptation Strategies for Human health in Europe
(cCASHh) website http://www.euro.who.int/eprise/main/who/progs
/cash/home
5. Engberg J., Neimann J., Nielsen E.M., Aerestrup F.M., Fussing V. Quinolone-
resistant Campylobacter infections: risk factors and clinical consequences.
Emer Infect Dis (2004) 10:1056-1063.
Table 5. Age distribution of cases by health board, 2002.  
Health board 0-4  5-9  10-14  15-19 20-24  25-34  35-44  45-54  55-64  65+  
ERHA 105 14 9 22 58 100 63 33 18 34
MHB 39 6 0 4 1 12 6 5 4 7
MWHB 22 2 0 6 7 13 7 3 6 5
NEHB 11 1 1 3 8 12 5 2 1 4
NWHB 23 9 5 2 2 12 7 9 10 8
SEHB 68 10 8 10 14 29 22 16 9 20
SHB 63 10 6 4 16 15 18 8 7 20
WHB 64 19 12 3 18 17 15 14 7 12
Non- Residents 0 0 0 0 2 0 0 1 2 0
Total  395 71 41 54 126 210 143 91 64 110
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 Figure 8: Age-gender adjusted incidence according to age-group in 2002.
Males Females
Table 4.  Crude incidence rates (CIR) and age standardised incidence rates (ASIR) 
(per 100,000 population) by health board in 2002
Health Board  CIR [95% CI]  ASIR [95% CI]
ERHA 33.3 [30.3 - 36.3] 31.9 [29.0 - 34.8]
Midland 39.9 [31.7 - 48.2] 36.0 [28.3 - 43.7]
Mid-Western 20.9 [16.0 - 25.8] 21.1 [16.2 - 26.0]
North Eastern 14.5 [10.5 - 18.5] 14.0 [10.0 - 17.9]
North Western 39.3 [31.0 - 47.5] 39.0 [30.8 - 47.2]
South Eastern 49.1 [42.4 - 55.8] 48.6 [42.0 - 55.3]
Southern 29.8 [25.4 - 34.3] 29.1 [24.7 - 33.6]
Western 48.6 [41.6 - 55.7] 48.9 [41.8 - 56.1]
IRELAND 34.0 [32.2 - 35.8]  
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Key Points
• Campylobacter spp is the commonest cause of
gastroenteritis of bacterial aetiology in Ireland
• In 2003, there were 1568 cases of confirmed
campylobacteriosis reported, which was an increase on
the previous two years (1336 cases in 2002 and 1286 in
2001)
• The crude incidence rate in 2003 was 39.9 cases per
100,000 persons
• The highest burden of illness was in children under 5
years of age
Introduction
Campylobacteriosis is the commonest bacterial cause of
human gastrointestinal illness in Ireland. C. jejuni is the
predominant species associated with human illness, with the
remainder mostly being C. coli and C. lari.
It is primarily a diarrhoeal illness. The diarrhoea is often
bloody and frequently associated with acute abdominal pain.
Symptoms may subside after a number of days or may persist
for weeks. Rarely, long-term sequelae may develop such as
reactive, arthritis, Reiter’s syndrome, or HUS and
approximately one in every 1000 cases leads to a severe
neurological disorder called Guillain-Barré Syndrome (GBS).
This review presents data from the fifth year of the NDSC
national survey of the incidence of human campylobacteriosis
in Ireland.
Methods
NDSC requested public health doctors and laboratories to
provide disaggregated information on all laboratory-confirmed
cases of campylobacteriosis diagnosed in 2003.
The following minimum dataset was requested: identifier, date
of birth/age, sex, address and date of
onset/isolation/reporting. In regions where laboratory
surveillance systems were in place, this information was
requested from their databases. Duplicates were removed
where detected. Data were assigned a health board and a
county where address was supplied. Analyses were carried out
using MS Access and SPSS. Direct methods of standardisation
Campylobacteriosis in Ireland,
2003
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were applied using the Irish population as the standard
population. Population data were taken from the 2002
census. Species differentiation of isolates was not requested.
Results
Information on Campylobacter was obtained from all Health
Boards. Information on age was missing in 1% of cases and
information on gender was incomplete in 5% of cases. Those
data without age were not presented in age standardised
charts, and without gender were not presented in age-gender
standardised charts.
Incidence
In total, 1568 cases of laboratory-confirmed
campylobacteriosis were reported in 2003 in Ireland
(including six cases in non-residents). This gives a crude
incidence rate (CIR) of 39.9 cases per 100,000 population
(table 1). This compared with a CIR of 34.0 cases per 100,000
in 2002. The number of cases by year is shown in Figure 1.
Crude rates by health board for 2003 are presented
graphically in figure 2.
Sex
Males accounted for 49.4% of cases and females 45.6% (with
5% of cases missing data on gender) as shown in table 2. This
trend of a greater incidence of male cases has been
consistently found since this survey began in 1999. The
gender distribution by health board is shown in table 2.
Seasonality
The distribution of cases by month is shown in Figure 3. A
rise in cases occurred in May 2003, reaching a peak in July in
2003. Campylobacter is known to have a well characterised
seasonal distribution with a peak seen in early summer each
year. The seasonal pattern broken down by health board is
shown in table 3.
Age
Age standardised rates were calculated to allow comparisons
to be made between health board regions without the
confounding effects of age (figure 4). In 2003, the highest
incidence was recorded in the Midland health board region
followed by the Western health board with the lowest
incidence rate seen in the NWHB.
Table 4 depicts crude incidence rates (CIR) and age
standardised incidence rates (ASIR) (per 100,000 population)
by health board in 2003.
The age-standardised data are mapped and presented in
Figure 5.
Table 5 shows the breakdown of cases in each age group by
health board in Ireland.
Figure 6 graphs the breakdown of cases by age-group. This
demonstrates that there is a large burden of illness in children
under 5 years of age, and mirrors the results consistently
Table 1: Number of cases and CIR of human campylobacteriosis in Ireland by 
health board and year, 2003. 
Health Board No of cases CIR - (incl. 95% C.I.)
ERHA  544 38.8 [35.6 - 42.1]
Midland  136 60.3 [50.2 - 70.5]
Mid-Western  103 30.3 [24.5 - 36.2]
North Eastern  95 27.5 [22.0 - 33.1]
North Western  52 23.5 [17.1 - 29.8]
South Eastern  213 50.3 [43.5 - 57.0]
Southern  208 35.8 [31.0 - 40.7]
Western  211 55.5 [48.0 - 63.0]
IRELAND  1562 39.9 [37.9 - 41.9]
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Figure 1. Number of laboratory confirmed cases of Campylobacteriosis in Ireland, 1999-2003
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Figure 2.  Crude incidence rates per 100,000 population for human 
campylobacteriosis by health board in Ireland in 2003
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found since 1999. When we examine age specific incidence
rates for each age group, the burden of illness in this age
group is even more evident (figure 7).
Gender distribution
The variance in gender distribution that has been noted since
1999 was again evident from analysis of the data in 2003. In
almost every age-group, there was a predominance of male
cases. This is shown in Figure 8 when the data are adjusted for
age and sex.
Outbreak data
There were two outbreaks of campylobacteriosis reported to
NDSC in 2003. One occurred in a residential institution with
19 people reported ill. The other occurred in a hospital with
six cases of illness. The mode of transmission was not
determined in these outbreaks, and no food vehicles were
identified during the investigations.
Discussion
The results presented here are from the fifth year of the
national survey of the incidence of human campylobacteriosis
in Ireland. It is evident from these data that
campylobacteriosis remains the greatest cause of bacterial
gastroenteric infection in Ireland (3.5 times the number of
salmonellosis cases reported in 2003).
The crude incidence rate (CIR) of campylobacteriosis was seen
to increase in Ireland in 2003 (39.9 cases/100,000 persons)
compared to 2002 (34.0/100,000). This was the highest rate
reported in Ireland since 2000. The increase was most notable
in the Midland and Western health board regions.
Higher rates were seen in 2003 for Northern Ireland1
(43.8/100,000), England and Wales2 (85.4/100,000) and
Scotland3 (87.9/100,000) but these rates represented a
decrease from the incidence reported in 2002 for all these
countries (provisional data).
Some consistent data trends are evolving as the
Campylobacter data are analysed year on year. The incidence
rate of this pathogen is consistently higher in young children
and there is a bias towards male cases in almost all age-
groups. A case-control study being conducted in the ERHA
region is due to be completed in the coming months. It is
hoped to identify and assess risk factors for sporadic cases of
human campylobacteriosis in Ireland.
Much work needs to be done to provide answers to many of
the epidemiological questions posed by the data presented in
this report. Detailed typing data of human isolates is needed
to be able to examine relationships between Campylobacter
isolates from food, food animals and humans, and to assist in
traceback in outbreak investigations. Information on risk
factors is needed to inform public health interventions. In
recent years, water has been increasingly featured as a
potential source of Campylobacter infection internationally,
and reports have described associations with swimming in
Table 2.  Number of cases by health board and sex, 2003
Health Board  Total Males  Females Unknown
ERHA 544 278 261 5
MHB 136 65 64 7
MWHB 103 59 44 0
NEHB 95 27 31 37
NWHB 52 32 20 0
SEHB 213 102 111 0
SHB 208 109 80 19
WHB 211 100 101 10
Non Irish Residents 6 2 4 0
Ireland 1568 774 716 78
Table 3.  Cases by month (2003) for each health board in Ireland
 E  M  MW  NE  NW  SE  S  W  N.r.* Total
Jan 39 2 8 8 4 19 13 23 0 116
Feb 31 16 6 9 8 12 16 15 0 113
Mar 38 10 6 5 2 14 10 15 0 100
Apr 33 5 9 5 0 16 11 9 0 88
May 61 26 12 7 0 30 23 20 0 179
Jun 37 13 11 5 8 27 24 29 1 155
Jul 75 16 12 14 9 27 26 24 3 206
Aug 48 14 9 12 4 14 22 21 2 146
Sep 69 8 6 12 4 14 27 21 0 161
Oct 34 7 9 6 7 16 11 9 0 99
Nov 39 10 8 3 2 11 10 14 0 97
Dec 40 9 6 5 4 13 15 9 0 101
NK 0 0 1 4 0 0 0 2 0 7
Total 544 136 103 95 52 213 208 211 6 1568
*Non resident
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Figure 5. Age-standardised rates of campylobacteriosis in Ireland by health board, 2003.
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Figure 7. Age specific incidence rates for campylobacteriosis in Ireland, 2003
0-4 65+55-64
45-
54
35-
44
25-
34
20-
24
15-
195-9
10-
14
160
100
140
120
80
60
40
20
0A
ge
-g
en
de
r 
ad
ju
st
ed
 in
ci
de
nc
e 
ra
te
Age group (years)
0-4 65+55-64
45-
54
35-
44
25-
34
20-
24
15-
195-9
10-
14
 Figure 8: Age-gender adjusted incidence according to age-group in 2003.
Males Females
180
NDSC Annual Report 2003 71
waters contaminated with sewage effluent, drinking of
untreated water and consumption of seafood.4,5 A study in
Northern Ireland, revealed significant levels of contamination
of untreated surface waters with Campylobacter spp.6 It is
hoped that the results of the first Irish case-control study will
identify risk factors for sporadic cases of campylobacteriosis in
this country.
It is clear that there is a very significant burden of illness
caused by this zoonotic agent, with the highest incidence in
four years reported in 2003. Efforts by all public health
professionals throughout the food chain must continue to aid
in our understanding of the complex epidemiology of this
globally important pathogen.
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Table 5. Age distribution of cases by health board, 2003.  
Age group (years) E  M  MW  NE  NW  SE  S  W  Total
0-4 81 58 30 24 16 56 75 81 421
05-9 23 13 4 7 3 11 13 11 85
10-14 18 5 5 4 1 9 12 10 64
15-19 27 6 4 5 2 10 7 8 69
20-24 58 7 7 12 5 23 18 18 148
25-34 115 18 14 13 3 32 26 22 245
35-44 80 6 14 10 7 17 18 10 163
45-54 43 9 4 5 5 12 13 19 112
55-64 34 6 6 8 3 18 8 10 93
65+ 56 6 13 7 7 25 16 21 152
Table 4.  Crude incidence rates (CIR) and age standardised incidence rates (ASIR) 
(per 100,000 population) by health board in 2003
Health Board  CIR [95% CI]  ASIR [95% CI]
ERHA 38.8 [35.6 - 42.1] 37.8 [34.5 - 41.0]
Midland 60.3 [50.2 - 70.5] 57.7 [47.9 - 67.5]
Mid-Western 30.3 [24.5 - 36.2] 29.9 [24.1 - 35.7]
North Eastern 27.5 [22.0 - 33.1] 27.2 [21.7 - 32.7]
North Western 23.5 [17.1 - 29.8] 23.5 [17.1 - 29.9]
South Eastern 50.3 [43.5 - 57.0] 50.6 [43.8 - 57.4]
Southern 35.8 [31.0 - 40.7] 36.1 [31.2 - 41.0]
Western 55.5 [48.0 - 63.0] 56.5 [48.8 - 64.2]
IRELAND 39.9 [37.9 - 41.9]  
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The Epidemiology of
Verocytotoxigenic E. coli
O157 in Ireland, 2003
Key Points
• E. coli O157 is an emerging pathogen and a serious
global health concern
• In 2003, there were 86 confirmed cases of VTEC O157
infection in Ireland, the highest number reported since
records began
• The highest burden of illness was recorded in children
under 5 years of age 
• Four cases of haemolytic uraemic syndrome were
reported among E.coli 0157 confirmed cases
• Forty-eight per cent of cases had a date of onset
between July and September
Verotoxigenic E. coli (VTEC) are so-called because of their
ability to produce one or both of two verotoxins (VT1 and
VT2). They cause a wide range of illnesses, from mild
diarrhoea to haemorrhagic colitis with severe abdominal pain
and bloody diarrhoea. Illness is usually self-limiting and
resolves after about eight days. Historically 9% of
symptomatic Irish cases have developed haemolytic uraemic
syndrome (HUS), a form of renal failure (1). In children under
15 years of age in Ireland, one in eight with confirmed VTEC
O157 develop HUS (one in seven of symptomatic cases).
The primary reservoir is cattle, although VTEC have been
isolated from a variety of healthy animal carriers including
sheep, horses, goats and wild birds. While this organism was
first recognized as a foodborne pathogen (the ‘burger bug’), it
is now known that it can also be transmitted through water,
the environment and by direct contact with animal carriers.
Person-to-person spread is important in households, crèches
and institutions.
E. coli O157 is the most commonly reported VTEC in Ireland
(1), the UK and the US, although other serogroups are capable
of causing the same spectrum of illness, including O26, O111,
O103 and O145. In particular, cases of VTEC O26 have been
reported in Ireland every year since 1999.
The Public Health Laboratory at Cherry Orchard Hospital,
Dublin provides an E. coli O157 and non-O157 diagnostic
service for clinical and food samples, including E. coli
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serotyping and verotoxin detection. Phage typing for VTEC
O157 is carried out at the HPA CPHL Colindale, London.
Methods
This is the fifth year that NDSC, in co-operation with
Directors of Public Health in each health board region, have
operated the epidemiological surveillance system for VTEC
O157.
Since 1999, specialists in public health medicine, (senior) area
medical officers, microbiologists, clinical scientists, surveillance
scientists, infection control nurses and (principal)
environmental health officers participate in a system whereby
a standard dataset of information is collected at health board
level on each case identified, and reported to NDSC. This
information includes socio-demographic data, clinical data,
possible risk factors and information on links between cases.
NDSC welcomes reports of cases infected with non-O157
VTEC. The case definitions that have been used in this system
are as follows:
• Suspected: a case of post-diarrhoeal HUS or TTP.
• Probable: a case with isolation of E. coli O157 from a clinical
specimen (asymptomatic or symptomatic), pending
confirmation of H7 or Shiga toxin or a clinically compatible
case that is epidemiologically linked to a confirmed or
probable case.
• Confirmed: a case that has isolation of E. coli O157:H7 from
a specimen or isolation of Shiga toxin-producing E. coli
O157:NM (non-motile) from a clinical specimen.
Probable cases that are subsequently confirmed as not H7 or
Shiga toxin producing are removed from the database. A
travel-associated case is defined as one where there has been
international travel within two weeks prior to onset of illness.
Results
Eighty-six confirmed cases of VTEC O157 were reported to
NDSC that had a date of onset of symptoms during 2003, an
incidence rate of 2.1 per 100,000. The numbers of confirmed
cases and the crude incidence rates of VTEC O157 in Ireland
from 1999-2003 are shown in table 1.
Regional distribution
As in previous years, regional variation was noted in the
numbers of cases reported (Table 2 and Figure 1), with the
highest incidence rates this year in the SEHB, MHB, SHB and
NWHB.
Age-sex distribution
The highest incidence was recorded in young children (Figure
2), a trend also recorded noted over the last few years. This
was particularly pronounced among male cases. There was
also a slightly higher incidence among adult females than
adult males.
Table 1. Number of cases of confirmed VTEC O157 and crude incidence rate (95% CI) 
in Ireland, 1999-2003
Year  Numbers of confirmed Crude incidence rate*  
 cases (incl.   (95% CI) per 100,000
 non-residents) population
1999 51 1.4 (1.0-1.8)
2000 37(42) 0.9 (0.6-1.3)
2001 50 (52) 1.3 (0.9-1.6)
2002 68 (70) 1.7 (1.3-2.2)
2003 82 (86) 2.1 (1.6-2.6)
*Data from 1996 census was used to calculate the rate in 1999 while the 2002 
  census were used to calculate rates from 2000-2003.  
Table 2. Number, crude incidence rate (CIR) and age-standardised incidence rate (ASIR) 
with 95% confidence intervals of confirmed cases of VTEC O157 by health board 
of residence, Ireland, 2003
Health Numbers of cases  CIR (95% CI) ASIR(95% CI)  
board VTEC (incl.  per 100,000 per 100,000
 non-residents) 
ERHA 12 0.9 (0.4-1.3) 0.9 (0.4-1.3)
MHB 8 3.5 (1.1-6.0)  3.4 (1.0-5.7)
MWHB 6 (8) 1.8 (0.4-3.2) 1.8 (0.4-3.2)
NEHB 1 0.3 (0.3-0.8) 0.3 (0.2-0.8)
NWHB 7 3.2 (0.8-5.5) -*
SEHB 20 (21) 4.7 (2.7-6.8) 4.7 (2.7-6.8)
SHB 20 3.4 (1.9-5.0) 3.5 (1.9-5.0)
WHB 8 (9) 2.1 (0.6-3.6) -*
Total 82 (86) 2.1 (1.6-2.6) 
All rates in this table exclude non-resident cases
*age was not reported for all cases in these health boards 
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Clinical Features
In total, 68 out of the 86 confirmed cases (79%) were
reported as symptomatic. Reported symptoms included:
bloody diarrhoea in 31 cases (46%), and HUS in 4 cases (6%).
Of the 4 cases of HUS, 3 occurred in children under 15 years
of age and there was one adult case.
Seasonality of VTEC O157 cases
The largest number of cases in 2003 occurred in the third
quarter, with a peak in August (figure 3), very similar to the
trend observed in 2002.
Travel-association
Eight cases were travel-associated. The countries visited
within 14 days of onset of illness were Canary Islands (4),
Italy (2), Austria/Germany (1) and Turkey (1).
Epidemiological Investigation
Two general outbreaks of VTEC O157 occurred during the
summer of 2003 (3). Both were centred in hotel restaurants in
the ERHA. Five confirmed and twelve probable cases were
reported in one outbreak; seven cases were hospitalised.
Investigations found no relationship between any specific food
or drink and the development of illness. In the second
outbreak, 3 confirmed cases including one who developed
HUS were reported; there were two hospital admissions.
Similarly, the source of this outbreak was not established.
As a result of following up apparently sporadic cases in 2003,
an additional 13 family/household outbreaks were detected
by health board personnel among 36 confirmed cases but no
links were confirmed with any food or water sources.
For six households served by private water supplies
(comprising 10 confirmed cases), there was documented
evidence of either coliforms or E. coli in the water supply.
However, E. coli O157 was not detected in any instance.
Risk exposures
Descriptive epidemiological information was collected on all
reported cases in an attempt to identify potential risk factors
for exposure to VTEC. Three (3.5%) cases reported
consumption of unpasteurised milk or cheese. Contact with
farm animals was reported in 17 (20%) cases. Of 56 cases
where information was collected on water source, the water
supply was public in 36 (64%) cases, private well water in 17
(31%) cases, from a group scheme in 2 (3.6%) cases and
recorded as other (not public and not well) in 1 (1.8%) cases.
Non-O157 VTEC
Non-O157 VTEC, in particular VTEC O26, remain a concern in
Ireland. While the enhanced surveillance system did not
routinely collect information on these subtypes in 2003 four
confirmed cases of VTEC O26 (1 in SEHB, 2 in NWHB and 1
in MWHB) were reported to the surveillance system. Most
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Figure 1: Crude incidence rate (CIR) of confirmed resident cases of VTEC O157 by health board of residence, Ireland, 2001-2003
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importantly, one child developed HUS in 2003 as a
consequence of infection with E. coli O26.
Discussion
The enhanced surveillance system for VTEC O157 has been
operating for 5 years and provides valuable information on
the epidemiology of VTEC O157 in Ireland. Eighty-six
confirmed cases of VTEC O157 infection (2.1 per 100,000
population) were reported in Ireland in 2003, the highest
annual number on record. This compares with provisional
incidence rates of 3.1/100,000 in Northern Ireland (4),
2.9/100,000 in Scotland (Mary Locking SCIEH personal
comm.) and 1.3 in England and Wales (Sue Le Baigue, CDSC
Colindale, personal communication) in 2003.
A further 4 cases of VTEC O26 were reported to the enhanced
surveillance system, increasing the overall VTEC rate to 2.2
per 100,000. The potential for illness by non-O157 VTEC
should not be overlooked; cases of VTEC O26 have been
reported in Ireland every year since 1999.
A large proportion of cases in 2003 were reported in late
summer with almost 48% per cent of cases having a date of
onset between July and September. While a higher incidence
during this time is a feature of VTEC infection, the particularly
high rate in the summer of 2003 was in part influenced by
the occurrence of 2 general outbreaks centred in the ERHA
involving 8 cases, and in part by the reporting of 8 confirmed
VTEC O157 cases with a date of onset in August from the
SHB alone. The SHB cases included one family outbreak of 3
cases, and while geographical and temporal clustering was
noted among 4 of the remaining 5 cases, no epidemiological
links were identified and 4 different phage types were
represented, making a general outbreak unlikely.
No sources or transmission routes were definitively identified
for any of the VTEC cases reported in 2003 although person-
to-person transmission is likely to have played some role in
family/household outbreaks. In several case control studies
internationally, contact with farm animals and farming
environments has been shown to be a strong risk factor for
VTEC infection among sporadic cases (5); 20% of cases here
in 2003 reported contact with farm animals although it has
not been demonstrated that this was the route by which
infection occurred in these instances. In Ireland, there is
increasing concern about the potential of water as a possible
transmission route. Those who consume water from supplies
other than public water supplies are over represented among
VTEC cases. The 2002 census recently reported that 72% of
persons in Ireland were served by public water supplies (6);
only 64% of VTEC O157 cases in 2003 had public water
supplies. Moreover, for a number of households served by
private supplies, there was documented evidence of either
coliforms or E. coli in their water supply, although E. coli O157
was not detected in any instance.
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The importance of co-operation in surveillance at national
and international level was demonstrated during
epidemiological investigations of some of the VTEC cases
reported here. A number of foreign tourists were involved in
the 2 general outbreaks in Ireland in the summer of 2003,
some of whom had travelled on to other regions of the
country prior to diagnosis; some had even travelled home
prior to diagnosis, necessitating international collaboration.
Significant changes have been made in 2004 in the reporting
of cases of VTEC. Illness caused by enterohaemorrhagic E. coli
(EHEC) became a notifiable disease on January 1st 2004.
Previously, VTEC were notified under the category of ‘Food
Poisoning (bacterial other than Salmonella)’. Under EHEC, all
verotoxin positive E. coli, and E. coli of serogroups O157, O26,
O111, O103, O145 regardless of whether verotoxin producers,
are reported.
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Invasive Haemophilus influenzae
in Ireland, 2003
Key Points
• 22 cases of invasive Haemophilus influenzae were
reported in 2003
• 14 of the cases were due to H. influenzae type b (Hib)
disease
• 64% of Hib cases occurred in children <5 years of age
• There were two true Hib vaccine failures in 2003
Introduction
Routine Haemophilus influenzae type b (Hib) immunisation
has resulted in a marked decrease in the incidence of invasive
H. influenzae disease. Since the introduction of the vaccine in
1992 the incidence of Hib disease has declined from
approximately 2.8 per 100,000 in the late 1980s to <0.4 per
100,000 more recently. Despite these preventive measures,
diseases due to Hib have not been completely eliminated and
the organism still causes serious invasive blood-borne
infections such as meningitis, septicaemia, epiglottitis,
cellulitis and septic arthritis.
Materials and methods
A case is defined as invasive H. influenzae disease in a person
with an isolate from a normally sterile site.
Two sources of data allowed NDSC to monitor the incidence
of invasive H. influenzae in Ireland in 2003.
1. Reports from laboratories which NDSC received via
Departments of Public Health
2. Updates from the HPA Haemophilus Reference Unit,
Oxford, UK
Details of all cases were inputted to an MS Access database at
NDSC. Analysis was preformed using MS Access and MS
Excel.
Incidence rates were calculated using population data taken
from 2002 Census of Population, as the denominator.
NDSC Annual Report 2003 79
Results
Overall incidence of Haemophilus influenzae
Twenty two cases of invasive H. influenzae were reported in
2003 (0.6/100,000), which was similar to the previous year
when 21 cases were reported (figure 1). The clinical
manifestations of the 22 cases reported were: meningitis
(n=2), septicaemia (n=4), meningitis and septicaemia (n=5),
pneumonia (n=3), osteomyelitis/septic arthritis (n=1),
cellulitis (n=1), epiglottitis (n=1) and unknown (n=5). The
highest number of H. influenzae type b (Hib) cases since 1994
was reported in 2003 (figure 2). The age distribution of cases
by serogroup is presented in table 1 and the age specific
incidence rates by serogroup are presented in figure 3. Sixty
four percent of cases were due to serotype b (14/22), 9%
(2/22) were non-b capsulated strains (1 serotype e and 1
serotype f) and the remainder (6/22) were non-capsulated.
Over half the cases (12/22) occurred in children <5 years of
age. Of the Hib cases reported, 64% (9/14) occurred in this
age group.
The highest incidence rates of invasive H. influenzae were in
the <5 year olds followed by the elderly (table 1 and figure
3). The predominant cause of disease in the <5 year olds was
due to serotype b strains whereas in the elderly non-
capsulated strains were more common.
Incidence of Haemophilus influenzae type b (Hib) in
childhood
Thirteen cases of invasive H. influenzae occurred in children
<15 years of age (table 1). Seventy seven percent of these
cases (10/13) were due to serotype b strains with non-
capsulated strains accounting for the remaining three cases.
The incidence of Hib was highest in the <1 year olds
(7.3/100,000), followed by 1-4 year olds (2.2/100,000) and
dropped thereafter in the older age groups ranging from 0.0
to 0.4 per 100,000 (figure 3). During 2003, the clinical
presentations of Hib disease in childhood were septicaemia
(n=7), pneumonia (n=2) and cellulitis (n=1).
Hib vaccine failures
Five of the 10 Hib cases in the <15 year olds had not been
vaccinated against Hib, while five had been vaccinated. Three
of the vaccinated children had received three doses of Hib
vaccine as per the childhood immunisation schedule at two,
four and six months and therefore were fully vaccinated.
These three cases constitute true vaccine failures and Hib
disease occurred between two to three and a half years after
receiving the third/final dose of vaccine. However it should be
noted that one of these true vaccine failures occurred in an
immunocompromised child. The number of true Hib vaccine
failures tends to fluctuate between two and four per year, no
change in this trend was observed in 2003.
The other two vaccinated Hib cases in 2003 had been
incompletely vaccinated, each receiving only one of the three
recommended doses. Therefore, these are classified as
apparent vaccine failures.
In 2003, true vaccine failures occurred in only 30% of the Hib
cases in children <15 year of age. Since 1996, the proportion
Hib disease in fully vaccinated children has ranged between
20-60% per annum.
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Discussion
A recent resurgence of Hib infections observed in the UK over
the last four years has predominantly been in vaccinated
children. Experts believe that a reduction in antibody levels
throughout the first five years of life in vaccinated children in
recent years has fuelled the rise in reported Hib cases in the
absence of an obvious increase in transmission.1
This trend has not been identified in Ireland. Although the
number of Hib cases reported in Ireland in 2003 increased
somewhat compared to previous years, the number of Hib
vaccine failures remained unchanged. In 2003, only 30% of
the Hib cases that occurred in those <15 years of age had
been fully vaccinated. Therefore, a concomitant rise in true
vaccine failures did not occur with the observed increase in
Hib disease in 2003. Furthermore, the proportion of Hib
disease in fully vaccinated children has never risen above 60%
when data from 1996-2003 are reviewed. Based on these
data for Ireland, there is no evidence to indicate that waning
immunity to the Hib vaccine is the reason for the increase in
Hib disease seen in 2003. The fact that at least 50% of the
children diagnosed with Hib disease in 2003 were
unvaccinated is more a cause for concern. Poor uptake of the
Hib vaccine (86% in 2003) in Ireland is potentially one of the
main contributory factors to the increase in childhood Hib
disease recently observed.
Incidence rates of non-b capsulated H. influenzae remain low
and no evidence of serotype replacement have been observed
despite over 10 years of Hib vaccination. Non capsulated
strains now account for approximately a third of invasive 
H. influenzae cases in Ireland and therefore highlights the
importance of referring strains to a reference centre for
accurate identification of all strains.
In conclusion, although the incidence of invasive Hib disease
dropped impressively in the years after the introduction of
appropriate vaccination, the disease did not disappear
completely. Continued surveillance is essential to monitor
trends in the incidence of invasive H. influenzae disease and
Hib vaccine failures. This information is vital in measuring the
impact of preventive measures being used and in examining
strategies to eliminate Hib disease in Ireland.
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Table 1.  Invasive Haemophilus influenzae cases reported in 2003, by serotype and age group
Serotype <1 1-4 5-9 10-14 15-19 20-44 45-64 >65 Total  
type b 4 5 0 1 0 0 3 1 14
Non-b capsulated 0 0 0 0 0 1 0 1 2
Non-capsulated (NC) 2 1 0 0 0 0 0 3 6
All H. influenzae 6 6 0 1 0 1 3 5 22
ASIR of all H. influenzae 11.0 2.7 0.0 0.4 0.0 0.1 0.4 1.2 0.6
ASIR, age specific rate per 100,000
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Corporate Services
The role of the corporate services division is to provide
NDSC with the necessary resources, skills, policies and
procedures, competencies, systems and internal support
structures to achieve its objectives.
The divisional objectives are:
• To ensure NDSC has a qualified and competent workforce
necessary to meet its objectives and that NDSC is an
employer of choice
• To develop and implement systems, policies and
procedures that ensure the most effective and efficient use
of NDSC’s financial resources to enable it to achieve its
objectives
• To facilitate the enhanced performance of NDSC by the
provision of office accommodation and other support
services
• To provide skilled administration support to the Board,
committees and functional teams at NDSC
• To ensure NDSC meets all its obligations and requirements
in relation to legal, planning and compliance issues
• To provide an effective information service for NDSC
Human Resources
By the end of 2003 NDSC employed 41 staff members,
including highly qualified and experienced medical, scientific,
IT and administration staff. NDSC encourages staff to avail
of training courses considered to be of value to them in their
work and in their personal development. In addition to
attendance at relevant courses, seminars and conferences
during 2003, many staff of NDSC availed of the opportunity
to attend computer skills courses during the year. In
continuing with NDSC’s policy of supporting a work-life
balance, improved flexible working arrangements were
introduced at the Centre in 2003.
Communications
Following the appointment of a Communications Officer at
NDSC in January 2003, a new communications division was
established at the Centre to facilitate the delivery of key
public health messages and information to the media and
the public, to develop an integrated communications
programme at NDSC, and to ensure the production of
quality publications, documents and information for the
public and allied health care professionals.
Library and Information Services
In order to develop the library and information services
provided at NDSC, a librarian was appointed to the Centre in
January 2003. This led to the development of an extensive
library collection including the provision of a range of
electronic resources, which was facilitated by the
introduction of the Liberty library management system.
Health Services Reform Programme
As part of the health services reform programme a
comprehensive communication and consultation process
was held at NDSC in August 2003 to allow staff to express
their hopes and concerns for the reforms. This resulted in the
production of a report on NDSC staff views, which was
submitted to the Office for Health Management and the
Department of Health and Children.
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Influenza activity during the
2003/2004 season
Key Points
• Influenza activity began early in Ireland during the
2003/2004 season, peaking in mid-November 2003
• The influenza A/Fujian/411/2002(H3N2)-like strain was
the predominant circulating strain worldwide, mainly
affecting younger age groups
• Avian influenza outbreaks were detected in East and
South East Asia, Canada and the US
Introduction
Influenza is one of the commonest and oldest diseases known
to man. The impact on public health varies depending on the
circulating strain of virus and the level of pre-existing immunity
in the community each season.1, 2 
There are three types of influenza virus A, B and C. Influenza C
rarely causes human illness. The clinical course of influenza B
changes little from year to year and is usually milder than
influenza A. Influenza A varies considerably and is responsible
for epidemics and pandemics.3 Influenza A viruses are divided
into three subtypes, on the basis of two surface glycoproteins,
haemagglutinin (H) and neuraminidase (N). Minor changes in
the surface glycoproteins are known as antigenic drift.
Antigenic drift occurs between each influenza season,
necessitating the annual reformulation of the influenza vaccine,
which is based on the current circulating strains. Major changes
in the surface glycoproteins occur infrequently and are known
as antigenic shift. These result in the emergence of a novel
virus that may be capable of causing an influenza pandemic.
During the 20th century, three influenza pandemics occurred,
separated by intervals of 11 to 44 years: Spanish flu 1918-
1919, Asian flu 1957-1958, and Hong Kong flu 1968-1969. The
Spanish influenza pandemic of 1918 is acknowledged as the
most devastating, resulting in an estimated 20-40 million
deaths worldwide.3, 4
The 2003/2004-influenza season was the fourth year of
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influenza surveillance utilising computerised sentinel general
practices in Ireland. The NDSC is working in collaboration with
the NVRL and the ICGP on this surveillance project. Increased
influenza activity was observed in Ireland at the start of the
2003/2004-influenza season, compared to previous seasons.
Influenza activity was mainly observed in younger age groups
during the 2003/2004 season. The predominant circulating
strain this season was influenza A/Fujian/411/2002(H3N2)-
like.
Materials and methods
Clinical data
Thirty-five general practices were recruited to report
electronically, on a weekly basis, the number of patients with
influenza-like illness (ILI). ILI is defined as the sudden onset of
symptoms with a temperature of 38OC or more, with two or
more of the following: headache, sore throat, dry cough and
myalgia. Patients were those attending for the first time with
these symptoms. In total, the 35 sentinel general practices,
comprising 66 general practitioners, represent 2.8% of the
national population. Practices were located in all health
boards with the number of sentinel practices in each health
board based on the population of each health board.
Virological data
Sentinel GPs were requested to send a combined nasal and
throat swab on at least one patient per week where a clinical
diagnosis of ILI was made. Swabs were sent to the NVRL for
testing using Shell Vial and PCR techniques and results were
reported to NDSC. The NVRL also reported on a weekly basis
the results of respiratory specimens referred mainly from
hospitals.
Regional influenza activity
The Departments of Public Health sent an influenza activity
index (no report, no activity, sporadic-, localised-, regional- or
widespread activity) every week, to NDSC. The activity index
is analogous to that used by the WHO global influenza
surveillance system and the European Influenza Surveillance
Scheme.5, 6 The index is based on sentinel GP ILI consultation
rates, laboratory-confirmed cases of influenza, sentinel
hospital admissions data and/or sentinel school absenteeism
levels. One sentinel hospital was located in each health board.
Sentinel primary and secondary schools in each health board
were located in close proximity to the sentinel GPs.
Weekly influenza surveillance report
NDSC produced a weekly influenza report, which was posted
on the NDSC website each Thursday. Results of clinical and
virological data were reported, along with a map of influenza
activity and a summary of influenza activity worldwide.
Enhanced influenza surveillance
In response to the increase in ILI activity in younger age
groups during the 2003/2004 season, an enhanced influenza
surveillance system was implemented to capture data on all
hospitalised influenza cases aged 0-14 years.
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Figure 1. GP consultation rate for ILI per 100,000 population by week, during the 2000/2001, 2001/2002, 2002/2003 & 2003/2004-influenza seasons
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Results 
Early school outbreaks
The 2003/2004-influenza season started early, with two
school outbreaks of ILI during September 2003, in the ERHA.
The first outbreak occurred during the first week of September
and involved 160 students and four teachers in a school in Co.
Kildare. The second school outbreak was in South County
Dublin and occurred during the end of the second week of
September 2003 and involved 81 pupils and one staff
member. Influenza A (H3N2) was identified in both outbreaks
and was later antigenically characterised as the A/Fujian/411/
2002(H3N2)-like strain.7, 8 Two further school ILI outbreaks
were reported during the 2003/2004 season, one in the SEHB
during week 42 and the other in the MHB during week 45.
Clinical data
The early influenza activity associated with the two school
outbreaks in the ERHA was also reflected in the GP sentinel
surveillance scheme. Influenza activity increased earlier than
usually observed by sentinel GPs, with GP consultation rates
for ILI peaking during week 46 at 82.3 per 100,000 population
(figure 1). This is the highest peak rate since the 2000/2001
season when rates peaked at 121.0 per 100,000 during week
8. During the peak in ILI consultation rates, the majority of
cases reported were aged between 0-4 and 5-14 years of age
(figure 2). A total of 625 ILI cases were reported by sentinel
GPs during the 2003/2004 season, compared to 348 during
the 2002/2003 season, 277 during the 2001/2002 season and
671 during the 2000/2001 season.
Virological data
The NVRL tested 350 sentinel specimens for influenza virus
during the 2003/2004-influenza season. One hundred and
forty-nine (42.6%) sentinel specimens were positive for
influenza virus: 142 influenza A (140 A H3N2 and 2 A
unsubtyped) and seven influenza B. The predominant influenza
virus subtype identified through the sentinel GP scheme this
season was influenza A (H3N2), accounting for 94.0% of
positive specimens. The number of positive influenza
specimens peaked during weeks 44 to 47 2003 (figure 3).
Positive specimens in all age groups with the exception of
those aged 65 years or older increased during the period of
peak clinical activity. The majority of positive sentinel cases
this season were in the 15-64 year age group, in contrast to
non-sentinel cases, which were mainly 0-4 years of age.
The NVRL tested a total of 1857 non-sentinel respiratory
specimens mostly from hospitals during the 2003/2004
influenza season. One hundred and twelve specimens (6.0%)
were positive for influenza virus: 98 influenza A and 14
influenza B. The number of influenza positive specimens
peaked between weeks 47 and 49. The majority of influenza
positive non-sentinel cases were 0-4 years of age (69/112;
61.6%). Six (5.4%) cases were 5-14 years of age, 32 (28.6%)
cases were 15-64 years of age and one case was 65 years of
age or older. Eight non-sentinel specimens (0.4%) were
positive for Adenovirus, 396 (21.3%) for respiratory syncytial
virus (RSV), six (0.3%) for parainfluenza virus type-1, five
(0.3%) for parainfluenza virus type-2 and 38 (2.0%) for
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Figure 2. Age specific GP consultation rate for ILI per 100,000 population by week for the 2003/2004-influenza season
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Figure 3. Number and percentage of sentinel specimens positive for influenza virus during the 2003/2004-influenza season
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parainfluenza virus type-3. Please note that non-sentinel
specimens include all respiratory specimens referred to the
NVRL; these specimens are mainly from hospitals and some GPs
and may include more than one specimen from each case.
The total number of influenza positive specimens from all
sources (sentinel and non-sentinel) this season was 261: 240
influenza A and 21 influenza B. Seventy-five influenza positive
cases this season were in the 0-4 year age group and 31 were
in the 5-14 year age group. One hundred and forty-five
influenza positive specimens were in cases aged between 15
and 64 years of age, six cases were 65 years or older and four
cases were of unknown age group.
RSV data
During the 2002/2003 and 2003/2004 seasons, the number
of RSV positive detections from hospital respiratory
specimens referred to the NVRL reached the highest levels on
record.9 Three hundred and ninety-six RSV positive specimens
were detected during the 2003/2004 season, peaking in
January 2004 (figure 4). Prior to the 2002/2003 season, the
largest seasonal outbreak of RSV occurred during the
1998/1999 season, with 250 RSV positive specimens detected
by the NVRL.
Vaccination status and antigenic characterisation
Of the 149 positive influenza virus detections from sentinel
specimens, 105 (70.5%) were not vaccinated, eight (5.4%)
were vaccinated and vaccination status was unknown in 36
(24.2%) cases. Of the eight cases that were vaccinated,
influenza A (H3N2) was detected in seven cases and influenza
A (unsubtyped) was detected in one case.
The NVRL referred representative specimens from the initial
ERHA school outbreaks and from sentinel specimens to the
WHO laboratory (Mill Hill) in London for antigenic
characterisation. Eight influenza A (H3N2) samples were
sequenced at the NVRL and phylogenetic analysis was carried
out at Mill Hill laboratory. All eight samples were
characterised as A/Fujian/411/2002 (H3N2)-like strains. An
influenza B virus isolate was antigenically characterised as
being closely related to the B/Hong Kong/330/2001-like
strain.
Regional influenza activity 
Regional influenza activity peaked between weeks 42 and 50
2003, with localised and sporadic influenza activity reported
in the ERHA and NEHB and sporadic activity reported in the
remaining health boards. In some health boards, increases in
sentinel hospital total admissions, A & E admissions and
respiratory admissions and increases in sentinel primary and
secondary school absenteeism were reported during the
period of peak clinical activity. Influenza positive specimens by
health board are detailed in table 1. The number of positive
specimens by health board is influenced by the number of
sentinel GPs in each health board and also the number of
respiratory specimens that regional and local laboratories refer
to the NVRL.
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Mortality data
Two influenza A associated deaths were reported to NDSC
during the 2003/2004 season. Both deaths occurred in 0-4
year olds in the SEHB, one during week 47 and the other
during week 48 2003.
Enhanced influenza surveillance
Seven influenza cases were reported to NDSC during
December 2003 and January 2004, through the enhanced
influenza surveillance system. The cases ranged in age from six
weeks to 13 years, with four cases aged 0-4 years and three
cases aged 5-14 years. Influenza A was detected in three of
the seven cases, influenza B in one case and three cases were
of unknown influenza type. The cases were all hospitalised for
a period ranging from 2-11 days. Complications associated
with these cases included: primary influenzal viral pneumonia,
secondary bacterial pneumonia and bronchitis. Two of the
cases were at risk of influenza related complications and
therefore had been vaccinated. The remaining five cases were
unvaccinated.
Six cases of influenza pneumonia were notified to NDSC in
2003 through the weekly infectious disease notification
system, all six cases were notified during November and
December 2003. Four of the six cases were 0-4 years of age,
one was in the 5-14 year age group and one case was in the
15-24 year age group. Please note that these cases may have
also been reported through the sentinel surveillance system or
the enhanced influenza surveillance system.
Influenza activity worldwide
During the 2003/2004 season, influenza activity began early
in Europe, with an initial surge of activity in Western Europe
beginning in Ireland, the UK, Spain and Portugal and followed
by Norway, France and Belgium, with incidence rates highest
amongst 0-4 year olds. A second wave of activity was
concentrated in Central and Eastern European countries. The
vast majority of characterised influenza strains in Europe
during the 2003/2004 season were influenza
A/Fujian/411/2002(H3N2)-like. A small percentage of
influenza B viruses were characterised, the majority of which
were B/Shanghai/361/002-like. 5
In the US, an early increase in influenza activity was reported
with activity levels above baseline level from week 45 2003.
The influenza A/Fujian/411/2002(H3N2)-like strain was the
predominant strain detected.10 Early influenza activity was
also reported in Canada, with the A/Fujian/411/2002(H3N2)-
like strain predominating mainly amongst younger age
groups.11
Influenza activity in Africa and Oceania also began earlier than
usual and was more severe than the preceding three years.
Influenza A (H3N2) viruses predominated in most countries
worldwide and were responsible for the majority of outbreaks.
Influenza A (H1) circulated at low levels in most parts of the
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Figure 4. Number and percentage of non-sentinel RSV positive specimens detected during the 2003/2004 and 2002/2003 influenza seasons
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Table 1. Total number of sentinel & non-sentinel* influenza A and B positive specimens by health board for the 2003/2004 season 
Health board Sentinel Non-Sentinel Sentinel & Non-Sentinel 
 Flu A Flu B Total Flu A Flu B Total Flu A Flu B Total
ERHA 63 2 65 55 7 62 118 9 127
MHB 3 0 3 6 2 8 9 2 11
MWHB 19 1 20 3 0 3 22 1 23
NEHB 20 2 22 15 1 16 35 3 38
NWHB 5 0 5 11 0 11 16 0 16
SEHB 15 1 16 5 2 7 20 3 23
SHB 10 0 10 1 0 1 11 0 11
WHB 7 1 8 2 2 4 9 3 12
Total 142 7 149 98 14 112 240 21 261
* Please note that non-sentinel specimens include all specimens referred to the NVRL; 
these specimens are mainly from hospitals and some GPs and may include more than one specimen from each case.
world, with outbreaks occurring in Iceland and the Ukraine.
Influenza B also circulated at low levels in most parts of the
world. 12
The most significant influenza event globally during the
2003/2004 season was the widespread epidemic in East and
Southeast Asia of highly pathogenic avian influenza (HPAI),
caused by influenza A (H5N1) in animal populations,
particularly domestic fowl and a variety of other birds. These
outbreaks posed a considerable potential human public health
risk and resulted in 23 human deaths in Vietnam and Thailand
and mass poultry culls in Asia. Low pathogenic avian influenza
detections (caused by influenza A H7N2 & A H2N2) were
reported in the eastern US, and HPAI (caused by influenza A
H5N2) was reported in Texas during the 2003/2004 season
(each of these viruses was different from the HPAI strain in
Asia). Avian influenza poultry outbreaks were also reported in
Canada, associated with influenza A (H7N3). Two human
cases of avian influenza A (H7) were reported in poultry
workers in Canada, both cases recovered.13
Discussion
Influenza activity peaked early in Ireland during the
2003/2004-influenza season; with higher levels of activity
reported than in the previous two seasons, when low
influenza activity levels were observed. 14 This early influenza
activity was also reflected throughout most of Western
Europe, the US and Canada. 5 The ERHA school outbreaks were
among the first influenza cases of the 2003/2004 season
reported in Europe. 7, 8
During the 2003/2004 season, some antigenic drift was
detected in the A (H3N2) strains circulating in Europe,
America, Australia and New Zealand. The A/Fujian-like strains
are related to the A/Panama-like strain included in the
2003/2004 vaccine and antibodies induced against this
vaccine strain cross-react with A/Fujian-like strains, but
generally at a reduced level. The 2003/2004 influenza vaccine
offered good protection against the virus strains in the
vaccine, and a degree of cross protection against the A/Fujian-
like strain.5 The 2003/2004-influenza vaccine offered the best
protection for those aged 65 years and over and those in at
risk groups. The WHO published its recommendations on the
composition of the influenza vaccine for use in the
2004/2005 Northern Hemisphere influenza season on the 27th
February 2004. The vaccine will include the following strains:
A/New Caledonia/20/99(H1N1)-like virus, A/Fujian/411/
2002(H3N2)-like virus and B/Shanghai/361/ 2002-like virus. 12
A/Fujian-like strains were first detected in very low numbers
during the 2002/2003-influenza season in Europe and also in
viruses circulating in Australia and New Zealand during July
and August 2003.5 The A/Fujian-like strains identified during
the 2003/2004 season in Ireland resulted in higher incidence
rates of influenza in 0-4 year olds and are likely to have been
the cause of some clinically severe cases (identified through
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the enhanced influenza surveillance system) and of two
influenza associated deaths in this age group. Detection of
higher incidence rates of influenza in younger age groups was
not unexpected as there has been very little influenza in
circulation for the last few seasons; therefore the opportunity
for development of immunity particularly amongst younger
age groups has been limited.
Avian outbreaks of influenza A (H5N1) have posed a
significant threat to human health in 2004. In a number of
outbreaks since the beginning of 2004 in Asia, the virus has
jumped from infected chickens or ducks directly to humans.
These direct human infections have produced severe and
sometimes fatal outcomes. The risk of virus transmission to
humans from infected poultry will continue as long as
outbreaks are occurring in poultry. Of greatest concern is the
risk that continuing transmission of the virus to humans will
give avian and human influenza viruses an opportunity to
exchange genes (reassortment), thereby acquiring the ability
to transmit easily from human to human and thus triggering a
pandemic.13
In light of the threat posed to human health from avian
influenza outbreaks, a number of additional measures have
been put in place in Ireland to strengthen and expand
surveillance of ILI. Work is in progress to increase the number
of sentinel GPs, thereby improving their geographical
representation. Sentinel GPs are also working towards
monitoring influenza on a year round basis. The NVRL will
begin testing sentinel specimens for RSV, as well as influenza,
in October 2004. In addition, influenza became a notifiable
disease in Ireland on January 1st 2004. This information will in
turn inform continuing progress on the Irish national influenza
pandemic preparedness plan.
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Surveillance of Outbreaks 
of Infectious Intestinal 
Disease (IID) in Ireland, 2002
Key Points
• 188 outbreaks of IID were reported to the national
outbreak surveillance system in 2002, compared to 64 in
2001
• These outbreaks were responsible for at least 8027
persons becoming ill
• Noroviruses have emerged as the primary cause of IID
outbreaks being the causative pathogen in 154 (82%) of
IID outbreaks in 2002
• In 2002, the majority of outbreaks occurred in healthcare
settings i.e. hospitals and residential homes
Introduction
Outbreak investigations aim to identify the source of the
outbreak, institute control measures and prevent additional
cases. The information gathered during outbreak
investigations can be used to determine possible ways of
preventing future outbreaks.
The principal objectives of the national outbreak surveillance
system are to gain information on the epidemiology of all
outbreaks of infectious disease in Ireland.
More specific objectives include measuring the burden of illness
caused by outbreaks, identifying high-risk groups in the
population and estimating the workload involved in the
management of outbreaks. The information gathered can be
used to inform public health professionals on the causes and
factors contributing to outbreaks, to target prevention
strategies and to monitor the effectiveness of prevention
programmes.
Outbreak definition
Outbreak
An outbreak of infection or foodborne illness may be defined
as two or more linked cases of the same illness or the
situation where the observed number of cases exceeds the
expected number, or a single case of disease caused by a
significant pathogen. Outbreaks may be confined to some of
the members of one family or may be more widespread and
involve cases either locally, nationally or internationally.
Methods 
Since July 2001, public health professionals are requested to
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report all investigated outbreaks of infectious intestinal
disease to the NDSC using a preliminary notification form (by
fax or email). A follow-up investigation form and/or final
report is then forwarded by the lead investigator at the end of
the investigation. The data collected include information on
the source of reporting of the outbreak, the extent of the
outbreak, mode of transmission, location, pathogen involved,
laboratory investigation, morbidity and mortality data,
suspect vehicle and factors contributing to the outbreak.
These data are stored and analysed in a Microsoft Access
database in NDSC.
Results
During 2002, 188 outbreaks of infectious gastrointestinal
disease were reported to NDSC, resulting in at least 8027
people becoming ill. 1296 people were reported to have been
hospitalised (16%). Table 1 shows the regional distribution of
outbreaks during 2002. Most outbreaks were reported from
the ERHA region (n=83).
Causative pathogen
The most notable feature of analysis of the IID outbreak data
from 2002 is the dramatic increase in the number of
outbreaks either confirmed or suspected to be due to
norovirus. This is most evident in figure 1 when outbreak data
from 1998 to 2002 are examined. The breakdown of the
2002 outbreaks by pathogen is shown in table 2. Noroviruses
are seen to account for 154/188 (82%) of all outbreaks of IID
reported to NDSC in 2002 (see figure 2). This compared to
2001 when suspect or confirmed norovirus accounted for
58% of all IID outbreaks. Other viral causes of outbreaks in
2002 included rotavirus, adenovirus and suspect enterovirus.
After norovirus, the next most commonly reported outbreaks
were Salmonella enterica and E. coli O157. All of the 
E. coli 0157 outbreaks occurred in private homes and were
identified as part of active case finding during epidemiological
investigations of single cases. There was an increase in the
number of S. enterica outbreaks reported compared to 2001.
Two were identified as S. Typhimurium, two as S. Enteritidis
and serotyping information was not available on the other
three. There was one small general outbreak of salmonellosis
that occurred in a residential institution, with all of the
remainder being family outbreaks. There was one outbreak of
Campylobacter jejuni reported in 2002, associated with eating
in a restaurant.
Mode of transmission
In the majority of outbreaks of IID in 2002, the principal
mode of transmission of the illness was reported as person-
to-person (table 3). Not surprisingly, the majority of
outbreaks with this mode of transmission were
norovirus/suspect viral as shown in figure 3. This also serves
to explain the high attack rates in these outbreaks.
Location
As is seen in table 4, the commonest location that outbreaks
occurred in 2002 was health-care settings i.e. hospitals and
residential institutions. 72% of all reported outbreaks
occurred in these settings. The greatest number of people ill
were also associated with outbreaks in these locations, with
over 5000 people known to be ill as a result of outbreaks in
the hospital sector alone.
Table 1. Number of outbreaks of IID and total numbers ill in each health board area 2002.
Health Board Number of Outbreaks  Number ill
ERHA 83 4316
SEHB 32 1386
MHB 19 368
SHB 17 1008
MWHB 12 433
NEHB 9 219
NWHB 9 102
WHB 7 195
Total 188 8027
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Figure 1. Confirmed or suspect norovirus outbreaks v. other causes, 1998-2002. 
(Data prior to July 2001 provided by FSAI)
0
160
120
80
40
100
60
140
20
19991998 2000 2001 2002
All other pathogens
Table 2.  Pathogens associated with outreaks and numbers ill, 2002.
Pathogen  Number of Outbreaks  Number ill
Norovirus 98 6776
Suspect Viral 56 881
Salmonella spp 7 27
E. coli O157 7 19
Cryptosporidium spp 3 63
Rotavirus 2 18
Adenovirus 1 11
Campylobacter jejuni 1 7
Clostridium difficile 1 6
Enterovirus (suspect) 1 132
Shigella sonnei 1 4
Staph. aureus 1 7
Not known 9 76
Total 188 8027
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Seasonal distribution
When the outbreaks in 2002 are analysed by month of
reporting, it is seen that the majority of outbreaks occurred in
January-February followed by another peak in September
(figure 4). Many of the norovirus outbreaks in hospitals and
residential institutions occurred in the early months of 2002.
The peak in September was linked to another wave of
norovirus outbreaks in health-care settings as well as
outbreaks of viral gastroenteritis linked to the tourist industry
i.e. hotels and tour-bus outbreaks.
Discussion
In 2002, there was a very significant rise in the number of IID
outbreaks reported to NDSC compared to previous years.
From 1998 to 2000, there was on average 34 outbreaks of IID
reported each year. This increased to 64 outbreaks in 2001,
and rose further to 188 outbreaks in 2002. This figure
represents all investigated and reported IID outbreaks and is
possibly even an under-estimate of the true figure.
The dramatic increase in outbreak reporting in 2002 was due
undoubtedly to the large upsurge in norovirus outbreaks that
occurred. Eighty-two percent of all reported outbreaks were
either suspected or confirmed to be caused by norovirus.
Seventy percent of all outbreaks occurred in health-care
settings and there was significant morbidity associated with
these outbreaks with at least 7650 people reported ill.
In 2002 there was an epidemic of viral gastroenteritis due to
norovirus seen across Europe, and Ireland was part of this
wave of outbreaks1. Typing studies carried out in the UK
reported that a new variant of the commonly circulating
Lordsdale virus (genogroup II4) was responsible for these
outbreaks2.
There are a number of features of the virus that can explain
the explosive nature of the outbreaks that were seen.
Norovirus has a low infectious dose, can survive in the
environment and be easily transmitted from person-to-person
often by aerosolisation of viral particles during episodes of
vomiting. Congregate and enclosed settings are perfect
environments for the virus to spread. With the added factor
of a vulnerable population in health-care settings, it is not
surprising that these locations are prone to outbreaks of this
virus.
In light of the epidemic of norovirus outbreaks that seriously
affected, in particular, the acute hospital sector in 2002, a
Viral Gastroenteritis sub-committee of the NDSC Scientific
Advisory Committee was established. One of the main Terms
of Reference was to develop national guidelines to assist
professionals in managing outbreaks of noroviruses in
healthcare settings. These guidelines3 were published and
launched by the Minister for Health and Children in December
2003.
Only 11% of outbreaks had a bacterial aetiology in 2003. The
most commonly isolated pathogens were Salmonella enterica
and E. coli O157. All of these outbreaks were small in size
and the majority were family outbreaks. This is also reflected
in the low percentage of outbreaks deemed to foodborne in
2002 (just 6%).
There were three outbreaks that were reported to have a
Table 3. Principal mode of transmission reported in outbreaks of IID (2002)
Mode of Transmission Number of Outbreaks 
Foodborne 7
Person-to-person 185
P-P/Foodborne 4
Waterborne 3
Waterborne/Animal 1
Unknown 8
Total 188 O
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Figure 2. Outbreaks of IID reported in 2002 by pathogen
Norovirus/Suspect Viral Cryptosporidium spp
E. coli O157 Not Known
Salmonella spp Other
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Table 4. Outbreaks by location and numbers ill, 2002.
Location Number of Outbreaks  Number ill
Hospital 72 5373
Residential institution 63 1638
Private house 14 47
Crèche 13 167
Hotel 11 452
Restaurant/café 4 37
School 4 181
Tour bus 1 15
Public house 1 7
Other 5 110
Total 188 8027
NDSC Annual Report 2003 93
waterborne mode of transmission (all Cryptosporidium spp)
and one with a waterborne and animal-contact transmission
route (family outbreak of E. coli O157). Sixty-three
individuals were reported ill as a result of the three
Cryptosporidium spp outbreaks. The potential for significant
numbers of people including vulnerable populations to be
affected in waterborne outbreaks reinforces the need for
stringent early control measures to be implemented in these
events.
Outbreak investigations are an important and challenging
component of epidemiology and public health, and help to
identify the source of the outbreak, institute control measures
and prevent additional cases. Extremely valuable information
has been derived from analyses of the national IID outbreak
data in 2002. As was clearly seen in light of the norovirus
epidemic, the information collated from the outbreak data
was used to formulate national guidelines on the
management of these outbreaks in order to reduce the overall
burden of illness due to this pathogen.
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Antimicrobial Resistance 
in Ireland, 2003
Key Points
• In 2003,1140 invasive isolates of Staphylococcus aureus
were reported. The proportion of isolates that were
methicillin-resistant S. aureus (MRSA) was 42.1%, which
remains one of the highest in countries reporting to
EARSS
• 364 invasive isolates of Streptococcus pneumoniae were
reported. The proportion that was penicillin-non-
susceptible S. pneumoniae (PNSP) was 11.8%, which is
moderately high compared to other European countries.
Of the 43 PNSP isolates identified, eight were found to be
high-level resistant [minimum inhibitory concentration
(MIC) >2 mg/L] and 32 were determined to have
intermediate levels of resistance (MIC 0.12–1.0 mg/L).
No MICs were available for three isolates
• 991 invasive isolates of Escherichia coli were reported.
The proportions of isolates that were resistant to third-
generation cephalosporins, fluoroquinolones and
aminoglycosides were 2.4%, 9.5% and 3.9%, respectively.
These figures are low compared with other European
countries
• 218 invasive isolates of Enterococcus faecalis were
reported. The proportion of isolates that were
vancomycin-resistant was 1.4%. Although this figure is
low, it is still slightly higher than observed in most other
European countries (<1%)
• 135 invasive isolates of Enterococcus faecium were
reported. The proportion of isolates that were
vancomycin-resistant was 19.4%, which is moderately
high compared with most other European countries
Introduction
The European Antimicrobial Resistance Surveillance System
(EARSS) was established in 1998 and is funded by DG SANCO
of the European Commission. It is an international network of
national surveillance systems, encompassing over 600
laboratories in 28 countries, which aims to collect comparable
and reliable antimicrobial resistance data on invasive infections
of Staphylococcus aureus, Streptococcus pneumoniae,
Escherichia coli, and Enterococcus faecium/faecalis for public
health action.
EARSS in Ireland started in 1999 with the surveillance of S.
aureus and S. pneumoniae and expanded in 2002 to include
three further pathogens, E. coli and the enterococci, E. faecalis
and E. faecium. Five additional laboratories joined the program
in 2003 bringing the total number of participating laboratories
to 28. The method for determining the percentage population
coverage has been revised from a very rough estimate of the
catchment populations reported by each participating hospital
laboratory in previous years to a calculation based on acute
public hospital activity data obtained from DoHC. This revised
calculation gives an estimated population coverage
approaching 90%, which represents an increase from the
revised 80% coverage in 2002.
Protocol
Data are collected on the first invasive isolate per patient per
quarter of S. aureus and the enterococci (from blood only) and
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S. pneumoniae and E. coli [from blood and cerebrospinal fluid
(CSF)]. Laboratories report routinely generated qualitative
disc diffusion data on:
• oxacillin/methicillin for S. aureus
• oxacillin/penicillin and erythromycin for S. pneumoniae  
• ampicillin, cetotaxime/ ceftriaxone and/or ceftazidime [third-
generation cephalosporins (3GCs)], ciprofloxacin/ofloxacin
(fluoroquinolones) and gentamicin/tobramycin (amino-
glycosides) for E. coli. Laboratories are also asked to
specifically test for the presence of extended-spectrum beta-
lactamases (ESBLs)
• ampicillin, high-level gentamicin and vancomycin for
enterococci
All methicillin-resistant S. aureus (MRSA) isolates are
submitted to the National MRSA Reference laboratory
(NMRSARL) at St James’s Hospital, where minimum inhibitory
concentrations (MICs) are determined for oxacillin and
vancomycin. Laboratories are requested to submit data on
MICs or Etests performed in-house for penicillin and
cefotaxime or ceftriaxone on all penicillin-non-susceptible S.
pneumoniae (PNSP) isolates.
Results
Staphylococcus aureus
In 2003, 1140 reports of S. aureus isolates from bacteraemia
were received from 26 laboratories, of which 480 (42.1%)
were resistant to methicillin. By comparison, the proportion
of S. aureus isolates that were methicillin-resistant in 2002
was 42.7%. In 2003, there was a peak in Q2 when the
proportion of MRSA was 46.5% compared with the other
three quarters of the year when the proportion ranged from
40.3-41.4% (figure 1). A similar pattern was seen in 2002.
Data from the NMRSARL showed that gentamicin resistance
among MRSA isolates decreased from 33.9% in 2001 (and an
initial high of 58.4% in 1999) to 24.0% in 2002 and again in
2003 to 13.1% (figure 2). This continues to reflect the
growing trend throughout Europe in which epidemic strains of
MRSA that are less multi-resistant to antibiotics are becoming
more prevalent.
The overall annual proportion of MRSA observed in Ireland
remains high and is comparable with proportions observed in
the UK, France and most Southern European countries (see
figure 3). For the first time since EARSS commenced in 1999,
a country (Greece) has reported a proportion of MRSA that is
over 50%. Increases have also been observed in Finland and
parts of Central Europe (Hungary and Slovakia). The
Scandinavian countries and The Netherlands report the lowest
proportions of MRSA.
Streptococcus pneumoniae
In 2003, 364 reports of S. pneumoniae isolates from
bacteraemia/meningitis were received from 24 laboratories.
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Figure 1.  Trends for S. aureus by time period: by year for 1999-2003 and by quarter 
for 2003 (Q1-Q4) – total numbers of S. aureus/MRSA and percentage MRSA with 
95% confidence intervals.  Changes in the numbers of laboratories participating 
in the surveillance system by year-end are indicated above the chart
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Figure 2.  Trend in gentamicin resistance among MRSA isolates referred to NMRSARL 
between 1999 and 2003 - total numbers of MRSA isolates tested and gentamicin-
resistant MRSA isolates identified and percentage gentamicin-resistant MRSA with 
95% confidence intervals. Changes in the numbers of laboratories participating in 
the surveillance system by year-end are indicated above the chart
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The majority of isolates (n = 359) were from blood but five
were from CSF. Forty-three isolates (11.8%) were PNSP. By
comparison, the proportion of S. pneumoniae isolates that
were penicillin-non-susceptible in 2002 was 11.5%.
As in previous years, a seasonal variation was seen in the
numbers of S. pneumoniae isolates reported with a trough in
Q3, reflecting the quieter summer period (see figure 4).
Of the 43 PNSP isolates reported, MIC data for penicillin and
cefotaxime were available for 40 and 24 isolates, respectively.
Eight isolates were found to be high-level penicillin resistant
(MIC ≥2 mg/L) and the remaining 32 isolates of the 40 tested
were determined to have intermediate levels of resistance
(MIC 0.12–1.0 mg/L). No MICs were available for three PNSP
isolates. One isolate was intermediately resistant to
cefotaxime (MIC 2 mg/L according to NCCLS non-meningitis
breakpoints) in addition to being high-level resistant to
penicillin (MIC 2 mg/L). The remaining 23 isolates of the 24
tested were susceptible to cefotaxime (MIC ≤1 mg/L).
Two additional isolates were reported that were oxacillin-
resistant on screening by disc diffusion but were subsequently
found to be penicillin-susceptible on MIC testing. This
highlights the importance of MIC testing on all isolates that
appear to be non-susceptible on the initial screening test.
Data on susceptibility to erythromycin or clarithromycin were
available for 344 isolates. Forty (11.6%) were reported to be
resistant.
Of the five CSF isolates reported in 2003, one (from a two-
year old child) was intermediately resistant to penicillin (MIC
1 mg/L) but susceptible to cefotaxime (MIC 0.5 mg/L,
interpreted using NCCLS meningitis breakpoints). The other
four isolates (from three children under 4 years and one adult
aged 48 years) were susceptible to penicillin.
Based on the total population of 3,917,203 in the Republic of
Ireland as determined in the 2002 census and approximately
90% coverage of the population by the EARSS surveillance
system, the crude incidence of invasive pneumococcal disease
in Ireland is estimated to be 10.4 per 100,000 population.
This represents an increase on the 8.8 per 100,000 population
in 2002 (previously reported as 7.8 per 100,000 population
but this figure has been revised based on acute public hospital
activity data, which is considered to give a better estimate of
population coverage). The corresponding revised figures for
1999, 2000 and 2001 are 8.2, 7.8 and 8.1 per 100,000
population, respectively. By comparison, the rates of invasive
pneumococcal disease reported in England and Wales in 1999
and 2000 were 8.6 and 8.9 per 100,000 population,
respectively.1,2 In Scotland, a recent study reported that the
overall incidence of invasive pneumococcal disease between
1999 and 2001 was 11 per 100,000.3
Figure 3.  Map illustrating the distribution of MRSA in EARSS countries in 2003.
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Figure 4.  Trends for S. pneumoniae by time period: by year for 1999-2003 and by 
quarter for 2003 (Q1-Q4) – total numbers of S. pneumoniae/PNSP and percentage 
PNSP with 95% confidence intervals.  Changes in the numbers of laboratories 
participating in the surveillance system by year-end are indicated above the chart
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The overall annual proportion of PNSP observed in Ireland
remains moderately high (see figure 5) compared to the UK,
Scandinavia and some Central European countries, such as
Germany, which are generally associated with lower PNSP
proportions. Higher proportions of PNSP are observed in
Belgium, Southern Europe and some countries of the former
Eastern Bloc.
Escherichia coli
In 2003, 991 reports of E. coli isolates from bacteraemia/
meningitis were received from 27 laboratories. The majority
of isolates (n = 989) were from blood but two were from CSF.
The proportions of isolates reported to be resistant to
ampicillin, 3GCs, ciprofloxacin/ofloxacin (fluoroquinolones)
and gentamicin were 61.9%, 2.4%, 9.5% and 3.9%,
respectively, compared with 62.2%, 3.0%, 5.4% and 2.7%,
respectively, reported in 2002.
The total numbers of E. coli isolates and proportion of
resistance reported by quarter for 3GCs, fluoroquinolones and
gentamicin are shown in figure 6.
Thirty-three isolates were identified as multi-drug resistant
[defined as resistance to three or more of the mandatory
antibiotics (ampicillin, 3GCs, fluoroquinolones and
gentamicin)]:
• six isolates were resistant to ampicillin, 3GCs,
fluoroquinolones and gentamicin - ESBL data were reported
on five of these, all of which were positive
• eighteen were resistant to ampicillin, fluoroquinolones and
gentamicin
• eight were resistant to ampicillin, 3GCs and
fluoroquinolones. Four of these were ESBL-positive
• one was resistant to ampicillin, 3GCs and gentamicin
In total, 576 (58%) of the 991 isolates were examined for the
presence of ESBLs. ESBLs were detected in 11 (1.9%) of
these.
The two CSF isolates, both from newborns aged 11 and 16
days, respectively, were susceptible to 3GCs, fluoroquinolones
and aminoglycosides. One of these isolates was resistant to
ampicillin while the other was susceptible.
The proportion of ampicillin resistance reported in
participating countries in Europe in 2003 was generally
categorised as moderately high (25-50%) to high (>50%).
The proportion in Ireland was high (61.9%) and was
comparable with proportions seen in Italy, Spain and Portugal.
The proportion of resistance to 3GCs, fluoroquinolones and
gentamicin observed in Ireland in 2003 was low compared
with most other European countries (figures 7-9). The lowest
proportions of resistance were observed in the Scandinavian
Figure 5.  Map illustrating the distribution of PNSP in EARSS countries in 2003.
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Figure 6.  Trends for E. coli by quarter for 2003 – total numbers of E. coli and percentage 
resistance to 3GCs, ciprofloxacin/ofloxacin (CIP/OFX) and gentamicin (GEN). 
 Number of participating laboratories is indicated for each quarter
% 3GC-R % CIP/OFX-RTotal E. coli
Q1
2002
Q2
2002
Q3
2002
Q4
2002
Q1
2003
Q2
2003
Q3
2003
Q4
2003
0
50
100
150
200
200
300
%
 R
es
is
ta
nc
e
0
4
6
8
10
14
12
% GEN-R
18 2119 2419 24 26 27 
2
NDSC Annual Report 200398
countries while the highest proportions were seen in Southern
and Eastern Europe.
Enterococcus faecalis
In 2003, 218 reports of E. faecalis isolates from bacteraemia
were received from 19 laboratories.
The total numbers of E. faecalis isolates and proportion of
resistance reported by quarter for ampicillin, high-level
gentamicin and vancomycin are shown in figure 10.
Eleven isolates (5.1%) were reported to be ampicillin-
resistant. Ampicillin resistance in E. faecalis is unusual and
further investigation of these isolates is warranted to confirm
their identity as it is generally acknowledged that speciation
of enterococci can be problematic.
Sixty-one isolates (34%) of the 179 tested were reported to
be high-level gentamicin resistant, of which 10 were
confirmed by MIC determination. By comparison, 39% of
isolates were reported to be high-level gentamicin resistant in
2002. The proportion of isolates tested for susceptibility to
high-level gentamicin increased from 30% in 2002 to 82% in
2003, indicating increased awareness of this susceptibility
testing issue and greater concordance with the protocol.
Three isolates (1.4%) were reported to be vancomycin
resistant. Two of these were also resistant to teicoplanin. The
other isolate was intermediately resistant to vancomycin (MIC
8 mg/L) and susceptible to teicoplanin, which would merit
confirmation of the species identification. By comparison,
2.4% of isolates were vancomycin-resistant in 2002.
No isolates were resistant to ampicillin, high-level gentamicin
and vancomycin. However, one isolate was resistant to high-
level gentamicin and vancomycin and susceptible to
ampicillin.
In 2003, the proportion of resistance to high-level gentamicin
observed in Ireland, as well as in most other European
countries (see figure 11), was generally high (≥25%). The
majority of countries reported proportions of <1% for
vancomycin resistance (see figure 12). The proportion of
vancomycin resistance in Ireland was slightly higher and was
comparable with France, Italy, the Netherlands and Poland.
Enterococcus faecium
In 2003, 135 reports of E. faecium isolates from bacteraemia
were received from 17 laboratories.
The total numbers of E. faecium isolates and proportion of
resistance reported by quarter for ampicillin, high-level
gentamicin and vancomycin are shown in figure 13.
One hundred and twenty-one (91%) of the 133 isolates for
which ampicillin susceptibility data were available were
Figure 7. Map illustrating the distribution of resistance to 3GCs among E. coli in EARSS 
countries in 2003
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Figure 8. Map illustrating the distribution of resistance to aminoglycosides among 
E. coli in EARSS countries in 2003
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reported to be ampicillin-resistant, which is not unexpected as
most E. faecium are resistant to this antibiotic.
Fifty-eight (54.7%) of 106 isolates tested were reported to be
high-level gentamicin resistant, which is a substantial increase
on 2002 when 16.7% of isolates tested were reported to be
resistant. Twenty-two of the 58 isolates were confirmed by
MIC determination. The proportion of isolates tested for
susceptibility to high-level gentamicin increased from 35% in
2002 to 79% in 2003, which is similar to the situation
observed with E. faecalis isolates.
Twenty-six isolates (19.4%) were reported to be vancomycin
resistant (16 confirmed by MICs). This represents an increase
on 2002 when 11.1% of isolates were vancomycin-resistant.
Twelve isolates were resistant to ampicillin, high-level
gentamicin (six confirmed by MICs) and vancomycin (seven
confirmed by MICs).
In 2003, the proportion of resistance to high-level gentamicin
in Ireland was one of the highest observed across Europe (see
figure 14). The majority of countries reported proportions of
<5% for vancomycin resistance (figure 15). The proportion in
Ireland was moderately high (10-25%) and together with Italy
and Greece was one of the highest observed in Europe.
Additional information
The quarterly EARSS Newsletters produced by NDSC can be
accessed on the NDSC website: http://www.ndsc.ie/
Publications/AntimicrobialResistance-EARSSReports/
Antimicrobial resistance data, including the most up-to-date
maps (in full colour) showing the distributions of resistance,
for all five pathogens surveyed in the 28 countries
participating in this surveillance system can be obtained from
the interactive database available on the EARSS website:
http://www.earss.rivm.nl/PAGINA/interwebsite/home_earss.
html
The future
The recent change in the Infectious Diseases legislation has
made reporting on the EARSS pathogens mandatory for all
Irish laboratories. It is anticipated that coverage of the Irish
population by EARSS will reach 100% in 2004 as the
remaining Irish laboratories join the surveillance system.
Using the acute public hospital activity data from DoHC, it is
planned to produce both national and regional rates of
invasive infections for the EARSS pathogens, which will be
useful for SARI local and regional committees. Collection of
enhanced clinical data has also commenced in a number of
laboratories and analysis of this data is currently being
undertaken.
Figure 9. Map illustrating the distribution of resistance to fluoroquinolones among 
E. coli in EARSS countries in 2003
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Figure 10.  Trends for E. faecalis by quarter for 2003 – total numbers of E. faecalis and 
percentage resistance to ampicillin (AMP), high-level gentamicin (GEH) and vancomycin 
(VAN).  Number of participating laboratories is indicated for each quarter
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Figure 11. Map illustrating the distribution of resistance of high-level resistence to
aminoglycosides among E. faecalis in EARSS countries in 2003
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Figure 12. Map illustrating the distribution of resistance to glycopeptides among E. faecalis
in EARSS countries in 2003
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Figure 13.  Trends for E. faecium by quarter for 2003 – total numbers of E. faecium and 
percentage resistance to ampicillin (AMP), high-level gentamicin (GEH) and 
vancomycin (VAN).  Number of participating laboratories is indicated for each quarter
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Figure 14. Map illustrating the distribution of high-level resistance to aminoglycosides
among E. faecium in EARSS countries in 2003
No data
<1%
1-5%
5-10%
10-25%
25-50%
>50%
NDSC Annual Report 2003 101
Figure 15. Map illustrating the distribution of resistance to glycopeptides among 
E. faecium in EARSS countries in 2003
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Infectious Disease Notifications,
2003
Key Points
• The Infectious Diseases Regulations were amended in
March 2003 to specify Severe Acute Respiratory
Syndrome (SARS) as a notifiable disease
• One probable SARS case was notified in 2003
• Food poisoning (bacterial other than salmonella) and
measles notifications increased in 2003 compared to
recent years
• Viral hepatitis type B notifications continued to rise
in 2003
• Whooping cough notifications continued to decline
in 2003
Introduction
In Ireland the Health Act, 1947 entitles the Minister for Health
and Children to declare by regulation diseases that are
infectious, covered by legislation and that require notification
to a medical officer of health. The list of infectious diseases
notifiable in Ireland in 2003 was regulated in the 1981
Infectious Diseases Regulations that were revised in the
Infectious Diseases (Amendment) Regulations of 1985, 1988,
1996 and 2003. The amendment, S.I. No. 115 of 2003,
specified the newly emerging disease Severe Acute Respiratory
Syndrome (SARS) as a notifiable disease.
Medical practitioners, who become aware of or who suspect
that a person is suffering from or is a carrier of an infectious
disease specified in the regulations, are required to notify the
relevant medical officer in the appropriate health board. This
notification data provides timely information about potential
or actual outbreaks of infectious disease enabling the health
boards to take action to prevent further spread of the disease.
The health boards forward the notification data to NDSC on a
weekly basis where a weekly infectious disease report on
national data is produced. The purposes of national
surveillance include monitoring infectious disease trends at a
national level, monitoring the need for and impact of national
infectious disease prevention and control programmes,
guiding national infectious disease policy development and
meeting international reporting requirements, for example,
providing infectious disease data to EU disease specific
networks and the World Health Organization (WHO).
This review attempts to summarise the 2003 infectious
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disease notification data and to describe disease trends in
2003.
Materials and methods
Since July 2000, the health boards provide case-based
information by the Wednesday of each week, to NDSC, on
infectious diseases (excluding sexually transmissible
infections) notified to them during the previous week. The
agreed dataset for each case includes identification number,
date of birth, age, sex, date of onset, date of notification/week
of notification, Community Care Area, county, disease and
organism (if available). At NDSC this information is entered
on a Microsoft Access database.
Incidence rates were calculated using population data taken
from the 2002 census. Data were analysed using MS Access
and MS Excel.
Notifiable infectious diseases in 2003, excluding sexually
transmissible infections (STIs), are presented in this report. A
report on the 2002 notifiable STIs is presented elsewhere
within this document.
Results
Notifiable infectious diseases
Table 1 compares annual notifiable infectious disease figures
for 2003 with annual figures obtained from 1982-2002. In
total, 6272 cases of notifiable infectious diseases (this figure
includes the provisional 2003 TB figure and excludes STI data)
were reported to NDSC during 2003, an increase of
approximately 14% compared to 2002. Of these 6272 cases,
63% were due to gastrointestinal infections while 18% were
due to vaccine preventable diseases (as per the childhood
immunisation schedule in Ireland). There were several notable
disease trends in 2003:
• food poisoning (bacterial other than salmonella)
notifications increased in 2003 compared to the previous
three years
• gastroenteritis (when contracted by children under 2 years
of age) notifications increased slightly in 2003 compared to
2002
• measles notifications doubled in 2003 compared to annual
figures for 2001 and 2002
• rubella notifications increased in 2003 compared to 2002
• salmonellosis notifications increased slightly in 2003
compared to 2002
• notifications of viral hepatitis type B continued to rise in
2003 compared to previous years
• whooping cough notifications continued to decline in 2003
compared to previous years, with cases declining threefold
since 2002.
In 2003, no cases of acute anterior poliomyelitis, anthrax,
cholera, variant Creutzfeldt Jakob disease (vCJD), diphtheria,
ornithosis, plague, rabies, smallpox, tetanus, typhus, viral
haemorrhagic disease or yellow fever were notified.
The breakdown of infectious diseases notified in 2003 by
health board, age group and sex are presented in tables 2, 3
and 4, respectively.
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Figure 1.  Food poisoning (bacterial other than salmonella) notifications in 2003 
by organism
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Table 2. Number of notifiable infectious diseases by health board in 2003
Infectious disease  ERHA  MHB MWHB NEHB  NWHB  SEHB  SHB  WHB  Total
Acute Encephalitis 3 1 0 0 0 1 1 0 6
Acute Viral Meningitis 24 1 0 4 1 5 3 1 39
Bacillary Dysentery (Shigellosis) 19 1 5 4 0 2 3 2 36
Bacterial Meningitis (including meningococcal septicaemia)* 107 25 29 29 15 38 54 14 311
Brucellosis 0 1 3 0 0 0 1 0 5
Creutzfeldt Jakob Disease        **        **        **        **        **        **        **        ** 2
Food Poisoning (bacterial other than salmonella) 583 137 75 87 67 245 231 198 1623
Gastroenteritis (when contracted by children under 2 years of age) 544 156 29 79 68 267 368 324 1835
Infectious Mononucleosis 18 1 11 42 0 6 21 23 122
Infectious Parotitis (Mumps)  20 4 1 4 0 4 5 2 40
Influenzal Pneumonia 1 0 0 0 2 2 0 1 6
Legionnaires' Disease 3 0 0 2 0 1 0 1 7
Leptospirosis 2 1 0 2 0 3 0 1 9
Malaria 11 2 4 2 0 1 1 0 21
Measles 363 123 24 15 1 6 5 35 572
Rubella 35 3 0 1 1 15 2 2 59
Salmonellosis (other than typhoid or paratyphoid) 168 29 19 40 19 64 59 51 449
Severe Acute Respiratory Syndrome (SARS)        **        **        **        **        **        **        **        ** 1
Tuberculosis† 168 13 46 27 13 33 95 26 421†
Typhoid & Paratyphoid 4 0 2 3 0 0 0 2 11
Viral Hepatitis Type A 8 4 3 3 0 3 3 1 25
Viral Hepatitis Type B 174 25 13 20 0 39 264 12 547
Viral Hepatitis Unspecified 37 8 4 2 3 18 12 1 85
Whooping Cough 14 1 2 5 2 6 7 3 40
*Taken from the Enhanced Bacterial Meningitis Surveillance System 
**Data not reported to health board level when total figures for Ireland less than 5 cases 
†Taken from the Enhanced TB Surveillance System, figure for 2003 provisional
Table 3. Number of notifiable infectious diseases by age group (years) in 2003
Infectious disease    0-4 5-9 10-14 15-19 20-24  25-34  35-44  45-54  55-64  65+  Unknown  Total
Acute Encephalitis 2 1 0 0 1 0 0 1 1 0 0 6
Acute Viral Meningitis 15 4 4 3 1 5 5 0 0 0 2 39
Bacillary Dysentery (Shigellosis) 10 0 2 1 5 9 2 3 1 3 0 36
Bacterial Meningitis (including meningococcal septicaemia)* 183 21 21 28 12 17 5 4 11 9 0 311
Brucellosis 0 0 0 0 0 1 0 2 2 0 0 5
Creutzfeldt Jakob Disease 0 0 0 0 0 0 0 0 0 2 0 2
Food Poisoning (bacterial other than salmonella) 430 79 62 66 146 252 167 124 99 148 50 1623
Gastroenteritis (when contracted by children under 2 years of age) 1810 0 0 0 0 0 0 0 0 0 25 1835
Infectious Mononucleosis 5 2 17 74 14 6 0 1 1 0 2 122
Infectious Parotitis (Mumps) 11 8 3 6 3 4 1 1 0 1 2 40
Influenzal Pneumonia 4 0 1 0 1 0 0 0 0 0 0 6
Legionnaires' Disease 0 0 0 0 0 1 0 0 2 4 0 7
Leptospirosis 0 0 0 0 0 1 1 2 2 2 1 9
Malaria 4 3 1 1 0 5 2 1 2 1 1 21
Measles 377 107 60 6 13 0 0 0 0 0 9 572
Rubella 50 4 1 0 1 1 2 0 0 0 0 59
Salmonellosis (other than typhoid or paratyphoid) 89 32 24 25 44 65 62 46 21 35 6 449
Severe Acute Respiratory Syndrome (SARS) 0 0 0 0 0 0 0 1 0 0 0 1
Tuberculosis† 10 7 6 19 52 89 51 50 33 101 3 421†
Typhoid & Paratyphoid 1 0 1 1 4 3 0 0 0 0 1 11
Viral Hepatitis Type A 3 2 3 2 4 4 6 0 0 1 0 25
Viral Hepatitis Type B 8 4 12 43 69 282 84 26 8 0 11 547
Viral Hepatitis Unspecified 0 0 0 2 19 36 18 6 2 0 2 85
Whooping Cough 29 5 1 2 1 0 0 0 1 0 1 40
*Taken from the Enhanced Bacterial Meningitis Surveillance System
†Taken from the Enhanced TB Surveillance System, figure for 2003 provisional
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Acute encephalitis
During 2003, six cases of acute encephalitis were notified,
similar to four cases in 2002. For one case in 2003 the
causative organism was reported as herpes virus, while the
causative organisms were not reported or were unknown for
the remaining five cases. Three of the cases in 2003 were
aged less than ten years.
Acute viral meningitis
In 2003, 39 (1.0/100,000) cases of acute viral meningitis were
notified, similar to 36 cases in 2002. Two thirds of the cases
(n=26) in 2003 occurred in those aged less than 20 years
while just over one third of cases (n=15) were in the age
group 0-4 years. The causative organisms were not reported
for any of the acute viral meningitis notifications in 2003.
Non-polio enteroviruses (NPEV) are the most common cause
of viral meningitis. The National Virus Reference Laboratory
reported 36 laboratory confirmed NPEV isolates in 2003, 20
(56%) of these isolates were echovirus type 11.1 Suspected
viral meningitis was known to be the clinical diagnosis for six
of the 36 NPEV isolates.
Bacillary dysentery (Shigellosis)
Thirty-six cases (0.9/100,000) of bacillary dysentery were
notified in 2003 compared to 26 cases in 2002. The majority
of cases (64%) in 2003 occurred in those aged 20 years or
older, however, the rate in the age group 0-4 years increased
slightly in 2003 (3.6/100,000) compared to 2002
(1.4/100,000). Of the 36 cases notified, 13 were due to
Shigella sonnei, 12 due to Shigella flexneri, one due to Shigella
boydii, one due to Shigella dysenteriae while species was not
reported for nine cases. For comparison, of the 26 cases
notified in 2002, 11 were due to S. sonnei, four due to S.
flexneri, two due to S. boydii while species was not reported
for nine cases. This suggests a slight increase in the number
of S. flexneri reported in 2003 compared to 2002.
Bacterial meningitis (including meningococcal septicaemia)
During 2003, 311 bacterial meningitis (including
meningococcal septicaemia) cases were notified, similar to
297 in 2002. An enhanced surveillance system for bacterial
meningitis (including meningococcal septicaemia)
commenced in Ireland in 1997. Data obtained through this
system, during 2003, are discussed in detail in a separate
chapter within this document.
Brucellosis
Five cases of brucellosis were notified in 2003, similar to four
cases in 2002. All five cases in 2003 were male and were
aged between 34 and 58 years.
Creutzfeldt Jakob disease (CJD)
In 2003, two cases of classical CJD were notified, compared
with five in 2002. Both cases in 2003 occurred in males and
were aged greater than 65 years.
Food poisoning (bacterial other than salmonella)
Food poisoning notifications increased by 16% in 2003 with
1623 cases (41.4/100,000) notified, compared to 1394 cases
in 2002. In 2003, the highest number of cases (n=430) and
the highest incidence rate (154.9/100,000) occurred in those
aged 0-4 years. The causative organisms were reported as
Campylobacter species (n=1440, 89%), Escherichia coli
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Figure 3. Annual number (log scale) of whooping cough notifications in Ireland 1948-2003
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(n=114, 7%) including verocytotoxigenic E. coli (VTEC),
Listeria monocytogenes (n=4), Yersinia enterocolitica (n=3)
and Staphylococcus species (n=2). The causative organism
was not provided for 60 (3.7%) cases (figure 1).
Comprehensive reports on campylobacteriosis and VTEC in
Ireland are presented as separate chapters elsewhere within
this document.
Gastroenteritis (when contracted by children under 2 years
of age)
Notifications of gastroenteritis in those under two years of age
increased slightly in 2003 (n=1835) compared to 2002
(n=1747). In 2003, the causative organisms were reported as
rotavirus (n=1149, 63%), adenovirus (n=315, 17%),
Cryptosporidium (n=106, 5.8%), norovirus (n=14), Giardia
lamblia (n=2), echovirus type 11 (n=1) and Entamoeba coli
(n=1). No organism details were provided for 247 (13.5%)
cases (figure 2).
Infectious mononucleosis
Infectious mononucleosis notifications declined in 2003 with
122 cases (3.1/100,000) notified compared to 173 in 2002.
In 2003, the highest number of cases (n=74) and the highest
age specific incidence rate (23.6/100,000) occurred in the age
group 15-19 years. Nearly two-thirds of cases in 2003 were
female (n=78).
Infectious parotitis (Mumps)
Forty cases (1.0/100,000) of mumps were notified in 2003
compared to 2002 when 32 cases were notified. In 2003, for
the 38 cases where age was provided, the cases were aged
between <1 year and 79 years (mean age, 15 years; median
age, 9 years) with just over half of all cases aged less than 15
years. Twenty-two of the cases were male and 18 were
female.
Influenzal pneumonia
Six cases of influenzal pneumonia were notified in 2003
compared to two cases in 2002. Four of the cases in 2003
were male and two were female. All six cases were notified
during November and December 2003. The influenzal
pneumonia cases coincided with an increase in influenza
activity in late 2003 that predominantly affected children in
the age group 0-4 years. All six influenzal pneumonia
notifications in 2003 were aged less than 25 years with four
of these in the age group 0-4 years, in contrast, both
influenzal pneumonia cases notified in 2002 were in the age
group 45-54 years. A report on influenza activity during the
2003/2004 season is included elsewhere in this document.
Legionnaires’ disease
Seven cases of Legionnaires’ disease were notified in 2003
while six cases were notified in 2002. The seven cases in
2003 were aged between 27 and 78 years (mean age, 62
years; median age, 69 years). Five of the cases were male and
two were female. One of the seven cases of Legionella was
confirmed by serology while six were confirmed by urinary
antigen detection. Two of the cases in 2003 died.
A case of Legionnaires’ disease is defined as travel-associated
if the patient spent one or more nights away form their home
in accommodation used for commercial or leisure purposes
e.g. hotels, holiday apartments etc. in the 10 days before the
onset of illness. Travel-associated cases may involve travel
within Ireland or travel abroad. In 2003, three of the cases
were travel-associated (Ireland, Malta & Tunisia) and were
notified to the European Working Group for Legionella
Infections (EWGLI) surveillance scheme. The aim of this
surveillance scheme (EWGLI) is to detect cases of travel-
associated Legionnaires’ disease and thereby rapidly identify
outbreaks and implement control measures.2
Leptospirosis
Nine cases of leptospirosis were notified in 2003. This was
similar to the number notified in previous years. All nine
cases were male and for the eight cases where age was known
all were aged between 34 and 73 years (mean age, 54 years;
median age, 57 years). The possible source of infection was;
contact with animals (n=4), contaminated water (n=1),
gardening (n=1) and unknown (n=3). Seven of the cases were
reported to have survived while the outcome was not
reported for two cases.
Malaria
During 2003, twenty-one cases of malaria were notified. Ten
cases were male and eleven were female. Age was reported
for 20 cases, these cases ranged in age from one year to 67
years with a median age of 28 years. Six of these cases were
Irish, three were Nigerian, one was French and nationality was
not reported for the remaining cases. Countries where the
malaria infection was acquired included Nigeria (n=5), Sudan
(n=4) and Congo, Gambia, Ghana, Kenya, Mali, Sierra Leona,
Tanzania, Uganda, and Zimbabwe (n=1 each). The reasons for
travel to a malarious region were: holiday (n=5), business/
professional travel (n=3), new entrant to Ireland (n=1),
visiting family in country of origin (n=1), Irish citizen living
abroad (n=1) and unknown (n=9). There was also one case
believed to have been congenitally acquired.
In nine cases Plasmodium falciparum was the causative
organism, Plasmodium vivax in three cases and the malarial
parasite was not reported for the remaining nine cases.
Information on malaria prophylaxis was available for eight of
the cases. Three cases did not take any malaria prophylaxis
while inappropriate prophylaxis was taken by one case. Of
the remaining four cases who took malaria prophylaxis while
abroad, all discontinued prophylaxis before one month after
their return to Ireland (it should be noted however that at
least two of these patients already displayed symptoms of
malaria within one month of return to Ireland).
Measles
During 2003, 572 measles cases (14.6/100,000) were notified.
This was more than double the number notified during 2002
(n=243) and 2001 (n=241). Enhanced details including
laboratory data were obtained on some of the measles
notifications in 2003, this data is discussed further in a
separate measles report elsewhere in this document.
Rubella
In 2003, 59 cases (1.5/100,000) of rubella were notified,
compared to 33 in 2002 and 57 in 2001. Fifty-five of the
cases (93%) notified in 2003 were less than 15 years, with 50
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(85%) of the cases aged less than five years. Thirty-two cases
were female, 26 cases were male while sex was not reported
for one case.
Salmonellosis (other than typhoid or paratyphoid)
Salmonella notifications increased slightly in 2003 compared
to 2002 with 449 cases (11.5/100,000) notified. In 2003, the
highest number of cases (n=89) and the highest age specific
incidence rate (32.1/100,000) were in those aged less than
five years. In 2003, the breakdown by serotype was as
follows: Salmonella Enteritidis (n=85), S. Typhimurium (n=60),
S. Kentucky (n=6), S. Virchow (n=6), S. Agona (n=4), S. Anatum
(n=4), S. Stanley (n=4), S. Newport (n=3), S. Saintpaul (n=3),
S. Bredeney (n=2), S. Hadar (n=2), S. Infantis (n=2), S. Reading
(n=2) and S. Arizonae, S. Blockley, S. Braenderup, S. Branden-
burg, S. Chester, S. Corvallis, S. Cotham, S. Durban, S. Hato,
S. Heidelberg, S. Java, S. Javiana, S. Litchfield, S. Mbandaka,
S. Mikawasima, S. Munchen, S. Ohio, S. Panama, S. Seftenberg,
S. Wangata and S. Welikade (n=1, each) while serotype details
were not provided for 55% of cases (n=245). A separate and
comprehensive report on salmonella is presented elsewhere
within this document.
Severe Acute Respiratory Syndrome (SARS)
Severe Acute Respiratory Syndrome (SARS) was recognised in
Asia as a newly emerging infectious disease during February
2003. In Ireland, SARS was specified as a notifiable disease in
March 2003. One probable case was notified in Ireland during
2003 in a patient who had travelled to Hong Kong. The
patient recovered. SARS is discussed further in a separate
chapter in this document.
Tuberculosis
The national enhanced TB surveillance system collects
information on all TB notifications. At present only a
provisional figure of 421 for TB notifications is available for
2003. Once follow up information on all cases has been
received and validation completed a final figure will become
available. During 2002 408 cases were notified. A compre-
hensive report on the finalised 2002 data is included as a
separate chapter within this document.
Typhoid and paratyphoid
Eleven cases of typhoid and paratyphoid were notified in
2003 compared to five cases notified in 2002. Seven (64%)
of the 11 cases were aged between 20 and 34 years while one
case was less than five years of age. The majority (73%) of
cases were male. Of the 11 cases notified seven were due to
Salmonella typhi and four due to Salmonella paratyphi. The
countries of infection were Pakistan (n=5), Bangladesh (n=2),
India (n=1) and not reported (n=3).
Viral hepatitis type A
There were 25 cases (0.6/100,000) of viral hepatitis type A
notified in 2003. This was similar to the number notified in
2002 (n=26). A comprehensive report on viral hepatitis is
presented as a separate chapter within this document.
Viral hepatitis type B
Viral hepatitis type B notifications continued to increase in
2003 with 547 cases notified (14.0/100,000) compared to
458 and 342 cases notified in 2002 and 2001, respectively. A
comprehensive report on viral hepatitis is presented as a
separate chapter within this document.
Viral hepatitis unspecified
In 2003, 85 cases (2.2/100,000) of viral hepatitis type
unspecified were notified, similar to 89 cases notified in 2002
and 90 cases in 2001. A comprehensive report on viral
hepatitis is presented as a separate chapter within this
document.
Whooping cough
Following the introduction of a vaccine in the 1950s
whooping cough notifications had declined to a low in 1972
compared to previous years with 231 cases notified, however,
following a whooping cough vaccine scare in the mid-1970s
notifications started to increase (figure 3). This trend was
reversed in the 1990s as notifications started to decline again,
notifications declined from nearly 900 per year in the early
1990s to 131 in 2002. Compared to 2002 notifications
decreased threefold in 2003 with 40 cases (1.0/100,000)
notified, this is the lowest number of whooping cough
notifications on record. The majority (73%) of cases in 2003
were in the age group 0-4 years. Twenty-one cases were
male while 19 cases were female.
Discussion
Overall there was an increase in the numbers of infectious
diseases notified during 2003 compared to 2002, in particular,
notifications of food poisoning (bacterial other than
salmonella) and measles increased compared to the previous
year. The majority (63%) of notifications in 2003 were
related to gastrointestinal illness while 18% were due to
vaccine preventable diseases (as per the childhood
immunisation schedule in Ireland).
During 2003, one probable case of the infectious disease SARS
was notified in Ireland. SARS is a viral respiratory illness and
is spread mainly by close person-to-person contact.
Respiratory droplets produced when an infected individual
sneezes or coughs are believed to spread the virus that causes
SARS the most readily. The main symptoms of the disease
include fever, chills, muscle aches, sore throat and headache.
These develop into pneumonia with some developing acute
breathing problems requiring respirators. SARS was first
recognised as a newly emerging infectious disease during
February 2003 in Asia. The illness subsequently spread to a
number of countries around the world, mostly through
international air travel, but was successfully contained by July
2003. The WHO reported a total of 8,096 SARS cases
worldwide and 774 deaths during the 2003 outbreak. In
Ireland the Infectious Diseases Regulations were amended in
March 2003 to specify SARS as a notifiable disease. One
probable case of SARS was notified in Ireland, during 2003, in
an individual who had travelled to Hong Kong. The case
recovered fully.
The list of diseases notifiable during 2003 was regulated in
the 1981 Infectious Diseases Regulations, which were revised
in 1985, 1988, 1996 and 2003. In an amendment to these
regulations that came into effect on 1st January 2004 a new
list of notifiable diseases was specified. This new list of
notifiable diseases specifies food-borne illness such as
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campylobacter infection and staphylococcal food poisoning
individually, whereas previously these were only notifiable
under the category of food poisoning (bacterial other than
salmonella). This new list also specifies cryptosporidiosis
individually, whereas previously it was only notifiable under
the disease category gastroenteritis (when contracted by
children under two years of age). Other additions to the list
include hepatitis C, influenza, biological threat agents such as
botulism and tularemia and several pathogens important in
the monitoring of antimicrobial resistance including
Staphylococcus aureus and Enterococcus species.
The amendment introduces the use of case definitions for
infectious diseases for the first time in Ireland, allowing more
effective analysis and interpretation of notification data. This
amendment also requires clinical directors of diagnostic
laboratories, in addition to medical practitioners, to notify
infectious diseases specified in the regulations. Diagnostic
laboratories are an important source of infectious disease
data. Prior to the revised legislation there was no
requirement for laboratories to notify infectious diseases
although voluntary reporting was occurring in some health
board regions. Unusual clusters or changing pattern of illness
that may be of public health concern must now also be
reported. The changes to the legislation were based on
recommendations from a subgroup of NDSCs’ Scientific
Advisory Committee following a review of the notification
system in Ireland. This review was carried out at the request
of the Department of Health and Children. The new
regulations came into effect at the beginning of 2004 and are
a welcome advancement in the surveillance of infectious
disease in Ireland.
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Table 4. Number of notifiable infectious diseases by sex in 2003
Infectious disease    Male Female  Unknown  Total
Acute Encephalitis 2 4 0 6
Acute Viral Meningitis 16 22 1 39
Bacillary Dysentery (Shigellosis) 17 19 0 36
Bacterial Meningitis (including meningococcal septicaemia)* 171 140 0 311
Brucellosis 5 0 0 5
Creutzfeldt Jakob Disease 2 0 0 2
Food Poisoning (bacterial other than salmonella) 824 768 31 1623
Gastroenteritis (when contracted by children under 2 years of age) 946 857 32 1835
Infectious Mononucleosis 42 78 2 122
Infectious Parotitis (Mumps) 22 18 0 40
Influenzal Pneumonia 4 2 0 6
Legionnaires' Disease 5 2 0 7
Leptospirosis 9 0 0 9
Malaria 10 11 0 21
Measles 283 282 7 572
Rubella 26 32 1 59
Salmonellosis (other than typhoid or paratyphoid) 225 218 6 449
Severe Acute Respiratory Syndrome (SARS) 1 0 0 1
Tuberculosis† 261 156 4 421†
Typhoid & Paratyphoid 8 3 0 11
Viral Hepatitis Type A 16 9 0 25
Viral Hepatitis Type B 259 275 13 547
Viral Hepatitis Unspecified 49 30 6 85
Whooping Cough 21 19 0 40
*Taken from the Enhanced Bacterial Meningitis Surveillance System
†Taken from the Enhanced TB Surveillance System, figure for 2003 provisional
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Immunisation Uptake 
in Ireland, 2003
Key Points
• Annual immunisation uptake rates for all vaccines at
both 12 and 24 months increased in 2003 when
compared with 2002
• Nationally, D3, P3, T3, Polio3 and Hib3 uptake at 24
months was 85-86% in 2003
• National MMR1 uptake at 24 months was 78% in 2003
• National MenC3 uptake at 24 months was 84% in 2003
Introduction
The current primary childhood immunisation schedule was
revised in 2002.1 In Ireland, it is recommended that children
receive three doses of vaccines against diphtheria, pertussis,
tetanus, Haemophilus influenzae type b, polio and
meningococcal group C at two, four and six months of age. It
is also recommended that children receive one dose of BCG
vaccine at birth or by one month of age and one dose of
vaccine against measles, mumps and rubella at 12-15 months.
A booster dose of DTaP/Polio is scheduled for children at four-
five years of age, as is a second dose of MMR vaccine.
The importance of vaccination in controlling disease cannot
be underestimated. In order to effectively control these
preventable diseases, it is recommended that at least 95% of
children complete the childhood immunisation schedule,
thereby decreasing the number of susceptible children in the
population and ensuring that outbreaks of these diseases are
prevented.
Immunisation uptake statistics for 2003 are presented. These
statistics relate to all children who are registered in the
immunisation databases at health board level. The proportion
of these children who completed the recommended
immunisation schedule by 12 or 24 months of age is
reported.
Materials and methods
In 2003, each health board provided NDSC with immunisation
uptake data on a quarterly basis. These data were calculated
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for all children on the health board immunisation databases
who reached their first or second birthday (uptake rates at 12
and 24 months, respectively) during the quarter in question.
Data included the number of children who had completed the
recommended immunisation schedule as well as the number
of children eligible for immunisation in each cohort and the
percentage of children immunised. Data were collected for
children who had received three doses of vaccine against
diphtheria (D3), pertussis (P3), tetanus (T3), Haemophilus
influenzae type B (Hib3), polio (Polio3), meningococcal type C
(MenC3), one dose of vaccine against measles, mumps and
rubella (MMR1; uptake measured at 24 months only) and one
dose of BCG vaccine (uptake measured at 12 months only).
NDSC collated and analysed these data in MS Excel and
quarterly reports were produced which are available from the
NDSC website. The annual uptake rates presented here
represent the collation of data collected from quarter 1 to
quarter 4, 2003 (cohorts born between 01/01/2002 &
31/12/2002 and 01/01/2001 & 31/12/2001, respectively).
These rates were calculated from quarterly data on the
number of children who had completed the recommended
immunisation schedule and the number of children eligible for
immunisation in each cohort submitted by the health boards.
Data for BCG immunisation uptake rates, calculated at 12
months of age, were available from Quarter 3 2003 onwards
only.
Results
Immunisation uptake rates at 12 months in 2003
National immunisation uptake at 12 months in 2003 (cohort
born between 01/01/2002 & 31/12/2002) was 81% for D3,
T3, Hib3 and Polio3 and 80% for P3 and MenC3. National
uptake rates at 12 months increased by 6% for each of these
vaccines when compared with 2002. The uptake rate for BCG
vaccine at 12 months was 89% (based on returns from 5
health boards for Q3 and Q4, 2003 only).
Uptake rates at 12 months in 2003 by health board are
presented in table 1. Uptake rates for D3, P3, T3, Hib3, Polio3
and MenC3 ranged from 73-76% (WHB) to 86-89% (NWHB).
Five health boards were in a position to provide uptake data
for the BCG vaccine in Q3 and Q4, 2003. Where data were
available, uptake ranged from 83% (MHB) to 92% (SEHB).
Figure 1 presents trends in quarterly immunisation uptake
rates at 12 months from Q3-2000 to Q4-2003. In 2003, a
slight decrease in uptake was observed between Q1 and Q2
with uptake increasing in Q3 and Q4. The highest
immunisation uptake rates for all vaccines in 2003 were
reported in Q4. The rates from Q4-2003 also represent the
highest uptake rates reported in children at 12 months in
Ireland since collection of these data began (Q3-2000). The
target rate of 95% uptake was achieved for BCG vaccination
in Q4-2003 in the SEHB.
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Figure 1. Quarterly immunisation uptake rates at 12 months in Ireland (Note scale ranges from 65-95% on this figure)
Hib3P3D3 Polio3 MenC3
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Immunisation uptake at 24 months in 2003
National annual immunisation uptake rates at 24 months in
2003 (cohort born between 01/01/2001 & 31/12/2001) were
86% for D3, T3, Hib3 and Polio3, 85% for P3 and 84% for
MenC3. The national uptake rate for MMR1 in 2003 was 78%.
Uptake rates at 24 months in 2003 by health board are
presented in table 2.
Uptake rates for D3, P3, T3 and Polio3 ranged from 83% in
the ERHA to 92-94% in the NWHB. Uptake rates for Hib3
and MenC3 ranged from 80-83% in the ERHA to 91-92% in
the MHB and NWHB. Uptake rates at 24 months for MMR1
ranged from 74% in the ERHA and WHB to 88% in the MHB.
Figure 2 presents annual national immunisation uptake rates
from 1999 to 2003. In 2003, annual immunisation uptake
rates for all vaccines at 24 months increased when compared
with 2002. Uptake of D3, P3, T3, Hib3 and Polio3 rose by 3%
while uptake of the MMR1 vaccine rose by 5%. The largest
increase was reported for the MenC3 vaccine, which increased
by 9% from 75% in 2002 to 84% in 2003.
Figure 3 presents trends in quarterly immunisation uptake
rates at 24 months from Q1-1999 to Q4-2003. In 2003, the
lowest uptake was reported in Q1 with increases in Q2 and
Q3. Uptake rates reported in Q4 were comparable with those
reported in Q3-2003. The national uptake rates for P3, Hib3
and MenC3 reported in Q3 and Q4-2003 represent the
highest rates reported for these vaccines in Ireland at 24
months since collection of these data began (Q1-1999).
Uptake rates for D3, T3 and Polio3 are the highest reported
since Q4-2000 while MMR1 uptake is still 3% lower than the
levels reported in Q4-2000. The target rate of 95% was
achieved in both Q3 and Q4 for D3 and T3 by the NWHB.
Discussion
Annual national immunisation uptake figures at 12 months in
2003 (80-81%) increased by 6% for D3, P3, T3, Hib3, Polio3
and MenC3 when compared with 2002 (74-75%).
2 In
addition, uptake rates at 24 months in 2003 (78-86%)
improved by 3-9% when compared with 2002 (73-83%).2
This is the first increase observed in annual national uptake
rates calculated at 24 months since these data were first
reported in 1999.
In general, quarterly uptake rates improved over the course of
2003 and were highest in Q3 and Q4. While the target rate of
95% uptake was achieved in the NWHB for D3 and T3 (Q3
and Q4) and in the SEHB for BCG (Q4), national
immunisation uptake rates for D3, P3, T3, Hib3 and Polio3 and
MenC3 in Q4-2003 were still 8-9% below the target rate of
95% while MMR1 uptake was 15% below the 95% target
rate. BCG was 4% below target rate of 95% but these data
are only representative of 5 health boards which account for
less than half the birth cohort for each quarter.
D3
95
90
85
80
75
70
P3 T3 Hib3 Polio3 MMR1
%
 u
pt
ak
e
Figure 2.  Annual immunisation uptake rates at 24 months, 1999-2003 
(Note scales range from 70-95% on this figure)
1999 2000 2001 2002 2003
95
85
75
90
80
70
60
65
Q1
1999
Q2
1999
Q3
1999
Q4
1999
Q1
2000
Q2
2000
Q3
2000
Q4
2000
Q1
2001
Q2
2001
Q3
2001
Q4
2001
Q1
2002
Q2
2002
Q3
2002
Q4
2002
Q1
2003
Q2
2003
Q3
2003
Q4
2003
Quarter/year
%
 u
pt
ak
e
Figure 3. Quarterly immunisation uptake rates at 24 months in Ireland (Note scale ranges from 60-95% on this figure)
Hib3P3D3 Polio3 MenC3 MMR1
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Despite the increases in immunisation uptake rates reported
over the course of 2003, further improvements are necessary
in order to prevent outbreaks of these vaccine preventable
diseases. For example, in 2003 the number of measles cases
more than doubled when compared with 2002. In order to
prevent such increases in disease in the future it is necessary
to extend the current upward trend to meet the WHO
recommended target rates for immunisation uptake.
Acknowledgements
The authors would like to thank the health boards for providing these data. In
particular, thanks to the specialists in public health medicine, the surveillance
scientists, the immunisation co-ordinators and the systems analysts for their
assistance.
References
1. Immunisation Guidelines for Ireland, 2002. A report by the National
Immunisation Committee of the Royal College of Physicians of Ireland.
Available at http://www.ndsc.ie/Publications/Immunisation/
ImmunisationGuidelines/
2. Immunisation uptake in Ireland, 2002. NDSC Annual Report 2002. Available
at http://www.ndsc.ie/Publications/AnnualReports/
3. Quarterly immunisation uptake reports. Available at http://www.ndsc.ie/
Publications/Immunisation/immunisationuptakequarterlyreports/
Table 1. Immunisation uptake rates in children 12 months of age in 2003
       % Uptake at 12 months
               Cohort born 01/01/2002 - 31/12/2002
Health Board No. in cohort D3 P3 T3 Hib3 Polio3 MenC3 BCG*
ERHA 22,750 77 77 77 77 77 78 na†
MHB 3,854‡ 86 85 86 86 86 85 83
MWHB 5,001 83 82 83 83 83 82 90
NEHB 6,039 81 81 81 81 81 81 na
NWHB 3,153 89 87 89 88 88 86 91
SEHB 6,614 85 85 85 85 85 84 92
SHB 8,628‡ 83 82 83 82 83 82 87§
WHB 5,449 76 76 76 76 76 73 na
Ireland 61,488‡? 81 80 81 81 81 80 89
*BCG data available for Q3-2003 and Q4-2003 only
†Not available at this time
‡As the number in cohort varied depending on the vaccine, the most commonly used 
number was taken
§SHB: part coverage of neonatal BCG (Kerry only)
?The number in cohort for BCG vaccine was 10,275
Table 2. Immunisation uptake rates in children 24 months of age in 2003
        % Uptake at 24 months
                Cohort born 01/01/2001 - 31/12/2001
Health Board No. in cohort D3 P3 T3 Hib3 Polio3 MenC3* MMR1
ERHA 21,753 83 83 83 83 83 80 74
MHB 3,616* 91 89 91 92 92 91 88
MWHB 4,881 87 85 87 86 87 84 80
NEHB 6,025 91 91 91 91 93 88 81
NWHB 3,124 94 92 94 92 94 91 83
SEHB 6,652 88 87 88 88 88 86 83
SHB 8,233* 85 84 85 85 85 84 80
WHB 5,270* 85 84 85 85 84 81 74
Ireland 59,554† 86 85 86 86 86 84 78
*As the number in cohort varied depending on the vaccine, the most commonly used 
number was taken.  
†Sum of the 8 birth cohorts listed in table 1
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Computerised Infectious 
Disease Reporting System (CIDR)
Key Points
• CIDR is an integrated electronic information system,
based on modern internet technologies, for surveillance
of clinical and laboratory information on communicable
diseases, outbreaks and antimicrobial resistance in
Ireland
• This shared national system has been developed in
partnership by the NDSC, Health Boards, FSAI, FSPB and
the DoHC
• Go live pilot implementation of CIDR started in May
2004 in NDSC, all laboratory, community care and public
health sites in the NEHB, and in the 4 national reference
laboratories. Recommendations on national
implementation of CIDR will be made shortly
• CIDR is a robust, enterprise-strength solution that will
be adaptable with changing surveillance needs
Introduction
Computerised Infectious Disease Reporting (CIDR) is a system
that has been developed by the NDSC in collaboration with
its partners, the DoHC, the Health Boards, the FSAI and the
FSPB, utilising modern internet-based technologies. CIDR
aims to provide an integrated and standardised electronic
surveillance system to collect, collate, analyse and
disseminate good quality laboratory-based and clinical
notification data on communicable disease in a timely
manner in Ireland. CIDR provides:
• An easily accessible one-stop shop for surveillance and
control of communicable diseases and antimicrobial
resistance
• One common system for all surveillance work 
• Standard reports on line and the ability to customise reports
to your needs
• Controlled and secure access to information 
• An adaptable and flexible system that can meet future
needs  
CIDR system development
CIDR was designed in 2002, and development of the system
commenced early in 2003. By April 2004, both development
and user acceptance testing of the system were completed.
The CIDR system has been built using the latest .NET
development environment with SQL Server 2000 as the
backend database and makes extensive use of XML
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technology, in line with the inter-operability requirements of
e-government initiatives.
To ensure that information within CIDR is stored and accessed
appropriately, the core system is firewall-protected and access
to the system is limited to authorised users. In addition to
usernames and passwords these users require authentication
provided by unique key fob tokens. Information transmitted
from local PCs to the core system is protected by 128-bit
encryption.
Access to the CIDR system is provided via the Government
Virtual Private Network (G-VPN). This provides a cost-
effective network with increased security and enhanced
bandwidth for public sector organisations, including the health
service.
Public health departments, community care offices and
clinical microbiology laboratories enter and retrieve infectious
disease information from CIDR via standard browser software
on their personal computers. No additional software is
required.
The information in CIDR comes from two principal sources.
Public health doctors working in community care offices and
public health departments register clinical notifications on the
system. Clinical microbiology laboratories in hospitals upload
files exported from their laboratory information systems into
CIDR, again using standard browser software. These files are
transformed and translated by the core system in the CIDR
format. Laboratories authorise all information prior to its
release for view by public health and other CIDR partners.
Alternatively, laboratories can enter data into CIDR manually.
The information collected and stored by CIDR is available for
analysis utilising a report writing / business intelligence
application called ‘Business Objects’. This software enables
information to be retrieved from complex relational databases
in a user-friendly fashion yet leaves the underlying data safe.
As with the CIDR application itself, viewing and analysing
CIDR information with ‘Business Objects’ requires only
standard browser software locally.
CIDR pilot implementation
Pilot go live implementation commenced in the NEHB, in
NDSC and in the 4 reference laboratories, namely the NVRL,
the Irish Meningococcal and Meningitis Reference Laboratory,
the Salmonella Reference Laboratory and the Methicillin
Resistant Staphylococcus Aureus Laboratory in May 2004. This
four month pilot implementation period is due to end shortly.
In May 2004, CIDR Project Board established a pilot
implementation evaluation committee. This committee is due
to report shortly on the findings of the evaluation and make
recommendations on the best way forward for national
implementation.
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CIDR training
NDSC has a team of six surveillance scientists and 2
surveillance assistants available to train users in CIDR. Training
is provided in the CIDR application, in CIDR business
processes, and in the use of Business Objects within the CIDR
environment. Modular structures are used to allow courses to
be tailored for each user group. Materials include a user
manual, and user guide, training slides, CD simulation and
hands-on exercises. Feedback from the training delivered
during pilot implementation has been very positive.
CIDR helpdesk
The CIDR helpdesk is based at NDSC. Helpdesk staff are
available to answer any queries about CIDR, whether they are
technical or relate to the business process. They provide a
quick turnaround time for providing answers to queries.
Approach to laboratory implementation
As part of the pilot go live implementation of CIDR, an
approach to laboratory implementation was developed. This
approach involves meeting with relevant laboratory personnel
to review and document current processes in relation to
infectious disease notification, and to document the expected
practice when each laboratory participates in CIDR. The
laboratory then decides whether entry of data to CIDR will be
manual or via upload from a Laboratory Information
Management System (LIMS). If entry will be via LIMS, then a
LIMS data extract questionnaire is completed, as well as a
data availability analysis, a data capture analysis, and a data
mapping exercise. Based on the data analysis documentation,
CIDR is configured uniquely for each laboratory. Rules for
extracting data, the format of the data to be imported, and in
some cases the type and content of data may vary. CIDR is
designed to facilitate all of this. It is important to note that
the CIDR System is the only software required to upload data
from LIMS systems. CIDR provides separate upload facilities
for notifiable disease and Antimicrobial Resistance (EARSS)
organisms and data. The CIDR design is open and flexible
enough to accept data from systems other than LIMS e.g.
Access databases. CIDR currently uploads delimited text files
from other systems. The system imposes very few restrictions
on data entry and or / upload and the number of mandatory
data items is minimised.
IT aspects of implementation
In advance of implementation, there needs to be a connection
for each CIDR user to the services configuration of
Government VPN. In addition there need to be modern PC(s)
available at each CIDR user site, though they do not need to
be dedicated to CIDR. Finally, local IT support is needed to
configure local CIDR user PCs appropriately.
Public health, business process issues during
implementation
The approach taken with regard to managing public health,
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business process issues was to initially identify a key
individual responsible for managing and coordinating all
aspects of the implementation. A steering committee was
established locally, with laboratory, community care, public
health and IT representation. The CIDR team held a joint
meeting to initiate the process. Several key decisions were
taken locally, e.g. whether to manage surveillance and control
within CIDR on a regional or a community care basis given
the requirements for daily interaction with CIDR,
identification of persons locally who would monitor data
quality in CIDR, remove duplicates and assign community care
areas to information that was not assigned below health
board level etc   All CIDR users were identified and assigned
the level of access to CIDR appropriate to each user. The
business rules template document, nationally agreed in 2002,
was adapted and signed by the CEO of each pilot
implementation organisation. A readiness for implementation
checklist was prepared and discussed with the users in
advance of go live. This dealt with data handling issues,
whom to contact if problems arose, IT configuration, access
control etc.
CIDR communications
In 2004, a CIDR newsletter was initiated. There have been four
editions to date, and the CIDR section of NDSC’s website is
actively updated. It includes a Frequently Asked Questions
section. During the summer of 2004, demonstrations of the
CIDR application were held in each Health Board, giving an
opportunity for hands-on practice with CIDR. These
demonstrations were very well received.
CIDR Disaster Recovery / Business Continuity
The core CIDR system is physically located within the
premises of NDSC and whilst there is some resilience within
the existing system, and data is backed up daily and stored
securely off-site, loss of equipment or access to that
equipment could result in significant downtime. To mitigate
this risk, a disaster recovery / business continuity solution is
being developed, in conjunction with Fujitsu, which replicates
data via the Government VPN to a Disaster Recovery CIDR
environment hosted in the Fujitsu data centre in Swords, Co.
Dublin. This is designed to be as transparent as possible to the
end user i.e. utilising the same URL, user accounts / profiles
etc and offering access to the same transactional data and
reports. This system would provide a working CIDR system
until the main system is restored.
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Antibiotic Consumption in 
the Community, 2003
Key Points
• Overall community antibiotic consumption rate for
Ireland in 2003 was 20.6 DID (Defined Daily Doses per
1000 Inhabitants per Day) representing a mid-range
usage rate among EU participants
• Rate for the last quarter of 2003 was 24.2 DID, the
highest in any individual quarter in the previous decade
• The relative proportion of narrow-spectrum penicillin
usage (8%) was consistent with those countries having a
higher level of resistance in key pathogens and much
lower than countries having low levels of resistance,
where the relative reliance on narrow-spectrum
penicillin was at 60-70%
• Consumption of two individual antibiotics – Amoxicillin
with enzyme inhibitors and Amoxicillin  - formed a high
proportion of total antibiotics used, 22.4% and 17.5%
respectively, and also represented some of the most
frequently prescribed pharmaceutical products in 2003
• Data for 2003 showed that geographical variation in
antibiotic utilisation that may reflect differences in
socio-economic factors and regional prescription
practices
• Sharp rise of 40% in total antibiotic distribution from
August (15.8 DID) to September (22.3 DID) for Ireland
for 2003, which stayed high for the last quarter. This
seasonal fluctuation has been seen every year and is
probably related to prescription of antibiotics for
respiratory tract infections in winter months
Introduction and methods
Surveillance of antimicrobial utilisation has been identified as
a key component of the Strategy for the Control of
Antimicrobial Resistance in Ireland (SARI).
Ireland now participates in the European Surveillance of
Antimicrobial Consumption (ESAC) which aims to construct
an inventory of antibiotic usage in the EU at national level by
collating data from both community and hospital areas on a
quarterly basis. This report covers community antibiotic
consumption for Ireland collected under ESAC guidelines for
2003 (http://www.ua.ac.be/main.asp?c=*ESAC).
In order to facilitate international comparisons, consumption
is expressed as Defined Daily Dose (DDD) per 1000
Inhabitants per Day (DID). DDD is the assumed average
maintenance dose per day for a drug used for its main
indication in adults. ESAC also uses the WHO Anatomical
Therapeutic Chemical (ATC) index to classify drugs through
five hierarchical levels. For example, all anti-infective
systemic drugs are grouped under J, antibacterial agents
(antibiotics) are denoted as J01, penicillins are classed as
J01C, broad-spectrum penicillins as J01CA and Amoxicillin as
J01CA04.
NDSC has purchased Irish pharmaceutical sales data from a
commercial organisation specialising in pharmaceutical
market research, IMS Health. This dataset contains regional,
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monthly wholesaler to retail community based pharmacy
sales data for 2003 from over 95% of the wholesalers and
manufactures in Ireland. An automated data-extraction
protocol was devised at NDSC to obtain the ATC/DDD
outputs for antibiotics.
Results
The overall community antibiotic consumption for Ireland in
2003 was 20.6 DID. Figure 1 shows the breakdown by
antibiotic class for each health board and for Ireland as a
whole. Penicillins accounted for the largest class of antibiotics
used (50% of total at 10.3 DID), followed by tetracyclines
(18%, 3.7 DID), macrolides (14%, 2.9 DID), cephalosporins
(10%, 2.1 DID), quinolones (4%, 0.7DID) and sulphonamides
(3%, 0.7 DID).
There was little variation among the health boards in terms
of total consumption. This is reflected in the apparent lack of
a geographical pattern in the regional distribution of total
DID for each county for the year 2003 (figure 2). However,
the proportion of tetracyclines over total usage by county for
2003 shows a much higher relative use in Dublin and much
lower relative use in the Midland and the North Western
counties (figure 3).
Penicillins 
Penicillin in combination with beta-lactamase inhibitor (such
as amoxicillin/clavulanate) accounted for the largest
proportion of penicillins, 45% at 4.6 DID. This was followed
by broad-spectrum (such as ampicillin and amoxicillin) at
39%, 4.0 DID, and then by beta-lactamase resistant
penicillins (such as cloxacillin and flucloxacillin) at 9%, 0.9
DID. The use of narrow spectrum penicillins, such as
benzylpenicillin formed the lowest proportion of all
penicillins at 8%, 0.8 DID.
Figure 4 shows that there was a slight difference in the
proportion of sub-classes of penicillins used in different
health boards. Furthermore, reliance on narrow-spectrum
penicillin was higher among the Western counties as
illustrated in figure 5.
Most commonly consumed antibiotics
Table 1 shows the top ten most commonly consumed
antibiotics in Ireland, which cumulatively accounted for 83%
of all antibiotics consumed by DID. The most commonly used
antibiotic, J01CR02 Amoxicillin and enzyme inhibitor,
accounted for 22% of all antibiotics at 4.6 DID.
Time series
Figure 6 shows the consumption of antibiotics in the
community, in DID, for Ireland by quarter since 1993.
Antibiotic usage has been rising steadily and rose to 24.2 DID
for the last quarter of 2003, the highest in any quarter in the
entire study period. Overall antibiotic use was highest during
the winter months. The mean difference between troughs
Table 1. Top ten most commonly used antibiotics in the community in Ireland, 2003.
Antibiotic DID Cumulative
J01CR02 Amoxicillin and enzyme inhibitor 4.63 22.4%
J01CA04 Amoxicillin 3.61 39.9%
J01FA09 Clarithromycin 2.00 49.6%
J01AA08 Minocycline 1.30 55.9%
J01AA02 Doxycycline 1.26 62.0%
J01DA08 Cefaclor 1.15 67.6%
J01CF05 Flucloxacillin 0.88 71.8%
J01CE02 Phenoxymethylpenicillin 0.77 75.6%
J01FA01 Erythromycin 0.75 79.2%
J01AA06 Oxytetracycline 0.73 82.7%
Others  3.57 100.0%
Total 20.64 
Ea
st
er
n
M
id
la
nd
M
id
-
W
es
te
rn
N
or
th
Ea
st
er
n
N
or
th
W
es
te
rn
So
ut
h
Ea
st
er
n
So
ut
he
rn
W
es
te
rn
Ire
la
nd
25
20
15
10
5
0
U
sa
ge
 D
ID
Health board
Figure 1. Community antibiotic consumption by therapeutic class in each 
health board in Ireland, 2003.
J01X Imidazole and Nitrofuran derivatives and All Others
J01M Qinolones
J01G Aminoglycosides
J01F Macrolides, Lincosamides and Streptogramins
J01E Sufonamides and Trimethoprim
J01D Cephalosporins, Monobactams and Carbapenems
J01C Penicillins
J01B Amphicols
J01A Tetracyclines
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(quarters 2 and 3) and peaks (quarters 1 and 4) in antibiotic
use was 23% (range 12% - 34%) and 22% for 2003.
The fluctuation in antibiotic utilisation during the course of a
year is further demonstrated in figure 7. The mean monthly
rate for the last four years (2000 – 03), dropped steadily
from 21.6 DID in January to 15.3 DID in July and stayed low
for August. The level rose sharply to a plateau in September,
October and November to about 21 DID, then peaked to
22.0 DID in December.
Discussion
Although the IMS dataset used in this report is very
comprehensive it does have some limitations. Firstly, the data
are based on pharmacy wholesale dataset, rather than on
individual prescriptions. Thus the data cannot be used to
determine the actual number of antibiotic courses taken and
do not provide information on dose or duration of therapy.
Secondly, factors such as stockpiling of antibiotics in
pharmacies and drug wastage (e.g. when antibiotics pass
their sell-by date) may introduce biases that cannot be
corrected for within the current method. Nevertheless the
data do show consistency over time and similar data sources
have been successfully used to calculate antibiotic
consumption in other countries.
There is a strong relationship between the level of antibiotic
use in the community and the level of antibiotic resistance.
This has been demonstrated for beta-lactam antibiotic use
and penicillin resistance in Streptococcus pneumoniae in a
number of European countries.1 A similar association has
been shown for macrolide use and resistance in group A
streptococci.2 In general the ESAC participants reporting the
lowest levels of antibiotic consumption are those with the
lowest levels of antibiotic resistance, while the reverse is true
of those reporting the highest levels of antibiotic
consumption. The overall level of antibiotic use here places
Ireland in the medium-range of usage among ESAC
participants.3
Variation in terms of overall antibiotic consumption among
the different health boards was minimal, however, variance
was observed at county level in two key areas. Firstly, the
proportion of tetracycline over total antibiotic usage was
shown to be much higher in the more prosperous Dublin
region and lower in the Midland and the North Western
counties. This may reflect that socio-economic factors are
associated with tetracycline usage. Overuse of tetracycline,
which is prescribed predominantly for respiratory tract and
skin infections, as well as for prophylactic prescription against
malaria, could lead to the selection of multi-resistant
pathogens. Secondly, the fact that there is a strong
geographical pattern in the relative reliance of narrow-
spectrum antibiotics in the Western counties indicates that
regional practices may also drive prescription patterns. For
the whole of Ireland, the relative proportion of narrow-
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Figure 4. Relative proportions of pencillins used in each health board in 
Ireland, 2003.
J01CF Beta-lactamase resistant penicillins
J01CR Combination with beta-lac inhibitors
J01CA Broad spectrum penicillins
J01CE Narrow spectrum penicillins
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spectrum penicillins (8%) is consistent with those countries
having a higher level of resistance among key indicator
pathogens, as in Belgium, Greece and the UK, and much
lower than the Nordic countries, which generally have low
levels of resistance, where the relative reliance on narrow-
spectrum penicillins is at 60-70%.4
The most commonly used antibiotic, J01CR02 Amoxicillin
and enzyme inhibitor, which accounted for 22% of all
antibiotics, is the sixth most commonly prescribed
pharmaceutical product in Ireland under the General Medical
Services (GMS) reimbursement scheme and the broad-
spectrum penicillin, J01CA04 Amoxicillin was the second
most commonly used antibiotic, ranking twelfth in the GMS
scheme of all products prescribed. Antibacterials for systemic
use (J01) account for 3.49% of the total cost of the GMS
reimbursement scheme.5
Seasonal variation in antibiotic consumption has been
observed in all ESAC participating countries and is most
likely related to increased prescribing for respiratory tract
infections during the winter months. Countries with high
levels of antibiotic consumption and resistance generally
show a very marked seasonal fluctuation (>30% difference
between winter and summer months), compared to those
with low levels (<25% fluctuation).4 The mean seasonal
fluctuation for Ireland over the last eleven years was 23%.
However, this calculation needs to be interpreted with
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caution as antibiotic-purchasing practices by pharmacies may
affect data on seasonality. For example, antibiotics purchased
during quarter three may not be dispensed until quarter four,
flattening the seasonality curve. Furthermore, there was a
sharp rise in total antibiotic distribution from August (15.8
DID) to September (22.3 DID) for Ireland for 2003, a rise of
over 40%.
In the coming year, expansion of the surveillance of
antimicrobial consumption is planned to include data from
the GMS scheme at prescription level using the same
ATC/DDD classification protocol as used in this report for
wholesaler dataset, thus addressing some of the limitations
encountered. Furthermore, it is hoped that sufficient
numbers of hospitals take part in the surveillance strategy to
allow Ireland to fully participate with ESAC.
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